U.S. patent application number 17/112351 was filed with the patent office on 2021-03-25 for sgc stimulators.
The applicant listed for this patent is Cyclerion Therapeutics, Inc.. Invention is credited to Rajesh R. Iyengar, Joon Jung, Thomas Wai-Ho Lee, Paul Allan Renhowe, Glen Robert Rennie, Kim Tang.
Application Number | 20210087198 17/112351 |
Document ID | / |
Family ID | 1000005253600 |
Filed Date | 2021-03-25 |
![](/patent/app/20210087198/US20210087198A1-20210325-C00001.TIF)
![](/patent/app/20210087198/US20210087198A1-20210325-C00002.TIF)
![](/patent/app/20210087198/US20210087198A1-20210325-C00003.TIF)
![](/patent/app/20210087198/US20210087198A1-20210325-C00004.TIF)
![](/patent/app/20210087198/US20210087198A1-20210325-C00005.TIF)
![](/patent/app/20210087198/US20210087198A1-20210325-C00006.TIF)
![](/patent/app/20210087198/US20210087198A1-20210325-C00007.TIF)
![](/patent/app/20210087198/US20210087198A1-20210325-C00008.TIF)
![](/patent/app/20210087198/US20210087198A1-20210325-C00009.TIF)
![](/patent/app/20210087198/US20210087198A1-20210325-C00010.TIF)
![](/patent/app/20210087198/US20210087198A1-20210325-C00011.TIF)
View All Diagrams
United States Patent
Application |
20210087198 |
Kind Code |
A1 |
Rennie; Glen Robert ; et
al. |
March 25, 2021 |
sGC STIMULATORS
Abstract
The present disclosure relates to stimulators of soluble
guanylate cyclase (sGC), pharmaceutical formulations comprising
them and their uses thereof, alone or in combination with one or
more additional agents, for treating various diseases, wherein an
increase in the concentration of nitric oxide (NO) or an increase
in the concentration of cyclic Guanosine Monophosphate (cGMP), or
both, or an upregulation of the NO pathway is desirable. The
compounds are of Formula I: ##STR00001##
Inventors: |
Rennie; Glen Robert;
(Somerville, MA) ; Iyengar; Rajesh R.; (West
Newton, MA) ; Lee; Thomas Wai-Ho; (Lexington, MA)
; Renhowe; Paul Allan; (Sudbury, MA) ; Jung;
Joon; (Newton, MA) ; Tang; Kim; (Belmont,
MA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Cyclerion Therapeutics, Inc. |
Cambridge |
MA |
US |
|
|
Family ID: |
1000005253600 |
Appl. No.: |
17/112351 |
Filed: |
December 4, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16273557 |
Feb 12, 2019 |
10858363 |
|
|
17112351 |
|
|
|
|
15693758 |
Sep 1, 2017 |
10472363 |
|
|
16273557 |
|
|
|
|
62482486 |
Apr 6, 2017 |
|
|
|
62468598 |
Mar 8, 2017 |
|
|
|
62423445 |
Nov 17, 2016 |
|
|
|
62382942 |
Sep 2, 2016 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07D 487/04 20130101;
A61K 31/52 20130101; A61K 31/4985 20130101; A61K 31/437 20130101;
C07D 471/04 20130101; C07D 473/00 20130101 |
International
Class: |
C07D 487/04 20060101
C07D487/04; A61K 31/437 20060101 A61K031/437; A61K 31/4985 20060101
A61K031/4985; A61K 31/52 20060101 A61K031/52; C07D 471/04 20060101
C07D471/04; C07D 473/00 20060101 C07D473/00 |
Claims
1. A method of treating a disease, health condition or disorder in
a subject in need of treatment, comprising administering a
therapeutically effective amount of a compound of Formula I-1, or a
pharmaceutically acceptable salt thereof, ##STR00159## to the
subject in need of treatment, wherein the disease, health condition
or disorder is a central nervous system (CNS) disease, health
condition or disorder selected from: Alzheimer's disease,
amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), Down
syndrome, dementia, vascular dementia, vascular cognitive
impairment, Binswanger's dementia (subcortical arteriosclerotic
encephalopathy), Cerebral Autosomal-Dominant Arteriopathy with
Subcortical Infarcts and Leukoencephalopathy (CADASIL or CADASIL
syndrome), frontotemporal lobar degeneration or dementia,
HIV-associated dementia, Lewy body dementia, pre-senile dementia
(mild cognitive impairment, MCI), glaucoma, Huntington's diseases
(or chorea, HD), multiple sclerosis (MS), multiple system atrophy
(MSA), Parkinson's disease, Parkinsonism Plus, spinocerebellar
ataxias, Steel-Richardson-Olszewski disease (progressive
supranuclear palsy), attention deficit disorder (ADD) and attention
deficit hyperactivity disorder (ADHD); neuropathic pain; a
psychiatric, mental, mood or affective disorder selected from a
bipolar disorder, schizophrenia, general psychosis, drug-induced
psychosis, a delusional disorder, schizoaffective disorder,
obsessive compulsive disorder (OCD), a depressive disorder, an
anxiety disorder, a panic disorder, or post-traumatic stress
disorder (PTSD); traumatic (closed or open, penetrating head
injuries) or non-traumatic (stroke, aneurism, hypoxia) injury to
the brain or cognitive impairment or dysfunction resulting from
brain injuries or neurodegenerative disorders; dystonias, including
generalized, focal, segmental, sexual, intermediate, acute dystonic
reaction, and genetic/primary dystonia; and dyskinesias, including
acute, chronic/tardive, and non-motor and levo-dopa induced
dyskinesia (LID); disorders characterized by a relative reduction
in synaptic plasticity and synaptic processes including, Fragile X,
Rhett's disorder, Williams syndrome, Renpenning's syndrome, autism
spectrum disorders, including autism, Asperger's syndrome,
pervasive development disorder and childhood disintegrative
disorder; chemo brain, levo-dopa induced addictive behavior,
alcoholism, narcotic dependence (including to amphetamine, opiates
or other substances) and substance abuse.
2. The method according to claim 1, wherein the disease, health
condition or disorder is selected from Alzheimer's disease,
amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), Down
syndrome, dementia, vascular dementia, vascular cognitive
impairment, Binswanger's dementia (subcortical arteriosclerotic
encephalopathy), Cerebral Autosomal-Dominant Arteriopathy with
Subcortical Infarcts and Leukoencephalopathy (CADASIL or CADASIL
syndrome), frontotemporal lobar degeneration or dementia,
HIV-associated dementia, Lewy body dementia, pre-senile dementia
(mild cognitive impairment, MCI), glaucoma, Huntington's diseases
(or chorea, HD), multiple sclerosis (MS), multiple system atrophy
(MSA), Parkinson's disease, Parkinsonism Plus, spinocerebellar
ataxias, Steel-Richardson-Olszewski disease (progressive
supranuclear palsy), attention deficit disorder (ADD) or attention
deficit hyperactivity disorder (ADHD).
3. The method according to claim 1, wherein the disease, health
condition or disorder is neuropathic pain.
4. The method according to claim 1, wherein the disease, health
condition or disorder is selected from a psychiatric, mental, mood
or affective disorder selected from a bipolar disorder,
schizophrenia, general psychosis, drug-induced psychosis, a
delusional disorder, schizoaffective disorder, obsessive compulsive
disorder (OCD), a depressive disorder, an anxiety disorder, a panic
disorder, or post-traumatic stress disorder (PTSD).
5. The method according to claim 1, wherein the disease, health
condition or disorder is selected from traumatic or non-traumatic
injury to the brain or cognitive impairment or dysfunction
resulting from brain injuries or neurodegenerative disorders.
6. The method according to claim 1, wherein the disease, health
condition or disorder is selected from Alzheimer's disease or
pre-Alzheimer's disease, mild to moderate Alzheimer's disease or
moderate to severe Alzheimer's disease.
7. The method according to claim 1, wherein the disease, health
condition or disorder is selected from a dystonia or a
dyskinesia.
8. The method according to claim 1, wherein the disease, health
condition or disorder is selected from a disorder characterized by
a relative reduction in synaptic plasticity and synaptic processes,
including Fragile X, Rhett's disorder, Williams syndrome,
Renpenning's syndrome, autism spectrum disorders, including autism,
Asperger's syndrome, pervasive development disorder and childhood
disintegrative disorder.
9. The method according to claim 1, wherein the disease, health
condition or disorder is selected from chemo brain, levo-dopa
induced addictive behavior, alcoholism, narcotic dependence
(including to amphetamine, opiates or other substances) and
substance abuse.
10. A method of treating a disease, health condition or disorder in
a subject in need of treatment, comprising administering a
therapeutically effective amount of a compound of Formula I-1, or a
pharmaceutically acceptable salt thereof, ##STR00160## to the
subject in need of treatment, wherein the disease, health condition
or disorder is selected from: disorders related to high blood
pressure and decreased coronary blood flow, increased acute and
chronic coronary blood pressure, arterial hypertension, vascular
disorder resulting from cardiac and renal complications, heart
disease, stroke, cerebral ischemia, renal failure, resistant
hypertension, diabetic hypertension, congestive heart failure,
diastolic or systolic dysfunction, coronary insufficiency,
arrhythmia, reduction of ventricular preload, cardiac hypertrophy,
heart failure/cardiorenal syndrome, portal hypertension,
endothelial dysfunction or injury; thromboembolic disorder,
ischemia, myocardial infarction, stroke, transient ischemic attack
(TIA), obstructive thromboanginitis, stable or unstable angina
pectoris, coronary spasms, variant angina, Prinzmetal's angina,
prevention of restenosis after thrombolysis therapies, thrombogenic
disorders; a CNS disease, health condition or disorder selected
from Alzheimer's disease, amyotrophic lateral sclerosis, Down
syndrome, dementia, vascular dementia, vascular cognitive
impairment, Binswanger's dementia, Cerebral Autosomal-Dominant
Arteriopathy with Subcortical infarcts and Leukoencephalopathy,
frontotemporal lobar degeneration or dementia, HIV-associated
dementia, Lewy body dementia, pre-senile dementia, glaucoma,
Huntington's diseases, multiple sclerosis, multiple system atrophy,
Parkinson's disease, Parkinsonism Plus, spinocerebellar ataxies,
Steel-Richardson-Olszewski disease, attention deficit disorder and
attention deficit hyperactivity disorder, Alzheimer's disease or
pre-Alzheimer's disease, mild to moderate Alzheimer's disease or
moderate to severe Alzheimer's disease, traumatic (closed or open,
penetrating head injuries) brain injury (TBI), nontraumatic
(stroke, aneurism, hypoxia) injury to the brain, cognitive
impairment or dysfunction resulting from brain injuries or
neurodegenerative disorder, dystonia, dyskinesia, a disorder
characterized by a relative reduction in synaptic plasticity and
synaptic processes, Fragile X, Rhett's disorder, Williams syndrome,
Renpenning's syndrome, autism spectrum disorders, including autism,
Asperger's syndrome, pervasive development disorder, childhood
disintegrative disorder, neuropathic pain, bipolar disorder,
schizophrenia, general psychosis, drug-induced psychosis, a
delusional disorder, schizoaffective disorder, obsessive compulsive
disorder, a depressive disorder, an anxiety disorder, a panic
disorder, post-traumatic stress disorder, chemo brain, levo-dopa
induced addictive behavior, alcoholism, narcotic dependence or
substance abuse; peripheral arterial disease, peripheral occlusive
arterial disease, peripheral vascular disease, hypertonia,
Raynaud's syndrome or phenomenon, critical limb ischemia,
vasculitis, peripheral embolism, intermittent claudication,
vaso-occlusive crisis, Duchenne muscular dystrophy, Becker muscular
dystrophy, microcirculation abnormalities, control of vascular
leakage or permeability; shock, sepsis, cardiogenic shock, control
of leukocyte activation, inhibition or modulation of platelet
aggregation; pulmonary hypertension, pulmonary arterial
hypertension, associated pulmonary vascular remodeling, localized
thrombosis, right heart hypertrophy, pulmonary hypertonia, primary
pulmonary hypertension, secondary pulmonary hypertension, familial
pulmonary hypertension, sporadic pulmonary hypertension,
pre-capillary pulmonary hypertension, idiopathic pulmonary
hypertension, thrombotic pulmonary arteriopathy, plexogenic
pulmonary arteriopathy, cystic fibrosis, bronchoconstriction or
pulmonary bronchoconstriction, acute respiratory distress syndrome,
lung fibrosis, lung transplant; pulmonary hypertension associated
with or related to: left ventricular dysfunction, hypoxemia, WHO
groups I, II, III, IV and V hypertensions, mitral valve disease,
constrictive pericarditis, aortic stenosis, cardiomyopathy,
mediastinal fibrosis, pulmonary fibrosis, anomalous pulmonary
venous drainage, pulmonary venooclusive disease, pulmonary
vasculitis, collagen vascular disease, congenital heart disease,
pulmonary venous hypertension, interstitial lung disease,
sleep-disordered breathing, sleep apnea, alveolar hypoventilation
disorders, chronic exposure to high altitude, neonatal lung
disease, alveolar-capillary dysplasia, sickle cell disease, other
coagulation disorders, chronic thromboembolism, pulmonary embolism
(due to tumor, parasites or foreign material), connective tissue
disease, lupus, schistosomiasis, sarcoidosis, chronic obstructive
pulmonary disease, asthma, emphysema, chronic bronchitis, pulmonary
capillary hemangiomatosis, histiocytosis X, lymphangiomatosis and
compressed pulmonary vessels (such as due to adenopathy, tumor or
fibrosing mediastinitis); atherosclerosis (e.g., associated with
endothelial injury, platelet and monocyte adhesion and aggregation,
smooth muscle proliferation and migration), restenosis (e.g.,
developed after thrombolysis therapies, percutaneous transluminal
angioplasties (PTAs), percutaneous transluminal coronary
angioplasties (PTCAs) and bypass), inflammation; cardiovascular
disease associated with metabolic syndrome (e.g., obesity,
dyslipidemia, diabetes, high blood pressure), dyslipidemia,
hypercholesterolemia, hypertriglyceridemia, sitosterolemia, fatty
liver disease, hepatitis, preeclampsia, polycystic kidney disease
progression, subcutaneous fat, obesity; liver cirrhosis associated
with chronic liver disease, hepatic fibrosis, hepatic stellate cell
activation, hepatic fibrous collagen and total collagen
accumulation; liver disease of necro-inflammatory and/or of
immunological origin; renal fibrosis and renal failure resulting
from chronic kidney diseases or insufficiency (e.g. due to
accumulation/deposition and tissue injury, progressive sclerosis,
glomerulonephritis); prostate hypertrophy systemic sclerosis;
cardiac interstitial fibrosis; cardiac remodeling and fibrosis;
cardiac hypertrophy; non-alcoholic steatohepatitis or NASH;
ischemia, reperfusion damage; ischemia/reperfusion associated with
organ transplant, lung transplant, pulmonary transplant, cardiac
transplant; conserving blood substituents in trauma patients;
erectile dysfunction; impotence; premature ejaculation; female
sexual dysfunction, vaginal atrophy, dyspaneuria, atrophic
vaginitis; benign prostatic hyperplasia (BPH) or hypertrophy or
enlargement; bladder outlet obstruction; bladder pain syndrome
(BPS), interstitial cystitis (IC), overactive bladder, neurogenic
bladder and incontinence; diabetic nephropathy; glaucoma,
retinopathy, diabetic retinopathy, blepharitis, dry eye syndrome,
Sjogren's Syndrome; hearing impairment, partial or total hearing
loss; partial or total deafness; tinnitus; noise-induced hearing
loss; dermal fibrosis, scleroderma, skin fibrosis; microvascular
perfusion improvement (e.g., following injury, to counteract the
inflammatory response in perioperative care), anal fissures,
diabetic ulcers; and cancer metastasis, osteoporosis,
gastroparesis; functional dyspepsia; diabetic complications,
diseases associated with endothelial dysfunction, neurologic
disorders associated with decreased nitric oxide production,
achalasia or esophageal achalasia.
11. A method of treating or preventing a disease, health condition
or disorder in a subject in need thereof, comprising administering,
alone or in combination therapy, a therapeutically effective amount
of a compound of Formula I-1, or a pharmaceutically acceptable salt
thereof, ##STR00161## wherein the disease or disorder is one that
benefits from sGC stimulation or from an increase in the
concentration of NO or cGMP or both, or the upregulation of the NO
pathway.
12. The method according to claim 1 further comprising a second
amount of an additional suitable therapeutic agent.
13. The method of claim 1, wherein the disease, health condition or
disorder is mixed dementia.
Description
RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 16/273,557, filed Feb. 12, 2019, which is a
continuation of U.S. patent application Ser. No. 15/693,758, filed
Sep. 1, 2017, now U.S. Pat. No. 10,472,363, which claims the
benefit of the filing date, under 35 U.S.C. .sctn. 119(e), of U.S.
Provisional Application No. 62/382,942, filed on Sep. 2, 2016; U.S.
Provisional Application No. 62/423,445, filed on Nov. 17, 2016;
U.S. Provisional Application No. 62/468,598, filed on Mar. 8, 2017;
and U.S. Provisional Application No. 62/482,486 filed on Apr. 6,
2017. The entire contents of each of the above-referenced
applications are incorporated herein by reference.
FIELD OF THE INVENTION
[0002] The present disclosure relates to stimulators of soluble
guanylate cyclase (sGC), pharmaceutical formulations comprising
them and their uses thereof, alone or in combination with one or
more additional agents, for treating various diseases, wherein an
increase in the concentration of nitric oxide (NO) or an increase
in the concentration of cyclic Guanosine 3',5'-Monophosphate (cGMP)
or both, or an upregulation of the NO pathway is desirable.
BACKGROUND OF THE INVENTION
[0003] Soluble guanylate cyclase (sGC) is the primary receptor for
nitric oxide (NO) in vivo. sGC can be activated via both
NO-dependent and NO-independent mechanisms. In response to this
activation, sGC converts guanosine 5'-triphosphate (GTP) into the
secondary messenger cyclic GMP (cGMP). The increased level of cGMP,
in turn, modulates the activity of downstream effectors including
protein kinases, phosphodiesterases (PDEs) and ion channels.
[0004] In the body, NO is synthesized from arginine and oxygen by
various nitric oxide synthase (NOS) enzymes and by sequential
reduction of inorganic nitrate. Three distinct isoforms of NOS have
been identified: inducible NOS (iNOS or NOS II) found in activated
macrophage cells; constitutive neuronal NOS (nNOS or NOS I),
involved in neurotransmission and long term potentiation; and
constitutive endothelial NOS (eNOS or NOS III) which regulates
smooth muscle relaxation and blood pressure. Experimental and
clinical evidence indicates that reduced concentrations,
bioavailability and/or responsiveness to endogenously produced NO
contributes to the development of disease.
[0005] NO-independent, heme-dependent, sGC stimulators, have
several important differentiating characteristics, when compared to
other types of sGC modulators, including crucial dependency on the
presence of the reduced prosthetic heme moiety for their activity,
strong synergistic enzyme activation when combined with NO and
stimulation of the synthesis of cGMP by direct stimulation of sGC,
independent of NO. The benzylimidazole compound YC-1 was the first
sGC stimulator to be identified. Additional sGC stimulators with
improved potency and specificity for sGC have since been
developed.
[0006] Compounds that stimulate sGC in an NO-independent manner
offer considerable advantages over other current alternative
therapies that either target the aberrant NO pathway or that are
directed at diseases wherein upregulation of the NO pathway is
beneficial. There is a need to develop novel stimulators of sGC.
These compounds are useful for treating various diseases, wherein
the diseases or disorders are ones that would benefit from sGC
stimulation or from an increase in the concentration of nitric
oxide (NO) or cyclic guanosine 3',5'-monophosphate (cGMP) or both,
or wherein an upregulation of the NO pathway is desirable.
SUMMARY OF THE INVENTION
[0007] The present invention is directed to compounds of Formula I,
or pharmaceutically acceptable salts thereof,
##STR00002##
wherein: rings E and A form the core of the molecule and are
aromatic; each instance of X and Y is independently selected from N
or C; wherein a maximum of 4 instances of X and Y are
simultaneously N; W is either i) absent, with J.sup.B connected
directly to the carbon atom bearing two J groups, each J is
independently selected from hydrogen or methyl, n is 1 and J.sup.B
is a C.sub.1-7 alkyl chain optionally substituted by up to 9
instances of fluorine; or ii) a ring B that is a phenyl, a
C.sub.3-7 cycloalkyl ring or a 5 or 6-membered heteroaryl ring,
containing 1 or 2 ring nitrogen atoms;
[0008] wherein when ring B is the phenyl or 5 or 6-membered
heteroaryl ring; each J is independently selected from hydrogen or
methyl; n is an integer selected from 0 to 3; and each J.sup.B is
independently selected from halogen, --CN, a C.sub.1-6 aliphatic,
--OR.sup.B or a C.sub.3-8 cycloaliphatic ring; and
[0009] wherein when ring B is the C.sub.3-7 cycloalkyl ring; each J
is hydrogen; n is an integer selected from 0 to 3 and each J.sup.B
is independently selected from halogen, --CN, a C.sub.1-6 aliphatic
or --OR.sup.B1;
[0010] wherein each J.sup.B that is a C.sub.1-6 aliphatic and each
J.sup.B that is a C.sub.3-8 cycloaliphatic ring is optionally and
independently substituted with up to 3 instances of R.sup.3;
each R.sup.B is independently selected from a C.sub.1-6 aliphatic
or a C.sub.3-8 cycloaliphatic ring; said R.sup.B optionally and
independently substituted with up to 3 instances of R.sup.3a; each
R.sup.B1 is independently selected from hydrogen, a C.sub.1-6
aliphatic or a C.sub.3-8 cycloaliphatic ring; wherein each of said
C.sub.1-6 aliphatic and each of said C.sub.3-8 cycloaliphatic ring
is optionally and independently substituted with up to 3 instances
of R.sup.3b; each R.sup.3, R.sup.3a and R.sup.3b is, in each
instance, independently selected from halogen, --CN, C.sub.1-4
alkyl, C.sub.1-4 haloalkyl, --O(C.sub.1-4 alkyl) or
--O(C.sub.1-4haloalkyl); p is an integer selected from 1, 2 or 3;
each J.sup.C is independently selected from hydrogen, halogen,
C.sub.1-4 aliphatic, C.sub.1-4 alkoxy or --CN; wherein each said
C.sub.1-4 aliphatic and C.sub.1-4 alkoxy is optionally and
independently substituted by up to 3 instances of C.sub.1-4 alkoxy,
C.sub.1-4 haloalkoxy, --OH or halogen; Q, G and Z are each
independently N, S or O, wherein at least two of Q, G and Z are N;
q is 0, 1 or 2; R.sup.10 is C.sub.1-6 alkyl optionally and
independently substituted with 0-3 occurrences of R.sup.15, phenyl
optionally and independently substituted with 0-3 occurrences of
R.sup.15, 5- or 6-membered heteroaryl optionally and independently
substituted with 0-3 occurrences of R.sup.15, C.sub.3-8 cycloalkyl
optionally and independently substituted with 0-3 occurrences of
R.sup.15 or 3-8 membered heterocyclyl optionally and independently
substituted with 0-3 occurrences of R.sup.15; wherein each of said
5- to 6-membered heteroaryl ring and each of said 3-8 membered
heterocyclyl contains up to 3 ring heteroatoms independently
selected from N, O or S; R.sup.11 is H, --NR.sup.a2R.sup.b2,
--C(O)NR.sup.a2R.sup.b2, --C(O)R.sup.15a, --SO.sub.2R.sup.b2,
--SR.sup.b2, halo, --OCF.sub.3, --CN, hydroxyl, C.sub.2-6 alkenyl
optionally and independently substituted with 0-2 occurrences of
R.sup.b2, C.sub.2-6 alkynyl optionally and independently
substituted with 0-2 occurrences of R.sup.b2; C.sub.1-6 alkyl
optionally and independently substituted with 0-3 occurrences of
R.sup.15, C.sub.1-6 alkoxy optionally and independently substituted
with 0-5 occurrences of R.sup.15, phenyl optionally and
independently substituted with 0-3 occurrences of R.sup.15, 5- to
6-membered heteroaryl optionally and independently substituted with
0-3 occurrences of R.sup.15, C.sub.3-8 cycloalkyl optionally and
independently substituted with 0-3 occurrences of R.sup.15 or 3-8
membered heterocyclyl optionally and independently substituted with
0-3 occurrences of R.sup.15; wherein each of said 5- to 6-membered
heteroaryl and each of said 3-8 membered heterocyclyl contains up
to 3 ring heteroatoms independently selected from N, O or S; or
when R.sup.10 is a substituent of Z, R.sup.10 and R.sup.11, taken
together with Z and the carbon to which R.sup.11 is attached, form
a 3-10 membered heterocyclic ring optionally and independently
substituted with 0-3 occurrences of R.sup.15; wherein each of said
3-10 membered heterocyclyl contains up to 3 ring heteroatoms
independently selected from N, O or S; R.sup.15 is halo,
--OR.sup.b2, --SR.sup.b2, --NR.sup.a2R.sup.b2, --C(O)R.sup.b2,
--C(O)NR.sup.a2R.sup.b2, --OC(O)NR.sup.a2R.sup.b2, C.sub.2-4
alkenoxy, C.sub.3-8 cycloalkyl optionally and independently
substituted with 0-3 occurrences of R.sup.18, phenyl optionally and
independently substituted with 0-3 occurrences of R.sup.18, 5- or
6-membered heteroaryl optionally and independently substituted with
0-3 occurrences of R.sup.18 or 3-10 membered heterocyclyl
optionally and independently substituted with 0-3 occurrences of
R.sup.18; wherein each of said 5- or 6-membered heteroaryl ring and
each of said 3-10 membered heterocyclyl contains up to 3 ring
heteroatoms independently selected from N, O or S; R.sup.15a is
C.sub.3-8 cycloalkyl optionally and independently substituted with
0-3 occurrences of R.sup.18, phenyl optionally and independently
substituted with 0-3 occurrences of R.sup.18, 5- or 6-membered
heteroaryl optionally and independently substituted with 0-3
occurrences of R.sup.18 or 3-10 membered heterocyclyl optionally
and independently substituted with 0-3 occurrences of R.sup.18;
wherein each of said 5- or 6-membered heteroaryl ring and each of
said 3-10 membered heterocyclyl contains up to 3 ring heteroatoms
independently selected from N, O or S; each R.sup.18 is
independently selected from halo, hydroxyl, C.sub.1-6 alkyl,
C.sub.1-6 alkoxy, C.sub.1-6 haloalkyl or phenyl; R.sup.a2 is
hydrogen, --C(O)R.sup.b2, C.sub.1-6 alkyl or C.sub.1-6 haloalkyl;
and R.sup.b2 is hydrogen, C.sub.1-6 alkyl or C.sub.1-6
haloalkyl.
[0011] The invention is also directed to a pharmaceutical
composition comprising a compound according to Formula I, or a
pharmaceutically acceptable salt thereof, and at least one
pharmaceutically acceptable excipient or carrier. The invention is
also directed to a pharmaceutical formulation or dosage form
comprising the pharmaceutical composition.
[0012] The invention also provides a method of treating or
preventing a disease, health condition or disorder in a subject in
need thereof, comprising administering, alone or in combination
therapy, a therapeutically effective amount of a compound of
Formula I or a pharmaceutically acceptable salt thereof to the
subject; wherein the disease is one that benefits from sGC
stimulation or from an increase in the concentration of NO or cGMP
or both, or from an upregulation of the NO pathway.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013] FIG. 1 is a plot of the long-term potentiation of wild type
(WT) mice hippocampal slices (top curve), R6/2 mice hippocampal
slices (bottom curve), and R6/2 mice hippocampal slices treated
with 7 nM Compound I-1 (middle curve).
[0014] FIG. 2 is a plot of the long-term potentiation of wild type
(WT) mice hippocampal slices (top curve, overlaps with middle
curve), R6/2 mice hippocampal slices (bottom curve), and R6/2 mice
hippocampal slices treated with 46 nM Compound I-1 (middle curve,
overlaps with top curve).
[0015] FIG. 3 is a plot of the long-term potentiation of wild type
(WT) mice hippocampal slices (top curve, overlaps with middle
curve), R6/2 mice hippocampal slices (bottom curve), and R6/2 mice
hippocampal slices treated with 308 nM Compound I-1 (middle curve,
overlaps with top curve).
[0016] FIG. 4 is a picture of the brain of a rat treated with a
peripherally restricted sGC stimulator (left) and a picture of the
brain of a rat treated with a compound of the invention
(right).
[0017] FIG. 5 is a picture of the brain of a mouse transferred
using an ice-cold spatula to mouse brain matrix with coronal
spacing for slicing at 1 mm intervals.
DETAILED DESCRIPTION OF THE INVENTION
[0018] Reference will now be made in detail to certain embodiments
of the invention, examples of which are illustrated in the
accompanying structures and formulae. While the invention will be
described in conjunction with the enumerated embodiments, it will
be understood that they are not intended to limit the invention to
those embodiments. Rather, the invention is intended to cover all
alternatives, modifications and equivalents that may be included
within the scope of the present invention as defined by the claims.
The present invention is not limited to the methods and materials
described herein but include any methods and materials similar or
equivalent to those described herein that could be used in the
practice of the present invention. In the event that one or more of
the incorporated literature references, patents or similar
materials differ from or contradict this application, including but
not limited to defined terms, term usage, described techniques or
the like, this application controls.
Definitions and General Terminology
[0019] For purposes of this disclosure, the chemical elements are
identified in accordance with the Periodic Table of the Elements,
CAS version, and the Handbook of Chemistry and Physics, 75.sup.th
Ed. 1994. Additionally, general principles of organic chemistry are
described in "Organic Chemistry", Thomas Sorrell, University
Science Books, Sausalito: 1999, and "March's Advanced Organic
Chemistry", 5.sup.th Ed., Smith, M. B. and March, J., eds. John
Wiley & Sons, New York: 2001, which are herein incorporated by
reference in their entirety.
[0020] As described herein, compounds of Formula I may be
optionally substituted with one or more substituents, such as
illustrated generally below, or as exemplified by particular
classes, subclasses and species of the invention. The phrase
"optionally substituted" is used interchangeably with the phrase
"substituted or unsubstituted." In general, the term "substituted"
refers to the replacement of one or more hydrogen radicals in a
given structure with the radical of a specified substituent. Unless
otherwise indicated, an optionally substituted group may have a
substituent at each substitutable position of the group. When more
than one position in a given structure can be substituted with more
than one substituent selected from a specified group, the
substituent may be either the same or different at each position
unless otherwise specified. The term "optionally and independently"
may be used to describe this situation. As an example, one
substituent disclosed herein is R.sup.10, which may be, among other
options, C.sub.1-6 alkyl optionally and independently substituted
with 0-3 occurrences of R.sup.15. In this instance, the C.sub.1-6
alkyl may be "optionally substituted": it may be unsubstituted
(i.e., 0 occurrences of R.sup.15) or substituted (i.e., 1, 2, or 3
occurrences of R.sup.15). When there are multiple occurrences of
R.sup.15 (e.g., 2), each R.sup.15 may be the same substituent
(e.g., two fluoro atoms) or different (e.g., --OH and chloro). As
will be apparent to one of ordinary skill in the art, groups such
as --H, halogen, --NO.sub.2, --CN, --OH, --NH.sub.2 or --OCF.sub.3
would not be substitutable groups.
[0021] The phrase "up to", as used herein, refers to zero or any
integer number that is equal or less than the number following the
phrase. For example, "up to 3" means any one of 0, 1, 2, or 3. As
described herein, a specified number range of atoms includes any
integer therein. For example, a group having from 1-4 atoms could
have 1, 2, 3 or 4 atoms. A group having from 0-3 atoms could have
0, 1, 2, or 3 atoms. When any variable occurs more than one time at
any position, its definition on each occurrence is independent from
every other occurrence.
[0022] Selection of substituents and combinations envisioned by
this disclosure are only those that result in the formation of
stable or chemically feasible compounds. Such choices and
combinations will be apparent to those of ordinary skill in the art
and may be determined without undue experimentation. The term
"stable", as used herein, refers to compounds that are not
substantially altered when subjected to conditions to allow for
their production, detection, and, in some embodiments, their
recovery, purification, and use for one or more of the purposes
disclosed herein. In some embodiments, a stable compound is one
that is not substantially altered when kept at a temperature of
25.degree. C. or less, in the absence of moisture or other
chemically reactive conditions, for at least a week. A chemically
feasible compound is a compound that can be prepared by a person
skilled in the art based on the disclosures herein supplemented, if
necessary, relevant knowledge of the art.
[0023] A compound, such as the compounds of Formula I or Table I or
other compounds herein disclosed, may be present in its free form
(e.g. an amorphous form, or a crystalline form or a polymorph).
Under certain conditions, compounds may also form co-forms. As used
herein, the term co-form is synonymous with the term
multi-component crystalline form. The formation of a salt is
determined by how large the difference is in the pKas between the
partners that form the mixture. For purposes of this disclosure,
compounds include pharmaceutically acceptable salts, even if the
term "pharmaceutically acceptable salts" is not explicitly
noted.
[0024] Unless only one of the isomers is drawn or named
specifically, structures depicted herein are also meant to include
all stereoisomeric (e.g., enantiomeric, diastereomeric,
atropoisomeric and cis-trans isomeric) forms of the structure; for
example, the R and S configurations for each asymmetric center, Ra
and Sa configurations for each asymmetric axis, (Z) and (E) double
bond configurations, and cis and trans conformational isomers.
Therefore, single stereochemical isomers as well as racemates, and
mixtures of enantiomers, diastereomers, and cis-trans isomers
(double bond or conformational) of the present compounds are within
the scope of the present disclosure. Unless otherwise stated, all
tautomeric forms of the compounds of the present disclosure are
also within the scope of the invention.
[0025] The present disclosure also embraces isotopically-labeled
compounds which are identical to those recited herein, but for the
fact that one or more atoms are replaced by an atom having an
atomic mass or mass number different from the atomic mass or mass
number usually found in nature. All isotopes of any particular atom
or element as specified are contemplated within the scope of the
compounds of the invention, and their uses. Exemplary isotopes that
can be incorporated into compounds of the invention include
isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur,
fluorine, chlorine, and iodine, such as .sup.2H, .sup.3H, .sup.11C,
.sup.13C, .sup.14C, .sup.13N, .sup.15N, .sup.15O, .sup.17O,
.sup.18O, .sup.32P, .sup.33P, .sup.35S, .sup.18F, .sup.36Cl,
.sup.123I, and .sup.125I, respectively. Certain
isotopically-labeled compounds of the present invention (e.g.,
those labeled with .sup.3H and .sup.14C) are useful in compound
and/or substrate tissue distribution assays. Tritiated (i.e.,
.sup.3H) and carbon-14 (i.e., .sup.14C) isotopes are useful for
their ease of preparation and detectability. Further, substitution
with heavier isotopes such as deuterium (i.e., .sup.2H) may afford
certain therapeutic advantages resulting from greater metabolic
stability (e.g., increased in vivo half-life or reduced dosage
requirements) and hence may be preferred in some circumstances.
Positron emitting isotopes such as .sup.15O, .sup.13N, .sup.11C,
and .sup.18F are useful for positron emission tomography (PET)
studies to examine substrate receptor occupancy. Isotopically
labeled compounds of the present invention can generally be
prepared by following procedures analogous to those disclosed in
the Schemes and/or in the Examples herein below, by substituting an
isotopically labeled reagent for a non-isotopically labeled
reagent.
[0026] The term "aliphatic" or "aliphatic group" or "aliphatic
chain", as used herein, means a straight-chain (i.e., unbranched)
or branched, substituted or unsubstituted hydrocarbon chain that is
completely saturated or that contains one or more units of
unsaturation. Unless otherwise specified, aliphatic groups contain
1-20 aliphatic carbon atoms. In some embodiments, aliphatic groups
contain 1-10 aliphatic carbon atoms. In other embodiments,
aliphatic groups contain 1-8 aliphatic carbon atoms. In still other
embodiments, aliphatic groups contain 1-6 aliphatic carbon atoms.
In other embodiments, aliphatic groups contain 1-4 aliphatic carbon
atoms and in yet other embodiments, aliphatic groups contain 1-3 or
1-2 aliphatic carbon atoms. Suitable aliphatic groups include, but
are not limited to, linear or branched, substituted or
unsubstituted alkyl, alkenyl, or alkynyl groups. Specific examples
of aliphatic groups include, but are not limited to: methyl, ethyl,
propyl, butyl, isopropyl, isobutyl, vinyl, sec-butyl, tert-butyl,
butenyl, propargyl, acetylene and the like. An aliphatic group will
be represented by the term "C.sub.x-y aliphatic"; wherein x and y
are the minimum and the maximum number of carbon atoms forming the
aliphatic chain.
[0027] The term "alkyl" (as in "alkyl chain" or "alkyl group"), as
used herein, refers to a saturated linear or branched-chain
monovalent hydrocarbon radical. Unless otherwise specified, an
alkyl group contains 1-20 carbon atoms (e.g., 1-20 carbon atoms,
1-10 carbon atoms, 1-8 carbon atoms, 1-6 carbon atoms, 1-4 carbon
atoms or 1-3 carbon atoms). Examples of alkyl groups include, but
are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl,
isobutyl, s-butyl (sec-butyl), t-butyl, pentyl, hexyl, heptyl,
octyl and the like. An alkyl group will be represented by the term
"C.sub.x-y alkyl"; wherein x and y are the minimum and the maximum
number of carbon atoms forming the alkyl chain.
[0028] The term "alkenyl" (as in "alkenyl chain" or "alkenyl
group"), refers to a linear or branched-chain monovalent
hydrocarbon radical with at least one site of unsaturation, i.e., a
carbon-carbon, sp.sup.2 double bond, wherein the alkenyl radical
includes radicals having "cis" and "trans" orientations, or
alternatively, "E" and "Z" orientations. Unless otherwise
specified, an alkenyl group contains 2-20 carbon atoms (e.g., 2-20
carbon atoms, 2-10 carbon atoms, 2-8 carbon atoms, 2-6 carbon
atoms, 2-4 carbon atoms or 2-3 carbon atoms). Examples include, but
are not limited to, vinyl, allyl and the like. An alkenyl group
will be represented by the term "C.sub.x-y alkenyl"; wherein x and
y are the minimum and the maximum number of carbon atoms forming
the alkenyl chain.
[0029] The term "alkynyl" (as in "alkynyl chain" or "alkynyl
group"), refers to a linear or branched monovalent hydrocarbon
radical with at least one site of unsaturation, i.e., a
carbon-carbon sp triple bond. Unless otherwise specified, an
alkynyl group contains 2-20 carbon atoms (e.g., 2-20 carbon atoms,
2-10 carbon atoms, 2-8 carbon atoms, 2-6 carbon atoms, 2-4 carbon
atoms or 2-3 carbon atoms). Examples include, but are not limited
to, ethynyl, propynyl, and the like. An alkynyl group will be
represented by the term "C.sub.x-y alkynyl"; wherein x and y are
the minimum and the maximum number of carbon atoms forming the
alkynyl chain.
[0030] The term "carbocyclic" refers to a ring system formed only
by carbon and hydrogen atoms. Unless otherwise specified,
throughout this disclosure, carbocycle is used as a synonym of
"non-aromatic carbocycle" or "cycloaliphatic". In some instances
the term could be used in the phrase "aromatic carbocycle", and in
this case it would refers to an "aryl group" as defined below.
[0031] The term "cycloaliphatic" (or "non-aromatic carbocycle",
"non-aromatic carbocyclyl", "non-aromatic carbocyclic" or
"cycloaliphatic ring") refers to a cyclic hydrocarbon that is
completely saturated or that contains one or more units of
unsaturation but which is not aromatic, and which has a single
point of attachment to the rest of the molecule. In one embodiment,
the term "cycloaliphatic" refers to a monocyclic C.sub.3-12
hydrocarbon. A cycloaliphatic ring will be represented by the term
"C.sub.x-y cycloaliphatic"; wherein x and y are the minimum and the
maximum number of carbon atoms forming the cycloaliphatic ring.
Suitable cycloaliphatic groups include, but are not limited to,
cycloalkyl, cycloalkenyl, and cycloalkynyl. Examples of aliphatic
groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl,
cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, norbornyl,
cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, and
the like.
[0032] "Cycloalkyl" or "cycloalkyl ring", as used herein, refers to
a ring system in which is completely saturated and which has a
single point of attachment to the rest of the molecule. In one
embodiment, the term "cycloalkyl" refers to a monocyclic C.sub.3-12
saturated hydrocarbon. Suitable cycloalkyl groups include, but are
not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cycloheptyl, cycloheptenyl, norbornyl, cyclooctyl, cyclononyl,
cyclodecyl, cycloundecyl, cyclododecyl, and the like. A cycloalkyl
ring will be represented by the term "C.sub.x-y cycloalkyl";
wherein x and y are the minimum and the maximum number of carbon
atoms forming the cycloalkyl ring.
[0033] "Heterocycle" (or "heterocyclyl" or "heterocyclic or
"heterocyclic ring"), as used herein, refers to a ring system in
which one or more ring members are an independently selected
heteroatom, which is completely saturated or that contains one or
more units of unsaturation but which is not aromatic, and which has
a single point of attachment to the rest of the molecule. Unless
otherwise specified, through this disclosure, heterocycle is used
as a synonym of "non-aromatic heterocycle". In some instances the
term could be used in the phrase "aromatic heterocycle", and in
this case it would refer to a "heteroaryl group" as defined below.
In some embodiments, the heterocycle has 3-10 ring members in which
one or more ring members is a heteroatom independently selected
from oxygen or nitrogen. In other embodiments, a heterocycle may be
a monocycle having 3-7 ring members (2-6 carbon atoms and 1-4
heteroatoms).
[0034] Examples of heterocyclic rings include, but are not limited
to, the following monocycles: 2-tetrahydrofuranyl,
3-tetrahydrofuranyl, 2-tetrahydrothiophenyl,
3-tetrahydrothiophenyl, 2-morpholino, 3-morpholino, 4-morpholino,
2-thiomorpholino, 3-thiomorpholino, 4-thiomorpholino,
1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl,
1-tetrahydropiperazinyl, 2-tetrahydropiperazinyl,
3-tetrahydropiperazinyl, 1-piperidinyl, 2-piperidinyl,
3-piperidinyl, 1-pyrazolinyl, 3-pyrazolinyl, 4-pyrazolinyl,
5-pyrazolinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl,
4-piperidinyl, 2-thiazolidinyl, 3-thiazolidinyl, 4-thiazolidinyl,
1-imidazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl,
5-imidazolidinyl.
[0035] The term "heteroaryl" (or "heteroaromatic" or "heteroaryl
group" or "aromatic heterocycle" or "heteroaryl ring") used alone
or as part of a larger moiety as in "heteroarylalkyl" or
"heteroarylalkoxy" refers to a ring which is aromatic and contains
one or more heteroatoms, has between 5 and 6 ring members and which
has a single point of attachment to the rest of the molecule.
Heteroaryl rings include, but are not limited to the following
monocycles: 2-furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl,
4-imidazolyl, 5-imidazolyl, 3-isoxazolyl, 4-isoxazolyl,
5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, N-pyrrolyl,
2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl,
2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, pyridazinyl (e.g.,
3-pyridazinyl), 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, tetrazolyl
(e.g., 5-tetrazolyl), triazolyl (e.g., 2-triazolyl and
5-triazolyl), 2-thienyl, 3-thienyl, pyrazolyl (e.g., 2-pyrazolyl),
isothiazolyl, 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl,
1,2,4-oxadiazolyl, 1,2,3-triazolyl, 1,2,3-thiadiazolyl,
1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, pyrazinyl,
1,3,5-triazinyl.
[0036] The term "ring atom" refers to an atom such as C, N, O or S
that is part of the ring of an aromatic ring, a cycloaliphatic
ring, a heterocyclic or a heteroaryl ring. A "substitutable ring
atom" is a ring carbon or nitrogen atom bonded to at least one
hydrogen atom. The hydrogen can be optionally replaced with a
suitable substituent group. Thus, the term "substitutable ring
atom" does not include ring nitrogen or carbon atoms which are
shared when two rings are fused. In addition, "substitutable ring
atom" does not include ring carbon or nitrogen atoms when the
structure depicts that they are already attached to one or more
moiety other than hydrogen and no hydrogens are available for
substitution.
[0037] "Heteroatom" refers to one or more of oxygen, sulfur,
nitrogen, including any oxidized form of nitrogen, sulfur, the
quaternized form of any basic nitrogen, or a substitutable nitrogen
of a heterocyclic or heteroaryl ring, for example N (as in
3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR.sup.+ (as
in N-substituted pyrrolidinyl).
[0038] In some embodiments, two independent occurrences of a
variable may be taken together with the atom(s) to which each
variable is bound to form a 5-8-membered aryl or heteroaryl ring or
a 3-8-membered cycloaliphatic ring or heterocyclyl. Exemplary rings
that are formed when two independent occurrences of a substituent
are taken together with the atom(s) to which each variable is bound
include, but are not limited to the following: a) two independent
occurrences of a substituent that are bound to the same atom and
are taken together with that atom to form a ring, where both
occurrences of the substituent are taken together with the atom to
which they are bound to form a heterocyclyl, heteroaryl,
cycloaliphatic or aryl ring, wherein the group is attached to the
rest of the molecule by a single point of attachment; and b) two
independent occurrences of a substituent that are bound to
different atoms and are taken together with both of those atoms to
form a heterocyclyl, heteroaryl, cycloaliphatic or aryl ring,
wherein the ring that is formed has two points of attachment with
the rest of the molecule.
[0039] It will be appreciated that a variety of other rings can be
formed when two independent occurrences of a substituent are taken
together with the atom(s) to which each substituent is bound and
that the examples detailed above are not intended to be
limiting.
[0040] As described herein, a bond drawn from a substituent to the
center of one ring within a multiple-ring system (as shown below),
represents substitution of the substituent at any substitutable
position in any of the rings within the multiple ring system. For
example, formula D3 represents possible substitution in any of the
positions shown in formula D4:
##STR00003##
[0041] This also applies to multiple ring systems fused to optional
ring systems (which would be represented by dotted lines). For
example, in Formula D5, X is an optional substituent both for ring
A and ring B.
##STR00004##
[0042] If, however, two rings in a multiple ring system each have
different substituents drawn from the center of each ring, then,
unless otherwise specified, each substituent only represents
substitution on the ring to which it is attached. For example, in
Formula D6, Y is an optional substituent for ring A only, and X is
an optional substituent for ring B only.
##STR00005##
[0043] As used herein, the term "alkoxy" refers to an alkyl group,
as previously defined, attached to the molecule, or to another
chain or ring, through an oxygen ("alkoxy" i.e., --O-alkyl)
atom.
[0044] As used herein, the terms "halogen" or "halo" mean F,
C.sub.1, Br, or I.
[0045] The terms "haloalkyl", "haloalkenyl", "haloaliphatic", and
"haloalkoxy" mean alkyl, alkenyl, aliphatic or alkoxy, as the case
may be, substituted with one or more halogen atoms. For example a
C.sub.1-3 haloalkyl could be --CFHCH.sub.2CHF.sub.2 and a C.sub.1-2
haloalkoxy could be --OC(Br)HCHF.sub.2. This term includes
perfluorinated alkyl groups, such as --CF.sub.3 and
--CF.sub.2CF.sub.3.
[0046] As used herein, the term "cyano" refers to --CN or
--C.ident.N.
[0047] The terms "cyanoalkyl", "cyanoalkenyl", "cyanoaliphatic",
and "cyanoalkoxy" mean alkyl, alkenyl, aliphatic or alkoxy, as the
case may be, substituted with one or more cyano groups. For example
a C.sub.1-3 cyanoalkyl could be --C(CN).sub.2CH.sub.2CH.sub.3 and a
C.sub.1-2 cyanoalkenyl could be .dbd.CHC(CN)H.sub.2.
[0048] As used herein, an "amino" group refers to --NH.sub.2.
[0049] The terms "aminoalkyl", "aminoalkenyl", "aminoaliphatic",
and "aminoalkoxy" mean alkyl, alkenyl, aliphatic or alkoxy, as the
case may be, substituted with one or more amino groups. For example
a C.sub.1-3 aminoalkyl could be
--CH(NH.sub.2)CH.sub.2CH.sub.2NH.sub.2 and a C.sub.1-2 aminoalkoxy
could be --OCH.sub.2CH.sub.2NH.sub.2.
[0050] The term "hydroxyl" or "hydroxy" refers to --OH.
[0051] The terms "hydroxyalkyl", "hydroxyalkenyl",
"hydroxyaliphatic", and "hydroxyalkoxy" mean alkyl, alkenyl,
aliphatic or alkoxy, as the case may be, substituted with one or
more --OH groups. For example a C.sub.1-3 hydroxyalkyl could be
--CH.sub.2(CH.sub.2OH)CH.sub.3 and a C.sub.4 hydroxyalkoxy could be
--OCH.sub.2C(CH.sub.3)(OH)CH.sub.3.
[0052] As used herein, a "carbonyl", used alone or in connection
with another group refers to --C(O)-- or --C(O)H. For example, as
used herein, an "alkoxycarbonyl," refers to a group such as
--C(O)O(alkyl).
[0053] As used herein, an "oxo" refers to .dbd.O, wherein oxo is
usually, but not always, attached to a carbon atom (e.g., it can
also be attached to a sulfur atom). An aliphatic chain can be
optionally interrupted by a carbonyl group or can optionally be
substituted by an oxo group, and both expressions refer to the
same: e.g. --CH.sub.2--C(O)--CH.sub.3. When an "oxo' group is
listed as a possible substituent on a ring or another moiety or
group (e.g. an alkyl chain) it will be understood that the bond
between the oxygen in said oxo group and the ring, or moiety it is
attached to will be a double bond, even though sometimes it may be
drawn generically with a single line. For example, in the example
depicted below, J.sup.D attached to the ring may be selected from a
number of different substituents. When J.sup.D is oxo, it will be
understood that the bond between J.sup.D and the ring is a double
bond. When J.sup.D is a halogen, it will be understood that the
bond between J.sup.D and the ring is a single bond. In some
instances, for example when the ring contains an unsaturation or it
has aromatic character, the compound may exist in two or more
possible tautomeric forms. In one of them the bond between the oxo
group and the ring will be a double bond. In the other one, a
hydrogen bond will be exchanged between atoms and substituents in
the ring, so that the oxo becomes a hydroxy and an additional
double bond is formed in the ring. Whereas the compound is depicted
as D7 or D8, both will be taken to represent the set of all
possible tautomers for that particular compound.
##STR00006##
could be, for example:
##STR00007##
could be, for example
##STR00008##
[0054] In all other situations, a "linker", as used herein, refers
to a divalent group in which the two free valences are on different
atoms (e.g. carbon or heteroatom) or are on the same atom but can
be substituted by two different substituents. For example, a
methylene group can be C.sub.1 alkyl linker (--CH.sub.2--) which
can be substituted by two different groups, one for each of the
free valences (e.g. as in Ph-CH.sub.2-Ph, wherein methylene acts as
a linker between two phenyl rings). Ethylene can be C.sub.2 alkyl
linker (--CH.sub.2CH.sub.2--) wherein the two free valences are on
different atoms. The amide group, for example, can act as a linker
when placed in an internal position of a chain (e.g. --CONH--). The
compounds of the invention are defined herein by their chemical
structures and/or chemical names. Where a compound is referred to
by both a chemical structure and a chemical name, and the chemical
structure and chemical name conflict, the chemical structure is
determinative of the compound's identity.
Compound Embodiments
[0055] The present invention is directed to compounds of Formula I,
or pharmaceutically acceptable salts thereof,
##STR00009##
wherein: rings E and A form the core of the molecule and are
aromatic; each instance of X and Y is independently selected from N
or C; wherein a maximum of 4 instances of X and Y are
simultaneously N; W is either i) absent, with J.sup.B connected
directly to the carbon atom bearing two J groups, each J is
independently selected from hydrogen or methyl, n is 1 and J.sup.B
is a C.sub.1-7 alkyl chain optionally substituted by up to 9
instances of fluorine; or ii) a ring B that is a phenyl, a
C.sub.3-7 cycloalkyl ring or a 5 or 6-membered heteroaryl ring,
containing 1 or 2 ring nitrogen atoms; wherein when ring B is the
phenyl or 5 or 6-membered heteroaryl ring; each J is independently
selected from hydrogen or methyl; n is an integer selected from 0
to 3; and each J.sup.B is independently selected from halogen,
--CN, a C.sub.1-6 aliphatic, --OR.sup.B or a C.sub.3-8
cycloaliphatic ring; and wherein when ring B is the C.sub.3-7
cycloalkyl ring; each J is hydrogen; n is an integer selected from
0 to 3 and each J.sup.B is independently selected from halogen,
--CN, a C.sub.1-6 aliphatic or --OR.sup.B1; wherein each J.sup.B
that is a C.sub.1-6 aliphatic and each J.sup.B that is a C.sub.3-8
cycloaliphatic ring is optionally and independently substituted
with up to 3 instances of R.sup.3; each R.sup.B is independently
selected from a C.sub.1-6 aliphatic or a C.sub.3-8 cycloaliphatic
ring; said R.sup.B optionally and independently substituted with up
to 3 instances of R.sup.3a; each R.sup.B1 is independently selected
from hydrogen, a C.sub.1-6 aliphatic or a C.sub.3-8 cycloaliphatic
ring; wherein each of said C.sub.1-6 aliphatic and each of said
C.sub.3-8 cycloaliphatic ring is optionally and independently
substituted with up to 3 instances of R.sup.3b; each R.sup.3,
R.sup.3a and R.sup.3b is, in each instance, independently selected
from halogen, --CN, C.sub.1-4 alkyl, C.sub.1-4 haloalkyl,
--O(C.sub.1-4 alkyl) or --O(C.sub.1-4 haloalkyl); p is an integer
selected from 1, 2 or 3; each J.sup.C is independently selected
from hydrogen, halogen, C.sub.1-4 aliphatic, C.sub.1-4 alkoxy or
--CN; wherein each said C.sub.1-4 aliphatic and each said C.sub.1-4
alkoxy is optionally and independently substituted by up to 3
instances of C.sub.1-4 alkoxy, C.sub.1-4 haloalkoxy, --OH or
halogen; Q, G and Z are each independently N, S or O, wherein at
least two of Q, G and Z are N; q is 0, 1 or 2; R.sup.10 is
C.sub.1-6 alkyl optionally and independently substituted with 0-3
occurrences of R.sup.15, phenyl optionally and independently
substituted with 0-3 occurrences of R.sup.15, 5- or 6-membered
heteroaryl optionally and independently substituted with 0-3
occurrences of R.sup.15, C.sub.3-8 cycloalkyl optionally and
independently substituted with 0-3 occurrences of R.sup.15 or 3-8
membered heterocyclyl optionally and independently substituted with
0-3 occurrences of R.sup.15; wherein each of said 5- to 6-membered
heteroaryl ring and each of said 3-8 membered heterocyclyl contains
up to 3 ring heteroatoms independently selected from N, O or S;
R.sup.11 is H, --NR.sup.a2R.sup.b2, --C(O)NR.sup.a2R.sup.b2,
--C(O)R.sup.15a, --SO.sub.2R.sup.b2, --SR.sup.b2, halo,
--OCF.sub.3, --CN, hydroxyl, C.sub.2-6 alkenyl optionally and
independently substituted with 0-2 occurrences of R.sup.b2,
C.sub.2-6 alkynyl optionally and independently substituted with 0-2
occurrences of R.sup.b2; C.sub.1-6 alkyl optionally and
independently substituted with 0-5 occurrences of R.sup.15,
C.sub.1-6 alkoxy optionally and independently substituted with 0-3
occurrences of R.sup.15, phenyl optionally and independently
substituted with 0-3 occurrences of R.sup.15, 5- or 6-membered
heteroaryl optionally and independently substituted with 0-3
occurrences of R.sup.15, C.sub.3-8 cycloalkyl optionally and
independently substituted with 0-3 occurrences of R.sup.15 or 3-8
membered heterocyclyl optionally and independently substituted with
0-3 occurrences of R.sup.15; wherein each of said 5- to 6-membered
heteroaryl and each of said 3-8 membered heterocyclyl contains up
to 3 ring heteroatoms independently selected from N, O or S; or
when R.sup.10 is a substituent of Z, R.sup.10 and R.sup.11, taken
together with Z and the carbon to which R.sup.11 is attached form a
3 to 10-membered heterocyclic ring optionally and independently
substituted with 0-3 occurrences of R.sup.15; wherein each of said
3 to 10 membered heterocyclyl contains up to 3 ring heteroatoms
independently selected from N, O or S; R.sup.15 is halo,
--OR.sup.b2, --SR.sup.b2, --NR.sup.a2R.sup.b2, --C(O)R.sup.b2,
--C(O)NR.sup.a2R.sup.b2, --NR.sup.b2C(O)OR.sup.b2,
--OC(O)NR.sup.a2R.sup.b2--, C.sub.2-4 alkenoxy, C.sub.3-8
cycloalkyl optionally and independently substituted with 0-3
occurrences of R.sup.18, phenyl optionally and independently
substituted with 0-3 occurrences of R.sup.18, 5- or 6-membered
heteroaryl optionally and independently substituted with 0-3
occurrences of R.sup.18 or 3-10 membered heterocyclyl optionally
and independently substituted with 0-3 occurrences of R.sup.18;
wherein each of said 3-10 membered heterocyclyl contains up to 3
ring heteroatoms independently selected from N, O or S; R.sup.15a
is C.sub.3-8 cycloalkyl optionally and independently substituted
with 0-3 occurrences of R.sup.18, phenyl optionally and
independently substituted with 0-3 occurrences of R.sup.18, 5- or
6-membered heteroaryl optionally and independently substituted with
0-3 occurrences of R.sup.18 or 3-10 membered heterocyclyl
optionally and independently substituted with 0-3 occurrences of
R.sup.18; wherein each of said 5- or 6-membered heteroaryl ring and
each of said 3-10 membered heterocyclyl contains up to 3 ring
heteroatoms independently selected from N, O or S; each R.sup.18 is
independently selected from halo, hydroxyl, C.sub.1-6 alkyl,
C.sub.1-6 alkoxy, C.sub.1-6 haloalkyl or phenyl; R.sup.a2 is
hydrogen, --C(O)R.sup.b2, C.sub.1-6 alkyl or C.sub.1-6 haloalkyl;
and R.sup.b2 is hydrogen, C.sub.1-6 alkyl or C.sub.1-6
haloalkyl.
[0056] In some embodiments of Formula I, W is absent and the
compound is one of Formula IIA, or a pharmaceutically acceptable
salt thereof:
##STR00010##
wherein J.sup.B is a C.sub.1-7 alkyl chain optionally substituted
by up to 9 instances of fluorine. In some embodiments of Formula
IIA, J.sup.B is a C.sub.1-4 alkyl chain, optionally substituted by
up to 5 instances of fluorine. In other embodiments, J.sup.B is a
C.sub.1-2 alkyl chain, optionally substituted by up to 5 instances
of fluorine. In still other instances, J.sup.B is an ethyl chain,
optionally substituted by either 3 or 5 instances of fluorine.
[0057] In some embodiments of Formula I, W is a ring B and the
compound is one of Formula IIB, or a pharmaceutically acceptable
salt thereof:
##STR00011##
In some embodiments of Formula IIB, n is an integer selected from 1
or 2 and each J.sup.B is independently selected from halogen, a
C.sub.1-4 alkyl, --OR.sup.B or --OR.sup.B1. In other embodiments,
each J.sup.B is independently selected from halogen atoms. In still
other embodiments, each J.sup.B is independently selected from
fluoro or chloro. In yet other embodiments, each J.sup.B is
fluoro.
[0058] In some embodiments of Formula IIB, each J.sup.B is a
C.sub.1-4 alkyl. In some of these embodiments, J.sup.B is ethyl or
methyl. In some embodiments, J.sup.B is methyl.
[0059] In some embodiments of Formula IIB, n is 0.
[0060] In some embodiments of Formula IIB, n is 1.
[0061] In some embodiments of Formula IIB, n is 1 and J.sup.B is
independently selected from halogen, a C.sub.1-4 alkyl, --OR.sup.B
or --OR.sup.B1. In some of these embodiments, J.sup.B is halogen.
In some embodiments, J.sup.B is chloro or fluoro. In other
embodiments, J.sup.B is fluoro. In still other embodiments, J.sup.B
is C.sub.1-4 alkyl. In still other embodiments, J.sup.B is methyl
or ethyl.
[0062] In some embodiments of Formula IIB, n is 2 and each J.sup.B
is a halogen atom. In some of these embodiments, each J.sup.B is
independently selected from chloro or fluoro. In other embodiments,
one J.sup.B is fluoro and the other J.sup.B is chloro. In still
other embodiments, each J.sup.B is fluoro.
[0063] In some embodiments of Formula IIB, ring B is phenyl. In
some of these embodiments, n is 1 or 2. In some of these
embodiments, a J.sup.B is ortho to the attachment of the methylene
linker between ring B and the core of the molecule, and the J.sup.B
is halogen. In some of these embodiments, J.sup.B is chloro. In
other embodiments, J.sup.B is fluoro.
[0064] In some embodiments of Formula IIB, ring B is a 6-membered
heteroaryl ring. In other embodiments, ring B is a pyridyl ring. In
still other embodiments, ring B is a pyrimidinyl ring.
[0065] In some embodiments of Formula IIB, ring B is a C.sub.3-7
cycloalkyl ring.
[0066] In some embodiments of Formula I, Formula IIA or Formula
IIB, G, Z and Q are each N.
[0067] In some embodiments of Formula I or Formula IIB, the
compound is one of Formula III, or a pharmaceutically acceptable
salt thereof, or any of its tautomers:
##STR00012##
[0068] In some embodiments of Formula I, Formula IIA, Formula IIB
and Formula III, R.sup.11 is H, NR.sup.a2R.sup.b2,
--C(O)NR.sup.a2R.sup.b2, --C(O)R.sup.15a, --SO.sub.2R.sup.b2,
--SR.sup.b2, halo, --OCF.sub.3, --CN, hydroxyl, C.sub.2-6 alkenyl
optionally and independently substituted with 0-2 occurrences of
R.sup.b2, C.sub.2-6 alkynyl optionally and independently
substituted with 0-2 occurrences of R.sup.b2; C.sub.1-6 alkyl
optionally and independently substituted with 0-5 occurrences of
R.sup.15, C.sub.1-6 alkoxy optionally and independently substituted
with 0-3 occurrences of R.sup.15, phenyl optionally and
independently substituted with 0-3 occurrences of R.sup.15, 5- or
6-membered heteroaryl optionally and independently substituted with
0-3 occurrences of R.sup.15, C.sub.3-8 cycloalkyl optionally and
independently substituted with 0-3 occurrences of R.sup.15 or 3-8
membered heterocyclyl optionally and independently substituted with
0-3 occurrences of R.sup.15. In some further embodiments, R.sup.11
is H or C.sub.1-6 alkyl optionally and independently substituted
with 0-5 occurrences of R.sup.15. In some further embodiments,
R.sup.11 is C.sub.1-6 alkyl optionally substituted with 0-5
occurrences of R.sup.15. In some further embodiments, R.sup.11 is
methyl optionally substituted with 0-3 occurrences of R.sup.15. In
some further embodiments, R.sup.11 is methyl optionally substituted
with 0-3 occurrences of R.sup.15, and R.sup.15 is halo (e.g.,
fluoro). In some further embodiments, R.sup.11 is methyl optionally
substituted with 0-3 occurrences of R.sup.15, and R.sup.15 is
fluoro. In some further embodiments, R.sup.11 is unsubstituted
methyl. In some further embodiments, R.sup.11 is methyl substituted
with 2 occurrences of R.sup.15. In some further embodiments,
R.sup.11 is methyl substituted with 2 occurrences of R.sup.15 and
R.sup.15 is halo. In some further embodiments, R.sup.11 is
--CF.sub.2H. In some embodiments, R.sup.11 is methyl substituted
with 3 occurrences of R.sup.15. In some embodiments, R.sup.11 is
methyl substituted with 3 occurrences of R.sup.15 and R.sup.15 is
halo. In some embodiments, R.sup.11 is --CF.sub.3.
[0069] In some embodiments of Formula I, Formula IIA, Formula IIB
and Formula III, R.sup.11 is ethyl substituted with 0-5 occurrences
of R.sup.15. In some further embodiments, R.sup.11 is ethyl
substituted with 5 occurrences of R.sup.15 and R.sup.15 is halo. In
some further embodiments, R.sup.11 is ethyl substituted with 5
occurrences of R.sup.15 and R.sup.15 is fluoro.
[0070] In some embodiments of Formula III, n is an integer selected
from 1 or 2 and each J.sup.B is independently selected from
halogen, a C.sub.1-4 alkyl, --OR.sup.B or --OR.sup.B1. In other
embodiments, each J.sup.B is independently selected from halogen
atoms. In still other embodiments, each J.sup.B is independently
selected from fluoro or chloro. In yet other embodiments, each
J.sup.B is fluoro.
[0071] In some embodiments of Formula III, each J.sup.B is a
C.sub.1-4 alkyl. In some of these embodiments, J.sup.B is ethyl or
methyl. In some embodiments, J.sup.B is methyl.
[0072] In some embodiments of Formula III, n is 0.
[0073] In some embodiments of Formula III, n is 1.
[0074] In some embodiments of Formula III, n is 1 and each J.sup.B
is independently selected from halogen, a C.sub.1-4 alkyl,
--OR.sup.B or --OR.sup.B1. In some of these embodiments, J.sup.B is
halogen. In some embodiments, J.sup.B is chloro or fluoro. In other
embodiments, J.sup.B is fluoro. In still other embodiments, J.sup.B
is C.sub.1-4 alkyl. In still other embodiments, J.sup.B is methyl
or ethyl.
[0075] In some embodiments of Formula III, n is 2 and each J.sup.B
is a halogen atom. In some of these embodiments, each J.sup.B is
independently selected from chloro or fluoro. In other embodiments,
one J.sup.B is fluoro and the other J.sup.B is chloro. In still
other embodiments, each J.sup.B is fluoro.
[0076] In some embodiments of Formula III, ring B is phenyl. In
some of these embodiments, n is 1 or 2. In some of these
embodiments, a J.sup.B is ortho to the attachment of the methylene
linker between ring B and the core of the molecule, and the J.sup.B
is halogen. In some of these embodiments, J.sup.B is chloro. In
other embodiments, J.sup.B is fluoro.
[0077] In some embodiments of Formula III, ring B is a 6-membered
heteroaryl ring. In other embodiments, ring B is a pyridyl ring. In
still other embodiments, ring B is a pyrimidinyl ring.
[0078] In some embodiments of Formula III, ring B is a C.sub.3-7
cycloalkyl ring.
[0079] In some embodiments of Formula I, Formula IIA, Formula IIB
and Formula III, q is 0. In some of these embodiments, R.sup.11 is
C.sub.1-6 alkyl optionally and independently substituted with 0-3
occurrences of R.sup.15. In some further embodiments, R.sup.11 is
methyl optionally and independently substituted with 0-3
occurrences of R.sup.15 and R.sup.15 is halo (e.g., fluoro). In
some further embodiments, R.sup.11 is methyl independently
substituted with 2 occurrences of R.sup.15 and R.sup.15 is halo
(e.g., fluoro). In some embodiments, R.sup.11 is methyl
independently substituted with 3 occurrences of R.sup.15 and
R.sup.15 is halo (e.g., fluoro).
[0080] In some embodiments of Formula I, Formula IIA, Formula IIB
and Formula III, the core formed by rings E and A is selected
from:
##STR00013## ##STR00014##
wherein the C atom with a symbol * represents the attachment point
to the ring containing G, Z, and Q and the C atom with a symbol **
represents the point of attachment of the 2 instances of J. In some
of these embodiments, each instance of J.sup.C is hydrogen.
[0081] In some embodiments of Formula I, Formula IIA, Formula IIB
and Formula III, the core formed by rings E and A is selected
from:
##STR00015##
In some of these embodiments, each instance of J.sup.C is
hydrogen.
[0082] In some embodiments of Formula I, Formula IIA, Formula IIB
and Formula III, Q, G and Z are each independently N, NH, S or O,
wherein at least two of Q, G and Z are N or NH.
[0083] In some embodiments of Formula I, the compound is one of
Formula IV, or a pharmaceutically acceptable salt thereof:
##STR00016##
wherein: Each Y is independently selected from N, NJ.sup.c, CH, or
CJ.sup.c; Each X is either N, NJ.sup.c, CH, or CJ.sup.c; wherein a
maximum of 3 instances of X and Y are simultaneously N or NJ.sup.c;
J.sup.c is halo, CN, or C.sub.1-3alkyl optionally substituted with
1 to 3 halo; Each J.sup.B is independently selected from halo or
C.sub.1-4 alkyl; n is 0, 1, 2, or 3; R.sup.10 is C.sub.1-4 alkyl
optionally substituted with 1, 2, or 3 groups independently
selected from halo, --C(O)R.sup.b2, phenyl, and 5- or 6-membered
heteroaryl, wherein the phenyl and 5- or 6-membered heteroaryl are
optionally substituted with 1, 2, or 3 halo or C.sub.1-4 alkyl,
wherein the heteroaryl includes 1, 2, or 3 heteroatoms
independently selected from N, O, and S; q is 0 or 1; R.sup.11 is
H, halo, --NR.sup.a2R.sup.b2, C.sub.1-4alkyl, 5- to 6-membered
heteroaryl, or C.sub.3-6 cycloalkyl, wherein the C.sub.1-4 alkyl,
5- to 6-membered heteroaryl, and C.sub.3-6 cycloalkyl are each
optionally substituted with 1, 2, or 3 groups independently
selected from halo, wherein the heteroaryl includes 1, 2, or 3
heteroatoms independently selected from N, O, and S; R.sup.a2 is
hydrogen or C.sub.1-4 alkyl; and R.sup.b2 is hydrogen or C.sub.1-4
alkyl.
[0084] In some embodiments of Formula I, the compound is one of
Formula V, or a pharmaceutically acceptable salt thereof:
##STR00017##
Wherein:
Y is N or CH;
[0085] Each J.sup.B is independently selected from halo or
C.sub.1-4 alkyl; n is 0, 1, 2, or 3; R.sup.11 is H, halo,
--NR.sup.a2R.sup.b2, C.sub.1-4alkyl, 5- to 6-membered heteroaryl,
or C.sub.3-6 cycloalkyl, wherein the C.sub.1-4 alkyl, 5- to
6-membered heteroaryl, and C.sub.3-6 cycloalkyl are each optionally
substituted with 1, 2, or 3 groups independently selected from
halo; R.sup.a2 is hydrogen or C.sub.1-4 alkyl; and R.sup.b2 is
hydrogen or C.sub.1-4 alkyl.
[0086] In some embodiments of Formula I, the compound is one of
Formula VI, or a pharmaceutically acceptable salt thereof:
##STR00018##
Wherein:
Y is N or CH;
[0087] Each J.sup.B is independently selected from halo or
C.sub.1-4 alkyl; n is 0, 1, 2, or 3; R.sup.11 is H, halo,
--NR.sup.a2R.sup.b2, C.sub.1-4alkyl, 5- to 6-membered heteroaryl,
or C.sub.3-6 cycloalkyl, wherein the C.sub.1-4 alkyl, 5- to
6-membered heteroaryl, and C.sub.3-6 cycloalkyl are each optionally
substituted with 1, 2, or 3 groups independently selected from
halo; R.sup.a2 is hydrogen or C.sub.1-4 alkyl; and R.sup.b2 is
hydrogen or C.sub.1-4 alkyl.
[0088] In some embodiments of Formulas IV, V and VI, R.sup.11 is
C.sub.1-4 alkyl optionally substituted with 1, 2, or 3 halo.
[0089] In some embodiments, the compounds of Formula I are selected
from those listed in Table I.
TABLE-US-00001 TABLE I ##STR00019## I-1 ##STR00020## I-2
##STR00021## I-3 ##STR00022## I-4 ##STR00023## I-5 ##STR00024## I-6
##STR00025## I-7 ##STR00026## I-8 ##STR00027## I-9 ##STR00028##
I-10 ##STR00029## I-11 ##STR00030## I-12 ##STR00031## I-13
##STR00032## I-14 ##STR00033## I-15 ##STR00034## I-16 ##STR00035##
I-17 ##STR00036## I-18 ##STR00037## I-19 ##STR00038## I-20
##STR00039## I-21 ##STR00040## I-22 ##STR00041## I-23 ##STR00042##
I-24 ##STR00043## I-25 ##STR00044## I-26 ##STR00045## I-27
##STR00046## I-28 ##STR00047## I-29 ##STR00048## I-30 ##STR00049##
I-31 ##STR00050## I-32 ##STR00051## I-33 ##STR00052## I-34
##STR00053## I-35 ##STR00054## I-36 ##STR00055## I-37 ##STR00056##
I-38 ##STR00057## I-39 ##STR00058## I-41 ##STR00059## I-42
##STR00060## I-47 ##STR00061## I-48 ##STR00062## I-50 ##STR00063##
I-51 ##STR00064## I-53 ##STR00065## I-54 ##STR00066## I-56
##STR00067## I-57 ##STR00068## I-58 ##STR00069## I-59 ##STR00070##
I-60 ##STR00071## I-62 ##STR00072## I-63 ##STR00073## I-64
##STR00074## I-65 ##STR00075## I-66 ##STR00076## I-67 ##STR00077##
I-68 ##STR00078## I-70 ##STR00079## I-71 ##STR00080## I-72
In some embodiments, the compound of Formula I is either in its
neutral form or as a pharmaceutically acceptable salt.
Pharmaceutically Acceptable Salts of the Invention.
[0090] The phrase "pharmaceutically acceptable salt," as used
herein, refers to pharmaceutically acceptable organic or inorganic
salts of a compound of Formula I. The pharmaceutically acceptable
salts of a compound of Formula I are used in medicine. Salts that
are not pharmaceutically acceptable may, however, be useful in the
preparation of a compound of Formula I or of their pharmaceutically
acceptable salts. A pharmaceutically acceptable salt may involve
the inclusion of another molecule such as an acetate ion, a
succinate ion or other counter ion. The counter ion may be any
organic or inorganic moiety that stabilizes the charge on the
parent compound. Furthermore, a pharmaceutically acceptable salt
may have more than one charged atom in its structure. Instances
where multiple charged atoms are part of the pharmaceutically
acceptable salt can have multiple counter ions. Hence, a
pharmaceutically acceptable salt can have one or more charged atoms
and/or one or more counter ion.
[0091] Pharmaceutically acceptable salts of the compounds described
herein include those derived from the compounds with inorganic
acids, organic acids or bases. In some embodiments, the salts can
be prepared in situ during the final isolation and purification of
the compounds. In other embodiments the salts can be prepared from
the free form of the compound in a separate synthetic step.
[0092] When a compound of Formula I is acidic or contains a
sufficiently acidic bioisostere, suitable "pharmaceutically
acceptable salts" refers to salts prepared from pharmaceutically
acceptable non-toxic bases including inorganic bases and organic
bases. Salts derived from inorganic bases include aluminum,
ammonium, calcium, copper, ferric, ferrous, lithium, magnesium,
manganic salts, manganous, potassium, sodium, zinc and the like.
Particular embodiments include ammonium, calcium, magnesium,
potassium and sodium salts. Salts derived from pharmaceutically
acceptable organic non-toxic bases include salts of primary,
secondary and tertiary amines, substituted amines including
naturally occurring substituted amines, cyclic amines and basic ion
exchange resins, such as arginine, betaine, caffeine, choline, N,
N'dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol,
2-dimethylaminoethanol, ethanolamine, ethylenediamine,
N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine,
histidine, hydrabamine, isopropylamine, lysine, methylglucamine,
morpholine, piperazine, piperidine, polyamine resins, procaine,
purines, theobromine, triethylamine, trimethylamine tripropylamine,
tromethamine and the like.
[0093] When a compound of Formula I is basic or contains a
sufficiently basic bioisostere, salts may be prepared from
pharmaceutically acceptable non-toxic acids, including inorganic
and organic acids. Such acids include acetic, benzenesulfonic,
benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric,
gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic,
maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic,
pantothenic, phosphoric, succinic, sulfuric, tartaric,
p-toluenesulfonic acid and the like. Particular embodiments include
citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric and
tartaric acids. Other exemplary salts include, but are not limited,
to sulfate, citrate, acetate, oxalate, chloride, bromide, iodide,
nitrate, bisulfate, phosphate, acid phosphate, isonicotinate,
lactate, salicylate, acid citrate, tartrate, oleate, tannate,
pantothenate, bitartrate, ascorbate, succinate, maleate,
gentisinate, fumarate, gluconate, glucuronate, saccharate, formate,
benzoate, glutamate, methanesulfonate, ethanesulfonate,
benzenesulfonate, p-toluenesulfonate, and pamoate (i.e.,
1,1'-methylene-bis-(2-hydroxy-3-naphthoate)) salts.
[0094] The preparation of the pharmaceutically acceptable salts
described above and other typical pharmaceutically acceptable salts
is more fully described by Berg et al., "Pharmaceutical Salts," J.
Pharm. Sci., 1977:66:1-19, incorporated here by reference in its
entirety.
[0095] In addition to the compounds described herein, their
pharmaceutically acceptable salts may also be employed in
compositions to treat or prevent the herein identified
disorders.
Pharmaceutical Compositions and Methods of Administration.
[0096] The compounds herein disclosed, and their pharmaceutically
acceptable salts thereof may be formulated as pharmaceutical
compositions or "formulations".
[0097] A typical formulation is prepared by mixing a compound of
Formula I, or a pharmaceutically acceptable salt thereof, and a
carrier, diluent or excipient. Suitable carriers, diluents and
excipients are well known to those skilled in the art and include
materials such as carbohydrates, waxes, water soluble and/or
swellable polymers, hydrophilic or hydrophobic materials, gelatin,
oils, solvents, water, and the like. The particular carrier,
diluent or excipient used will depend upon the means and purpose
for which a compound of Formula I is being formulated. Solvents are
generally selected based on solvents recognized by persons skilled
in the art as safe (GRAS-Generally Regarded as Safe) to be
administered to a mammal. In general, safe solvents are non-toxic
aqueous solvents such as water and other non-toxic solvents that
are soluble or miscible in water. Suitable aqueous solvents include
water, ethanol, propylene glycol, polyethylene glycols (e.g.,
PEG400, PEG300), etc. and mixtures thereof. The formulations may
also include other types of excipients such as one or more buffers,
stabilizing agents, antiadherents, surfactants, wetting agents,
lubricating agents, emulsifiers, binders, suspending agents,
disintegrants, fillers, sorbents, coatings (e.g. enteric or slow
release) preservatives, antioxidants, opaquing agents, glidants,
processing aids, colorants, sweeteners, perfuming agents, flavoring
agents and other known additives to provide an elegant presentation
of the drug (i.e., a compound of Formula I or pharmaceutical
composition thereof) or aid in the manufacturing of the
pharmaceutical product (i.e., medicament).
[0098] The formulations may be prepared using conventional
dissolution and mixing procedures. For example, the bulk drug
substance (i.e., a compound of Formula I, a pharmaceutically
acceptable salt thereof, or a stabilized form of the compound, such
as a complex with a cyclodextrin derivative or other known
complexation agent) is dissolved in a suitable solvent in the
presence of one or more of the excipients described above. A
compound having the desired degree of purity is optionally mixed
with pharmaceutically acceptable diluents, carriers, excipients or
stabilizers, in the form of a lyophilized formulation, milled
powder, or an aqueous solution. Formulation may be conducted by
mixing at ambient temperature at the appropriate pH, and at the
desired degree of purity, with physiologically acceptable carriers.
The pH of the formulation depends mainly on the particular use and
the concentration of compound, but may range from about 3 to about
8. When the agent described herein is a solid amorphous dispersion
formed by a solvent process, additives may be added directly to the
spray-drying solution when forming the mixture such as the additive
is dissolved or suspended in the solution as a slurry which can
then be spray dried. Alternatively, the additives may be added
following spray-drying process to aid in the forming of the final
formulated product.
[0099] The compound of Formula I or a pharmaceutically acceptable
salt thereof is typically formulated into pharmaceutical dosage
forms to provide an easily controllable dosage of the drug and to
enable patient compliance with the prescribed regimen.
Pharmaceutical formulations of a compound of Formula I, or a
pharmaceutically acceptable salt thereof, may be prepared for
various routes and types of administration. Various dosage forms
may exist for the same compound, since different medical conditions
may warrant different routes of administration.
[0100] The amount of active ingredient that may be combined with
the carrier material to produce a single dosage form will vary
depending upon the subject treated and the particular mode of
administration. For example, a time-release formulation intended
for oral administration to humans may contain approximately 1 to
1000 mg of active material compounded with an appropriate and
convenient amount of carrier material which may vary from about 5
to about 95% of the total compositions (weight: weight). The
pharmaceutical composition can be prepared to provide easily
measurable amounts for administration. For example, an aqueous
solution intended for intravenous infusion may contain from about 3
to 500 .mu.g of the active ingredient per milliliter of solution in
order that infusion of a suitable volume at a rate of about 30
mL/hr can occur. As a general proposition, the initial
pharmaceutically effective amount of the inhibitor administered
will be in the range of about 0.01-100 mg/kg per dose, namely about
0.1 to 20 mg/kg of patient body weight per day, with the typical
initial range of compound used being 0.3 to 15 mg/kg/day.
[0101] The term "therapeutically effective amount" as used herein
means that amount of active compound or pharmaceutical agent that
elicits the biological or medicinal response in a tissue, system,
animal or human that is being sought by a researcher, veterinarian,
medical doctor or other clinician. The therapeutically or
pharmaceutically effective amount of the compound to be
administered will be governed by such considerations, and is the
minimum amount necessary to ameliorate, cure or treat the disease
or disorder or one or more of its symptoms.
[0102] The pharmaceutical compositions of Formula I will be
formulated, dosed, and administered in a fashion, i.e., amounts,
concentrations, schedules, course, vehicles, and route of
administration, consistent with good medical practice. Factors for
consideration in this context include the particular disorder being
treated, the particular mammal being treated, the clinical
condition of the individual patient, the cause of the disorder, the
site of delivery of the agent, the method of administration, the
scheduling of administration, and other factors known to medical
practitioners, such as the age, weight, and response of the
individual patient.
[0103] The term "prophylactically effective amount" refers to an
amount effective in preventing or substantially lessening the
chances of acquiring a disease or disorder or in reducing the
severity of the disease or disorder before it is acquired or
reducing the severity of one or more of its symptoms before the
symptoms develop. Roughly, prophylactic measures are divided
between primary prophylaxis (to prevent the development of a
disease) and secondary prophylaxis (whereby the disease has already
developed and the patient is protected against worsening of this
process).
[0104] Acceptable diluents, carriers, excipients, and stabilizers
are those that are nontoxic to recipients at the dosages and
concentrations employed, and include buffers such as phosphate,
citrate, and other organic acids; antioxidants including ascorbic
acid and methionine; preservatives (such as octadecyldimethylbenzyl
ammonium chloride; hexamethonium chloride; benzalkonium chloride,
benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl
parabens such as methyl or propyl paraben; catechol; resorcinol;
cyclohexanol; 3-pentanol; and m-cresol); proteins, such as serum
albumin, gelatin, or immunoglobulins; hydrophilic polymers such as
polyvinylpyrrolidone; amino acids such as glycine, glutamine,
asparagine, histidine, arginine, or lysine; monosaccharides,
disaccharides, and other carbohydrates including glucose, mannose,
or dextrins; chelating agents such as EDTA; sugars such as sucrose,
mannitol, trehalose or sorbitol; salt-forming counter-ions such as
sodium; metal complexes (e.g. Zn-protein complexes); and/or
non-ionic surfactants such as TWEEN.TM., PLURONICS.TM. or
polyethylene glycol (PEG). The active pharmaceutical ingredients
may also be entrapped in microcapsules prepared, for example, by
coacervation techniques or by interfacial polymerization, e.g.,
hydroxymethylcellulose or gelatin-microcapsules and
poly-(methylmethacylate) microcapsules, respectively; in colloidal
drug delivery systems (for example, liposomes, albumin
microspheres, microemulsions, nanoparticles and nanocapsules) or in
macroemulsions. Such techniques are disclosed in Remington's: The
Science and Practice of Pharmacy, 21.sup.st Edition, University of
the Sciences in Philadelphia, Eds., 2005 (hereafter
"Remington's").
[0105] "Controlled drug delivery systems" supply the drug to the
body in a manner precisely controlled to suit the drug and the
conditions being treated. The primary aim is to achieve a
therapeutic drug concentration at the site of action for the
desired duration of time. The term "controlled release" is often
used to refer to a variety of methods that modify release of drug
from a dosage form. This term includes preparations labeled as
"extended release", "delayed release", "modified release" or
"sustained release". In general, one can provide for controlled
release of the agents described herein through the use of a wide
variety of polymeric carriers and controlled release systems
including erodible and non-erodible matrices, osmotic control
devices, various reservoir devices, enteric coatings and
multiparticulate control devices.
[0106] "Sustained-release preparations" are the most common
applications of controlled release. Suitable examples of
sustained-release preparations include semipermeable matrices of
solid hydrophobic polymers containing the compound, which matrices
are in the form of shaped articles, e.g. films, or microcapsules.
Examples of sustained-release matrices include polyesters,
hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or
poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919),
copolymers of L-glutamic acid and gamma-ethyl-L-glutamate,
non-degradable ethylene-vinyl acetate, degradable lactic
acid-glycolic acid copolymers, and poly-D-(-)-3-hydroxybutyric
acid.
[0107] "Immediate-release preparations" may also be prepared. The
objective of these formulations is to get the drug into the
bloodstream and to the site of action as rapidly as possible. For
instance, for rapid dissolution, most tablets are designed to
undergo rapid disintegration to granules and subsequent
deaggregation to fine particles. This provides a larger surface
area exposed to the dissolution medium, resulting in a faster
dissolution rate.
[0108] Agents described herein can be incorporated into an erodible
or non-erodible polymeric matrix controlled release device. By an
erodible matrix is meant aqueous-erodible or water-swellable or
aqueous-soluble in the sense of being either erodible or swellable
or dissolvable in pure water or requiring the presence of an acid
or base to ionize the polymeric matrix sufficiently to cause
erosion or dissolution. When contacted with the aqueous environment
of use, the erodible polymeric matrix imbibes water and forms an
aqueous-swollen gel or matrix that entraps the agent described
herein. The aqueous-swollen matrix gradually erodes, swells,
disintegrates or dissolves in the environment of use, thereby
controlling the release of a compound described herein to the
environment of use. One ingredient of this water-swollen matrix is
the water-swellable, erodible, or soluble polymer, which may
generally be described as an osmopolymer, hydrogel or
water-swellable polymer. Such polymers may be linear, branched, or
cross linked. The polymers may be homopolymers or copolymers. In
certain embodiments, they may be synthetic polymers derived from
vinyl, acrylate, methacrylate, urethane, ester and oxide monomers.
In other embodiments, they can be derivatives of naturally
occurring polymers such as polysaccharides (e.g. chitin, chitosan,
dextran and pullulan; gum agar, gum arabic, gum karaya, locust bean
gum, gum tragacanth, carrageenans, gum ghatti, guar gum, xanthan
gum and scleroglucan), starches (e.g. dextrin and maltodextrin),
hydrophilic colloids (e.g. pectin), phosphatides (e.g. lecithin),
alginates (e.g. ammonium alginate, sodium, potassium or calcium
alginate, propylene glycol alginate), gelatin, collagen, and
cellulosics. Cellulosics are cellulose polymer that has been
modified by reaction of at least a portion of the hydroxyl groups
on the saccharide repeat units with a compound to form an
ester-linked or an ether-linked substituent. For example, the
cellulosic ethyl cellulose has an ether linked ethyl substituent
attached to the saccharide repeat unit, while the cellulosic
cellulose acetate has an ester linked acetate substituent. In
certain embodiments, the cellulosics for the erodible matrix
comprises aqueous-soluble and aqueous-erodible cellulosics can
include, for example, ethyl cellulose (EC), methylethyl cellulose
(MEC), carboxymethyl cellulose (CMC), CMEC, hydroxyethyl cellulose
(HEC), hydroxypropyl cellulose (HPC), cellulose acetate (CA),
cellulose propionate (CP), cellulose butyrate (CB), cellulose
acetate butyrate (CAB), CAP, CAT, hydroxypropyl methyl cellulose
(HPMC), HPMCP, HPMCAS, hydroxypropyl methyl cellulose acetate
trimellitate (HPMCAT), and ethylhydroxy ethylcellulose (EHEC). In
certain embodiments, the cellulosics comprises various grades of
low viscosity (MW less than or equal to 50,000 daltons, for
example, the Dow Methocel.TM. series E5, E15LV, E50LV and K100LY)
and high viscosity (MW greater than 50,000 daltons, for example,
E4MCR, E10MCR, K4M, K15M and K100M and the Methocel.TM. K series)
HPMC. Other commercially available types of HPMC include the Shin
Etsu Metolose 90SH series.
[0109] Other materials useful as the erodible matrix material
include, but are not limited to, pullulan, polyvinyl pyrrolidone,
polyvinyl alcohol, polyvinyl acetate, glycerol fatty acid esters,
polyacrylamide, polyacrylic acid, copolymers of ethacrylic acid or
methacrylic acid (EUDRAGIT.RTM., Rohm America, Inc., Piscataway,
N.J.) and other acrylic acid derivatives such as homopolymers and
copolymers of butylmethacrylate, methylmethacrylate,
ethylmethacrylate, ethylacrylate, (2-dimethylaminoethyl)
methacrylate, and (trimethylaminoethyl) methacrylate chloride.
[0110] Alternatively, the agents of the present invention may be
administered by or incorporated into a non-erodible matrix device.
In such devices, an agent described herein is distributed in an
inert matrix. The agent is released by diffusion through the inert
matrix. Examples of materials suitable for the inert matrix include
insoluble plastics (e.g., methyl acrylate-methyl methacrylate
copolymers, polyvinyl chloride, polyethylene), hydrophilic polymers
(e.g. ethyl cellulose, cellulose acetate, cross linked
polyvinylpyrrolidone (also known as crospovidone)), and fatty
compounds (e.g. carnauba wax, microcrystalline wax, and
triglycerides). Such devices are described further in Remington:
The Science and Practice of Pharmacy, 20th edition (2000).
[0111] As noted above, the agents described herein may also be
incorporated into an osmotic control device. Such devices generally
include a core containing one or more agents as described herein
and a water permeable, non-dissolving and non-eroding coating
surrounding the core which controls the influx of water into the
core from an aqueous environment of use so as to cause drug release
by extrusion of some or all of the core to the environment of use.
In certain embodiments, the coating is polymeric,
aqueous-permeable, and has at least one delivery port. The core of
the osmotic device optionally includes an osmotic agent which acts
to imbibe water from the surrounding environment via such a
semi-permeable membrane. The osmotic agent contained in the core of
this device may be an aqueous-swellable hydrophilic polymer or it
may be an osmogen, also known as an osmagent. Pressure is generated
within the device which forces the agent(s) out of the device via
an orifice (of a size designed to minimize solute diffusion while
preventing the build-up of a hydrostatic pressure head). Non
limiting examples of osmotic control devices are disclosed in U.S.
patent application Ser. No. 09/495,061.
[0112] The amount of water-swellable hydrophilic polymers present
in the core may range from about 5 to about 80 wt % (including for
example, 10 to 50 wt %). Non limiting examples of core materials
include hydrophilic vinyl and acrylic polymers, polysaccharides
such as calcium alginate, polyethylene oxide (PEO), polyethylene
glycol (PEG), polypropylene glycol (PPG), poly (2-hydroxyethyl
methacrylate), poly (acrylic) acid, poly (methacrylic) acid,
polyvinylpyrrolidone (PVP) and cross linked PVP, polyvinyl alcohol
(PVA), PVA/PVP copolymers and PVA/PVP copolymers with hydrophobic
monomers such as methyl methacrylate, vinyl acetate, and the like,
hydrophilic polyurethanes containing large PEO blocks, sodium
croscarmellose, carrageenan, hydroxyethyl cellulose (HEC),
hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose
(HPMC), carboxymethyl cellulose (CMC) and carboxyethyl cellulose
(CEC), sodium alginate, polycarbophil, gelatin, xanthan gum, and
sodium starch glycolate. Other materials include hydrogels
comprising interpenetrating networks of polymers that may be formed
by addition or by condensation polymerization, the components of
which may comprise hydrophilic and hydrophobic monomers such as
those just mentioned. Water-swellable hydrophilic polymers include
but are not limited to PEO, PEG, PVP, sodium croscarmellose, HPMC,
sodium starch glycolate, polyacrylic acid and cross linked versions
or mixtures thereof.
[0113] The core may also include an osmogen (or osmagent). The
amount of osmogen present in the core may range from about 2 to
about 70 wt % (including, for example, from 10 to 50 wt %). Typical
classes of suitable osmogens are water-soluble organic acids, salts
and sugars that are capable of imbibing water to thereby effect an
osmotic pressure gradient across the barrier of the surrounding
coating. Typical useful osmogens include but are not limited to
magnesium sulfate, magnesium chloride, calcium chloride, sodium
chloride, lithium chloride, potassium sulfate, sodium carbonate,
sodium sulfite, lithium sulfate, potassium chloride, sodium
sulfate, mannitol, xylitol, urea, sorbitol, inositol, raffinose,
sucrose, glucose, fructose, lactose, citric acid, succinic acid,
tartaric acid, and mixtures thereof. In certain embodiments, the
osmogen is glucose, lactose, sucrose, mannitol, xylitol, sodium
chloride, including combinations thereof.
[0114] The rate of drug delivery is controlled by such factors as
the permeability and thickness of the coating, the osmotic pressure
of the drug-containing layer, the degree of hydrophilicity of the
hydrogel layer, and the surface area of the device. Those skilled
in the art will appreciate that increasing the thickness of the
coating will reduce the release rate, while any of the following
will increase the release rate: increasing the permeability of the
coating; increasing the hydrophilicity of the hydrogel layer;
increasing the osmotic pressure of the drug-containing layer; or
increasing the device's surface area.
[0115] In certain embodiments, entrainment of particles of agents
described herein in the extruding fluid during operation of such
osmotic device is desirable. For the particles to be well
entrained, the agent drug form is dispersed in the fluid before the
particles have an opportunity to settle in the tablet core. One
means of accomplishing this is by adding a disintegrant that serves
to break up the compressed core into its particulate components.
Non limiting examples of standard disintegrants include materials
such as sodium starch glycolate (e. g., Explotab.TM. CLV),
microcrystalline cellulose (e. g., Avicel.TM.), microcrystalline
silicified cellulose (e. g., ProSolv.TM.) and croscarmellose sodium
(e. g., Ac-Di-Sol.TM.), and other disintegrants known to those
skilled in the art. Depending upon the particular formulation, some
disintegrants work better than others. Several disintegrants tend
to form gels as they swell with water, thus hindering drug delivery
from the device. Non-gelling, non-swelling disintegrants provide a
more rapid dispersion of the drug particles within the core as
water enters the core. In certain embodiments, non-gelling,
non-swelling disintegrants are resins, for example, ion-exchange
resins. In one embodiment, the resin is Amberlite.TM. IRP 88
(available from Rohm and Haas, Philadelphia, Pa.). When used, the
disintegrant is present in amounts ranging from about 1-25% of the
core agent.
[0116] Another example of an osmotic device is an osmotic capsule.
The capsule shell or portion of the capsule shell can be
semipermeable. The capsule can be filled either by a powder or
liquid consisting of an agent described herein, excipients that
imbibe water to provide osmotic potential, and/or a water-swellable
polymer, or optionally solubilizing excipients. The capsule core
can also be made such that it has a bilayer or multilayer agent
analogous to the bilayer, trilayer or concentric geometries
described above.
[0117] Another class of osmotic device useful in this invention
comprises coated swellable tablets, for example, as described in
EP378404. Coated swellable tablets comprise a tablet core
comprising an agent described herein and a swelling material,
preferably a hydrophilic polymer, coated with a membrane, which
contains holes, or pores through which, in the aqueous use
environment, the hydrophilic polymer can extrude and carry out the
agent. Alternatively, the membrane may contain polymeric or low
molecular weight water-soluble porosigens. Porosigens dissolve in
the aqueous use environment, providing pores through which the
hydrophilic polymer and agent may extrude. Examples of porosigens
are water-soluble polymers such as HPMC, PEG, and low molecular
weight compounds such as glycerol, sucrose, glucose, and sodium
chloride. In addition, pores may be formed in the coating by
drilling holes in the coating using a laser or other mechanical
means. In this class of osmotic devices, the membrane material may
comprise any film-forming polymer, including polymers which are
water permeable or impermeable, providing that the membrane
deposited on the tablet core is porous or contains water-soluble
porosigens or possesses a macroscopic hole for water ingress and
drug release. Embodiments of this class of sustained release
devices may also be multilayered, as described, for example, in
EP378404.
[0118] When an agent described herein is a liquid or oil, such as a
lipid vehicle formulation, for example as described in WO05/011634,
the osmotic controlled-release device may comprise a soft-gel or
gelatin capsule formed with a composite wall and comprising the
liquid formulation where the wall comprises a barrier layer formed
over the external surface of the capsule, an expandable layer
formed over the barrier layer, and a semipermeable layer formed
over the expandable layer. A delivery port connects the liquid
formulation with the aqueous use environment. Such devices are
described, for example, in U.S. Pat. Nos. 6,419,952, 6,342,249,
5,324,280, 4,672,850, 4,627,850, 4,203,440, and 3,995,631.
[0119] As further noted above, the agents described herein may be
provided in the form of microparticulates, generally ranging in
size from about 10 .mu.m to about 2 mm (including, for example,
from about 100 .mu.m to 1 mm in diameter). Such multiparticulates
may be packaged, for example, in a capsule such as a gelatin
capsule or a capsule formed from an aqueous-soluble polymer such as
HPMCAS, HPMC or starch; dosed as a suspension or slurry in a
liquid; or they may be formed into a tablet, caplet, or pill by
compression or other processes known in the art. Such
multiparticulates may be made by any known process, such as wet-
and dry-granulation processes, extrusion/spheronization,
roller-compaction, melt-congealing, or by spray-coating seed cores.
For example, in wet- and dry-granulation processes, the agent
described herein and optional excipients may be granulated to form
multiparticulates of the desired size.
[0120] The agents can be incorporated into microemulsions, which
generally are thermodynamically stable, isotropically clear
dispersions of two immiscible liquids, such as oil and water,
stabilized by an interfacial film of surfactant molecules
(Encyclopedia of Pharmaceutical Technology, New York: Marcel
Dekker, 1992, volume 9). For the preparation of microemulsions,
surfactant (emulsifier), co-surfactant (co-emulsifier), an oil
phase and a water phase are necessary. Suitable surfactants include
any surfactants that are useful in the preparation of emulsions,
e.g., emulsifiers that are typically used in the preparation of
creams. The co-surfactant (or "co-emulsifier") is generally
selected from the group of polyglycerol derivatives, glycerol
derivatives and fatty alcohols. Preferred emulsifier/co-emulsifier
combinations are generally although not necessarily selected from
the group consisting of: glyceryl monostearate and polyoxyethylene
stearate; polyethylene glycol and ethylene glycol palmitostearate;
and caprilic and capric triglycerides and oleoyl
macrogolglycerides. The water phase includes not only water but
also, typically, buffers, glucose, propylene glycol, polyethylene
glycols, preferably lower molecular weight polyethylene glycols
(e.g., PEG 300 and PEG 400), and/or glycerol, and the like, while
the oil phase will generally comprise, for example, fatty acid
esters, modified vegetable oils, silicone oils, mixtures of mono-
di- and triglycerides, mono- and di-esters of PEG (e.g., oleoyl
macrogol glycerides), etc.
[0121] The compounds described herein can be incorporated into
pharmaceutically-acceptable nanoparticle, nanosphere, and
nanocapsule formulations (Delie and Blanco-Prieto, 2005, Molecule
10:65-80). Nanocapsules can generally entrap compounds in a stable
and reproducible way. To avoid side effects due to intracellular
polymeric overloading, ultrafine particles (sized around 0.1 .mu.m)
can be designed using polymers able to be degraded in vivo (e.g.
biodegradable polyalkyl-cyanoacrylate nanoparticles). Such
particles are described in the prior art.
[0122] Implantable devices coated with a compound of this invention
are another embodiment of the present invention. The compounds may
also be coated on implantable medical devices, such as beads, or
co-formulated with a polymer or other molecule, to provide a "drug
depot", thus permitting the drug to be released over a longer time
period than administration of an aqueous solution of the drug.
Suitable coatings and the general preparation of coated implantable
devices are described in U.S. Pat. Nos. 6,099,562; 5,886,026; and
5,304,121. The coatings are typically biocompatible polymeric
materials such as a hydrogel polymer, polymethyldisiloxane,
polycaprolactone, polyethylene glycol, polylactic acid, ethylene
vinyl acetate, and mixtures thereof. The coatings may optionally be
further covered by a suitable topcoat of fluorosilicone,
polysaccharides, polyethylene glycol, phospholipids or combinations
thereof to impart controlled release characteristics in the
composition.
[0123] The formulations include those suitable for the
administration routes detailed herein. The formulations may
conveniently be presented in unit dosage form and may be prepared
by any of the methods well known in the art of pharmacy. Techniques
and formulations generally are found in Remington's. Such methods
include the step of bringing into association the active ingredient
with the carrier which constitutes one or more accessory
ingredients. In general the formulations are prepared by uniformly
and intimately bringing into association the active ingredient with
liquid carriers or finely divided solid carriers or both, and then,
if necessary, shaping the product.
[0124] The terms "administer", "administering" or "administration"
in reference to a compound, composition or formulation of the
invention means introducing the compound into the system of the
animal in need of treatment. When a compound of the invention is
provided in combination with one or more other active agents,
"administration" and its variants are each understood to include
concurrent and/or sequential introduction of the compound and the
other active agents.
[0125] The compositions described herein may be administered
systemically or locally, e.g.: orally (e.g. using capsules,
powders, solutions, suspensions, tablets, sublingual tablets and
the like), by inhalation (e.g. with an aerosol, gas, inhaler,
nebulizer or the like), to the ear (e.g. using ear drops),
topically (e.g. using creams, gels, liniments, lotions, ointments,
pastes, transdermal patches, etc.), ophthalmically (e.g. with eye
drops, ophthalmic gels, ophthalmic ointments), rectally (e.g. using
enemas or suppositories), nasally, buccally, vaginally (e.g. using
douches, intrauterine devices, vaginal suppositories, vaginal rings
or tablets, etc.), via an implanted reservoir or the like, or
parenterally depending on the severity and type of the disease
being treated. The term "parenteral" as used herein includes, but
is not limited to, subcutaneous, intravenous, intramuscular,
intra-articular, intra-synovial, intrasternal, intrathecal,
intrahepatic, intralesional and intracranial injection or infusion
techniques. Preferably, the compositions are administered orally,
intraperitoneally or intravenously.
[0126] The pharmaceutical compositions described herein may be
orally administered in any orally acceptable dosage form including,
but not limited to, capsules, tablets, aqueous suspensions or
solutions. Liquid dosage forms for oral administration include, but
are not limited to, pharmaceutically acceptable emulsions,
microemulsions, solutions, suspensions, syrups and elixirs. In
addition to the active compounds, the liquid dosage forms may
contain inert diluents commonly used in the art such as, for
example, water or other solvents, solubilizing agents and
emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl
carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate,
propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in
particular, cottonseed, groundnut, corn, germ, olive, castor, and
sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene
glycols and fatty acid esters of sorbitan, and mixtures thereof.
Besides inert diluents, the oral compositions can also include
adjuvants such as wetting agents, emulsifying and suspending
agents, sweetening, flavoring, and perfuming agents.
[0127] Solid dosage forms for oral administration include capsules,
tablets, pills, powders, and granules. In such solid dosage forms,
the active compound is mixed with at least one inert,
pharmaceutically acceptable excipient or carrier such as sodium
citrate or dicalcium phosphate and/or a) fillers or extenders such
as starches, lactose, sucrose, glucose, mannitol, and silicic acid,
b) binders such as, for example, carboxymethylcellulose, alginates,
gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants
such as glycerol, d) disintegrating agents such as agar, calcium
carbonate, potato or tapioca starch, alginic acid, certain
silicates, and sodium carbonate, e) solution retarding agents such
as paraffin, f) absorption accelerators such as quaternary ammonium
compounds, g) wetting agents such as, for example, cetyl alcohol
and glycerol monostearate, h) absorbents such as kaolin and
bentonite clay, and i) lubricants such as talc, calcium stearate,
magnesium stearate, solid polyethylene glycols, sodium lauryl
sulfate, and mixtures thereof. Tablets may be uncoated or may be
coated by known techniques including microencapsulation to mask an
unpleasant taste or to delay disintegration and adsorption in the
gastrointestinal tract and thereby provide a sustained action over
a longer period. For example, a time delay material such as
glyceryl monostearate or glyceryl distearate alone or with a wax
may be employed. A water soluble taste masking material such as
hydroxypropyl-methylcellulose or hydroxypropyl-cellulose may be
employed.
[0128] Formulations of a compound of Formula I that are suitable
for oral administration may be prepared as discrete units such as
tablets, pills, troches, lozenges, aqueous or oil suspensions,
dispersible powders or granules, emulsions, hard or soft capsules,
e.g. gelatin capsules, syrups or elixirs. Formulations of a
compound intended for oral use may be prepared according to any
method known to the art for the manufacture of pharmaceutical
compositions.
[0129] Compressed tablets may be prepared by compressing in a
suitable machine the active ingredient in a free-flowing form such
as a powder or granules, optionally mixed with a binder, lubricant,
inert diluent, preservative, surface active or dispersing agent.
Molded tablets may be made by molding in a suitable machine a
mixture of the powdered active ingredient moistened with an inert
liquid diluent.
[0130] Formulations for oral use may also be presented as hard
gelatin capsules wherein the active ingredient is mixed with an
inert solid diluent, for example, calcium carbonate, calcium
phosphate or kaolin, or as soft gelatin capsules wherein the active
ingredient is mixed with water soluble carrier such as
polyethyleneglycol or an oil medium, for example peanut oil, liquid
paraffin, or olive oil.
[0131] The active compounds can also be in microencapsulated form
with one or more excipients as noted above.
[0132] When aqueous suspensions are required for oral use, the
active ingredient is combined with emulsifying and suspending
agents. If desired, certain sweetening and/or flavoring agents may
be added. Syrups and elixirs may be formulated with sweetening
agents, for example glycerol, propylene glycol, sorbitol or
sucrose. Such formulations may also contain a demulcent, a
preservative, flavoring and coloring agents and antioxidant.
[0133] Sterile injectable forms of the compositions described
herein (e.g. for parenteral administration) may be aqueous or
oleaginous suspension. These suspensions may be formulated
according to techniques known in the art using suitable dispersing
or wetting agents and suspending agents. The sterile injectable
preparation may also be a sterile injectable solution or suspension
in a non-toxic parenterally-acceptable diluent or solvent, for
example as a solution in 1,3-butanediol. Among the acceptable
vehicles and solvents that may be employed are water, Ringer's
solution and isotonic sodium chloride solution. In addition,
sterile, fixed oils are conventionally employed as a solvent or
suspending medium. For this purpose, any bland fixed oil may be
employed including synthetic mono- or di-glycerides. Fatty acids,
such as oleic acid and its glyceride derivatives are useful in the
preparation of injectables, as are natural
pharmaceutically-acceptable oils, such as olive oil or castor oil,
especially in their polyoxyethylated versions. These oil solutions
or suspensions may also contain a long-chain alcohol diluent or
dispersant, such as carboxymethyl cellulose or similar dispersing
agents which are commonly used in the formulation of
pharmaceutically acceptable dosage forms including emulsions and
suspensions. Other commonly used surfactants, such as Tweens, Spans
and other emulsifying agents or bioavailability enhancers which are
commonly used in the manufacture of pharmaceutically acceptable
solid, liquid, or other dosage forms may also be used for the
purposes of injectable formulations.
[0134] Oily suspensions may be formulated by suspending a compound
of Formula I in a vegetable oil, for example arachis oil, olive
oil, sesame oil or coconut oil, or in mineral oil such as liquid
paraffin. The oily suspensions may contain a thickening agent, for
example beeswax, hard paraffin or cetyl alcohol. Sweetening agents
such as those set forth above, and flavoring agents may be added to
provide a palatable oral preparation. These compositions may be
preserved by the addition of an anti-oxidant such as butylated
hydroxyanisol or alpha-tocopherol.
[0135] Aqueous suspensions of a compound of Formula I contain the
active materials in admixture with excipients suitable for the
manufacture of aqueous suspensions. Such excipients include a
suspending agent, such as sodium carboxymethylcellulose,
croscarmellose, povidone, methylcellulose, hydroxypropyl
methylcelluose, sodium alginate, polyvinylpyrrolidone, gum
tragacanth and gum acacia, and dispersing or wetting agents such as
a naturally occurring phosphatide (e.g., lecithin), a condensation
product of an alkylene oxide with a fatty acid (e.g.,
polyoxyethylene stearate), a condensation product of ethylene oxide
with a long chain aliphatic alcohol (e.g.,
heptadecaethyleneoxycetanol), a condensation product of ethylene
oxide with a partial ester derived from a fatty acid and a hexitol
anhydride (e.g., polyoxyethylene sorbitan monooleate). The aqueous
suspension may also contain one or more preservatives such as ethyl
or n-propyl p-hydroxy-benzoate, one or more coloring agents, one or
more flavoring agents and one or more sweetening agents, such as
sucrose or saccharin.
[0136] The injectable formulations can be sterilized, for example,
by filtration through a bacterial-retaining filter, or by
incorporating sterilizing agents in the form of sterile solid
compositions which can be dissolved or dispersed in sterile water
or other sterile injectable medium prior to use.
[0137] In order to prolong the effect of a compound described
herein, it is often desirable to slow the absorption of the
compound from subcutaneous or intramuscular injection. This may be
accomplished by the use of a liquid suspension of crystalline or
amorphous material with poor water solubility. The rate of
absorption of the compound then depends upon its rate of
dissolution that, in turn, may depend upon crystal size and
crystalline form. Alternatively, delayed absorption of a
parenterally administered compound form is accomplished by
dissolving or suspending the compound in an oil vehicle. Injectable
depot forms are made by forming microencapsulated matrices of the
compound in biodegradable polymers such as
polylactide-polyglycolide. Depending upon the ratio of compound to
polymer and the nature of the particular polymer employed, the rate
of compound release can be controlled. Examples of other
biodegradable polymers include poly(orthoesters) and
poly(anhydrides). Depot injectable formulations are also prepared
by entrapping the compound in liposomes or microemulsions that are
compatible with body tissues.
[0138] The injectable solutions or microemulsions may be introduced
into a patient's bloodstream by local bolus injection.
Alternatively, it may be advantageous to administer the solution or
microemulsion in such a way as to maintain a constant circulating
concentration of the instant compound. In order to maintain such a
constant concentration, a continuous intravenous delivery device
may be utilized. An example of such a device is the Deltec
CADD-PLUS.TM. model 5400 intravenous pump.
[0139] Compositions for rectal or vaginal administration are
preferably suppositories which can be prepared by mixing the
compounds described herein with suitable non-irritating excipients
or carriers such as cocoa butter, beeswax, polyethylene glycol or a
suppository wax which are solid at ambient temperature but liquid
at body temperature and therefore melt in the rectum or vaginal
cavity and release the active compound. Other formulations suitable
for vaginal administration may be presented as pessaries, tampons,
creams, gels, pastes, foams or sprays.
[0140] The pharmaceutical compositions described herein may also be
administered topically, especially when the target of treatment
includes areas or organs readily accessible by topical application,
including diseases of the eye, the ear, the skin, or the lower
intestinal tract. Suitable topical formulations are readily
prepared for each of these areas or organs.
[0141] Dosage forms for topical or transdermal administration of a
compound described herein include ointments, pastes, creams,
lotions, gels, powders, solutions, sprays, inhalants or patches.
The active component is admixed under sterile conditions with a
pharmaceutically acceptable carrier and any needed preservatives or
buffers as may be required. Ophthalmic formulation, eardrops, and
eye drops are also contemplated as being within the scope of this
invention. Additionally, the present invention contemplates the use
of transdermal patches, which have the added advantage of providing
controlled delivery of a compound to the body. Such dosage forms
can be made by dissolving or dispensing the compound in the proper
medium. Absorption enhancers can also be used to increase the flux
of the compound across the skin. The rate can be controlled by
either providing a rate controlling membrane or by dispersing the
compound in a polymer matrix or gel. Topical application for the
lower intestinal tract can be effected in a rectal suppository
formulation (see above) or in a suitable enema formulation.
Topically-transdermal patches may also be used.
[0142] For topical applications, the pharmaceutical compositions
may be formulated in a suitable ointment containing the active
component suspended or dissolved in one or more carriers. Carriers
for topical administration of the compounds of this invention
include, but are not limited to, mineral oil, liquid petrolatum,
white petrolatum, propylene glycol, polyoxyethylene,
polyoxypropylene compound, emulsifying wax and water.
Alternatively, the pharmaceutical compositions can be formulated in
a suitable lotion or cream containing the active components
suspended or dissolved in one or more pharmaceutically acceptable
carriers. Suitable carriers include, but are not limited to,
mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters
wax, cetearyl alcohol, 2 octyldodecanol, benzyl alcohol and
water.
[0143] For ophthalmic use, the pharmaceutical compositions may be
formulated as micronized suspensions in isotonic, pH adjusted
sterile saline, or, preferably, as solutions in isotonic, pH
adjusted sterile saline, either with or without a preservative such
as benzylalkonium chloride. Alternatively, for ophthalmic uses, the
pharmaceutical compositions may be formulated in an ointment such
as petrolatum. For treatment of the eye or other external tissues,
e.g., mouth and skin, the formulations may be applied as a topical
ointment or cream containing the active ingredient(s) in an amount
of, for example, 0.075 to 20% w/w. When formulated in an ointment,
the active ingredients may be employed with either an oil-based,
paraffinic or a water-miscible ointment base.
[0144] Alternatively, the active ingredients may be formulated in a
cream with an oil-in-water cream base. If desired, the aqueous
phase of the cream base may include a polyhydric alcohol, i.e. an
alcohol having two or more hydroxyl groups such as propylene
glycol, butane 1,3-diol, mannitol, sorbitol, glycerol and
polyethylene glycol (including PEG 400) and mixtures thereof. The
topical formulations may desirably include a compound which
enhances absorption or penetration of the active ingredient through
the skin or other affected areas. Examples of such dermal
penetration enhancers include dimethyl sulfoxide and related
analogs.
[0145] The oily phase of emulsions prepared using a compound of
Formula I may be constituted from known ingredients in a known
manner. While the phase may comprise merely an emulsifier
(otherwise known as an emulgent), it desirably comprises a mixture
of at least one emulsifier with a fat or an oil or with both a fat
and an oil. A hydrophilic emulsifier may be included together with
a lipophilic emulsifier which acts as a stabilizer. In some
embodiments, the emulsifier includes both an oil and a fat.
Together, the emulsifier(s) with or without stabilizer(s) make up
the so-called emulsifying wax, and the wax together with the oil
and fat make up the so-called emulsifying ointment base which forms
the oily dispersed phase of the cream formulations. Emulgents and
emulsion stabilizers suitable for use in the formulation of a
compound of Formula I include Tween.TM.-60, Span.TM.-80,
cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl
mono-stearate and sodium lauryl sulfate.
[0146] The pharmaceutical compositions may also be administered by
nasal aerosol or by inhalation. Such compositions are prepared
according to techniques well-known in the art of pharmaceutical
formulation and may be prepared as solutions in saline, employing
benzyl alcohol or other suitable preservatives, absorption
promoters to enhance bioavailability, fluorocarbons, and/or other
conventional solubilizing or dispersing agents. Formulations
suitable for intrapulmonary or nasal administration have a particle
size for example in the range of 0.1 to 500 micros (including
particles in a range between 0.1 and 500 microns in increments
microns such as 0.5, 1, 30, 35 microns, etc.) which is administered
by rapid inhalation through the nasal passage or by inhalation
through the mouth so as to reach the alveolar sacs.
[0147] The pharmaceutical composition (or formulation) for use may
be packaged in a variety of ways depending upon the method used for
administering the drug. Generally, an article for distribution
includes a container having deposited therein the pharmaceutical
formulation in an appropriate form. Suitable containers are
well-known to those skilled in the art and include materials such
as bottles (plastic and glass), sachets, ampoules, plastic bags,
metal cylinders, and the like. The container may also include a
tamper-proof assemblage to prevent indiscreet access to the
contents of the package. In addition, the container has deposited
thereon a label that describes the contents of the container. The
label may also include appropriate warnings.
[0148] The formulations may be packaged in unit-dose or multi-dose
containers, for example sealed ampoules and vials, and may be
stored in a freeze-dried (lyophilized) condition requiring only the
addition of the sterile liquid carrier, for example water, for
injection immediately prior to use. Extemporaneous injection
solutions and suspensions are prepared from sterile powders,
granules and tablets of the kind previously described. Preferred
unit dosage formulations are those containing a daily dose or unit
daily sub-dose, as herein above recited, or an appropriate fraction
thereof, of the active ingredient.
[0149] In another aspect, a compound of Formula I or a
pharmaceutically acceptable salt thereof may be formulated in a
veterinary composition comprising a veterinary carrier. Veterinary
carriers are materials useful for the purpose of administering the
composition and may be solid, liquid or gaseous materials which are
otherwise inert. In the veterinary art and are compatible with the
active ingredient. These veterinary compositions may be
administered parenterally, orally or by any other desired
route.
Therapeutic Methods
[0150] In a third aspect, the invention relates to the treatment of
certain disorders by using sGC stimulators, either alone or in
combination, or their pharmaceutically acceptable salts or
pharmaceutical compositions comprising them, in a patient in need
thereof.
[0151] The present disclosure relates to stimulators of soluble
guanylate cyclase (sGC), pharmaceutical formulations thereof and
their use, alone or in combination with one or more additional
agents, for treating and/or preventing various diseases, wherein an
increase in the concentration of NO or an increase in the
concentration of cGMP might be desirable. The diseases that can be
treated include but are not limited to pulmonary hypertension,
arterial hypertension, heart failure, atherosclerosis,
inflammation, thrombosis, renal fibrosis and failure, liver
cirrhosis, erectile dysfunction, female sexual disorders, disorders
related to diabetes, ocular disorders and other related
cardiovascular disorders.
[0152] Increased concentration of cGMP leads to vasodilation,
inhibition of platelet aggregation and adhesion, anti-hypertensive
effects, anti-remodeling effects, anti-apoptotic effects,
anti-inflammatory effects and neuronal signal transmission effects.
Thus, sGC stimulators may be used to treat and/or prevent a range
of diseases and disorders, including but not limited to a
peripheral, pulmonary, hepatic, liver, cardiac or
cerebrovascular/endothelial disorders or conditions, a
urogenital-gynecological or sexual disorder or condition, a
thromboembolic disease, an ischemic disease, a fibrotic disorder, a
topical or skin disorder, a pulmonary or respiratory disorder, a
renal or hepatic disorder, a metabolic disorder, atherosclerosis,
or a lipid related disorder.
[0153] In other embodiments, the compounds here disclosed are sGC
stimulators that may be useful in the prevention and/or treatment
of diseases and disorders characterized by undesirable reduced
bioavailability of and/or sensitivity to NO, such as those
associated with conditions of oxidative stress or nitrosative
stress.
[0154] In other embodiments, the compounds here disclosed are sGC
stimulators that may be useful in the prevention and/or treatment
of diseases and disorders characterized by increased
neuroinflammation. One embodiment of the invention is a method of
decreasing neuroinflammation in a subject in need thereof by
administering to the subject any one of the compounds of Formula I,
IIA, IIB, II, III, IV, V, VI, I-1, I-2, I-3, I-4, I-5, I-6, I-7,
I-8, I-9, I-10, I-11, I-12, I-13, I-14, I-15, I-16, I-17 through
I-39, I-41, I-42, I-47, I-48, I-50, I-51, I-53, I-54, I-56 through
I-60, I-62 through I-68, I-70, I-7, and I-72 or a pharmaceutically
acceptable salt thereof. In particular the diseases and disorders
is a CNS disease or disorder as described in sections (9)-(16),
below.
[0155] In other embodiments, the compounds here disclosed are sGC
stimulators that may be useful in the prevention and/or treatment
of diseases and disorders characterized by increased neurotoxicity.
One embodiment of the invention is a method of reducing
neurotoxicity in a subject in need thereof by administering to the
subject any one of the compounds of Formula I, IIA, IIB, II, III,
IV, V, VI, I-1, I-2, I-3, I-4, I-5, I-6, I-7, I-8, I-9, I-10, I-11,
I-12, I-13, I-14, I-15, I-16, I-17 through I-39, I-41, I-42, I-47,
I-48, I-50, I-51, I-53, I-54, I-56 through I-60, I-62 through I-68,
I-70, I-7, and I-72, or a pharmaceutically acceptable salt thereof.
In particular the diseases and disorders is a CNS disease or
disorder as described in sections (9)-(16), below.
[0156] In other embodiments, the compounds here disclosed are sGC
stimulators that may be useful in the prevention and/or treatment
of diseases and disorders characterized by impaired
neurorengeneration. One embodiment of the invention is a method of
restoring neuroregeneration in a subject in need thereof by
administering to the subject any one of the compounds of Formula I,
IIA, IIB, II, III, IV, V, VI, I-1, I-2, I-3, I-4, I-5, I-6, I-7,
I-8, I-9, I-10, I-11, I-12, I-13, I-14, I-15, or I I-16, I-17
through I-39, I-41, I-42, I-47, I-48, I-50, I-51, I-53, I-54, I-56
through I-60, I-62 through I-68, I-70, I-7, and 1-72, or a
pharmaceutically acceptable salt thereof. In particular the
diseases and disorders is a CNS disease or disorder as described in
sections (9)-(16), below.
[0157] In other embodiments, the compounds here disclosed are sGC
stimulators that may be useful in the prevention and/or treatment
of diseases and disorders characterized by impaired synaptic
function. One embodiment of the invention is a method of restoring
synaptic function in a subject in need thereof by administering to
the subject any one of the compounds of Formula I, IIA, IIB, II,
III, IV, V, VI, I-1, I-2, I-3, I-4, I-5, I-6, I-7, I-8, I-9, I-10,
I-11, I-12, I-13, I-14, I-15, or I-16, I-17 through I-39, I-41,
I-42, I-47, I-48, I-50, I-51, I-53, I-54, I-56 through I-60, I-62
through I-68, I-70, I-7, and I-72, or a pharmaceutically acceptable
salt thereof. In particular the diseases and disorders is a CNS
disease or disorder as described in sections (9)-(16), below.
[0158] In other embodiments, the compounds here disclosed are sGC
stimulators that may be useful in the prevention and/or treatment
of diseases and disorders characterized by downregulated
neurotransmitters. One embodiment of the invention is a method of
normalizing neurotransmitter in a subject in need thereof by
administering to the subject any one of the compounds of Formula I,
IIA, IIB, II, III, IV, V, VI, I-1, I-2, I-3, I-4, I-5, I-6, I-7,
I-8, I-9, I-10, I-11, I-12, I-13, I-14, I-15, or 1-16, I-17 through
I-39, I-41, I-42, I-47, I-48, I-50, I-51, I-53, I-54, I-56 through
I-60, I-62 through I-68, I-70, I-7, and 1-72, or a pharmaceutically
acceptable salt thereof. In particular the diseases and disorders
is a CNS disease or disorder as described in sections (9)-(16),
below. Specifically, the disease is Alzheimer's Disease.
Specifically, the disease is Mixed Dementia.
[0159] In other embodiments, the compounds here disclosed are sGC
stimulators that may be useful in the prevention and/or treatment
of diseases and disorders characterized by impaired cerebral blood
flow. One embodiment of the invention is a method of restoring
cerebral blood flow in a subject in need thereof by administering
to the subject any one of the compounds of Formula I, IIA, IIB, II,
III, IV, V, VI, I-1, I-2, I-3, I-4, I-5, I-6, I-7, I-8, I-9, I-10,
I-11, I-12, I-13, I-14, I-15, or 1-16, I-17 through I-39, I-41,
I-42, I-47, I-48, I-50, I-51, I-53, I-54, I-56 through I-60, I-62
through I-68, I-70, I-7, and 1-72, or a pharmaceutically acceptable
salt thereof. In particular the diseases and disorders is a CNS
disease or disorder as described in sections (9)-(16), below.
Specifically, the disease is Vascular Dementia or Alzheimer's
Disease. Specifically, the disease is Mixed Dementia. In other
embodiments CNS disorder is selected from either traumatic (closed
or open, penetrating head injuries), traumatic brain injury (TBI),
or nontraumatic (stroke, aneurism, hypoxia) injury to the brain or
cognitive impairment or dysfunction resulting from brain injuries
or neurodegenerative disorders.
[0160] In other embodiments, the compounds here disclosed are sGC
stimulators that may be useful in the prevention and/or treatment
of diseases and disorders characterized by increased
neurodegeneration. One embodiment of the invention is a method of
decreasing neurodegeneration in a subject in need thereof by
administering to the subject any one of the compounds of Formula I,
IIA, IIB, II, III, IV, V, VI, I-1, I-2, I-3, I-4, I-5, I-6, I-7,
I-8, I-9, I-10, I-11, I-12, I-13, I-14, I-15, or 1-16, I-17 through
I-39, I-41, I-42, I-47, I-48, I-50, I-51, I-53, I-54, I-56 through
I-60, I-62 through I-68, I-70, I-7, and 1-72, or a pharmaceutically
acceptable salt thereof. In particular the diseases and disorders
is a CNS disease or disorder as described in sections (9)-(16),
below.
[0161] In other embodiments, the compounds here disclosed are sGC
stimulators are neuroprotective. In particular, the compounds of
Formula I, IIA, IIB, II, III, IV, V, VI, I-1, I-2, I-3, I-4, I-5,
I-6, I-7, I-8, I-9, I-10, I-11, I-12, I-13, I-14, I-15, or I-16,
I-17 through I-39, I-41, I-42, I-47, I-48, I-50, I-51, I-53, I-54,
I-56 through I-60, I-62 through I-68, I-70, I-7, and I-72, or a
pharmaceutically acceptable salt thereof may be useful protect the
neurons in a subject in need thereof. In particular, the diseases
and disorders is a CNS disease or disorder as described in sections
(9)-(16), below.
[0162] In other embodiments, the compounds here disclosed are sGC
stimulators that may be useful in the prevention and/or treatment
orphan pain indications. One embodiment of the invention is a
method of treating an orphan pain indication in a subject in need
thereof by administering to the subject any one of the compounds of
Formula I, IIA, IIB, II, III, IV, V, VI, I-1, I-2, I-3, I-4, I-5,
I-6, I-7, I-8, I-9, I-10, I-11, I-12, I-13, I-14, I-15, or I-16,
I-17 through I-39, I-41, I-42, I-47, I-48, I-50, I-51, I-53, I-54,
I-56 through I-60, I-62 through I-68, I-70, I-7, and I-72, or a
pharmaceutically acceptable salt thereof. In particular, the orphan
pain indication is selected from Acetazolamide-responsive myotonia,
Autoerythrocyte sensitization syndrome, Autosomal dominant
Charcot-Marie-Tooth disease type 2V, Autosomal dominant
intermediate Charcot-Marie-Tooth disease with neuropathic pain,
Autosomal recessive limb-girdle muscular dystrophy type 2A,
Channelopathy-associated congenital insensitivity to pain, Chronic
pain requiring intraspinal analgesia, Complex regional pain
syndrome, Complex regional pain syndrome type 1, Complex regional
pain syndrome type 2, Congenital insensitivity to pain with
hyperhidrosis, Congenital insensitivity to pain with severe
intellectual disability, Congenital insensitivity to
pain-hypohidrosis syndrome, Diffuse palmoplantar keratoderma with
painful fissures, Familial episodic pain syndrome, Familial
episodic pain syndrome with predominantly lower limb involvement,
Familial episodic pain syndrome with predominantly upper body
involvement, Hereditary painful callosities, Hereditary sensory and
autonomic neuropathy type 4, Hereditary sensory and autonomic
neuropathy type 5, Hereditary sensory and autonomic neuropathy type
7, Interstitial cystitis, Painful orbital and systemic
neurofibromas-marfanoid habitus syndrome, Paroxysmal extreme pain
disorder, Persistent idiopathic facial pain, Qualitative or
quantitative defects of calpain, and Tolosa-Hunt syndrome.
[0163] Throughout this disclosure, the terms "hypertension",
"arterial hypertension" or "high blood pressure (HBP)" are used
interchangeable and refer to an extremely common and highly
preventable chronic condition in which blood pressure (BP) in the
arteries is higher than normal. If not properly controlled, it
represents a significant risk factor for several serious
cardiovascular and renal conditions. Hypertension may be a primary
disease, called "essential hypertension" or "idiopathic
hypertension", or it may be caused by other diseases, in which case
it is classified as "secondary hypertension". Essential
hypertension accounts for 90-95% of all cases.
[0164] As used herein, the term "resistant hypertension" refers to
hypertension that remains above goal blood pressure (usually less
than 140/90 mmHg, although a lower goal of less than 130/80 mmHg is
recommended for patients with comorbid diabetes or kidney disease),
in spite of concurrent use of three antihypertensive agents
belonging to different antihypertensive drug classes. People who
require four or more drugs to control their blood pressure are also
considered to have resistant hypertension. Hypertension is an
extremely common comorbid condition in diabetes, affecting
.about.20-60% of patients with diabetes, depending on obesity,
ethnicity, and age. This type of hypertension is herein referred to
as "diabetic hypertension". In type 2 diabetes, hypertension is
often present as part of the metabolic syndrome of insulin
resistance also including central obesity and dyslipidemia. In type
1 diabetes, hypertension may reflect the onset of diabetic
nephropathy.
[0165] "Pulmonary hypertension (PH)", as used herein, is a disease
characterized by sustained elevations of blood pressure in the
pulmonary vasculature (pulmonary artery, pulmonary vein and
pulmonary capillaries), which results in right heart hypertrophy,
eventually leading to right heart failure and death. Common
symptoms of PH include shortness of breath, dizziness and fainting,
all of which are exacerbated by exertion. Without treatment, median
life expectancy following diagnosis is 2.8 years. PH exists in many
different forms, which are categorized according to their etiology.
Categories include pulmonary arterial hypertension (PAH), PH with
left heart disease, PH associated with lung diseases and/or
hypoxaemia, PH due to chronic thrombotic and/or embolic disease and
miscellaneous PH. PAH is rare in the general population, but the
prevalence increases in association with certain common conditions
such as HIV infection, scleroderma and sickle cell disease. Other
forms of PH are generally more common than PAH, and, for instance,
the association of PH with chronic obstructive pulmonary disease
(COPD) is of particular concern. Current treatment for pulmonary
hypertension depends on the stage and the mechanism of the
disease.
[0166] As used herein "heart failure" is a progressive disorder of
left ventricular (LV) myocardial remodeling that culminates in a
complex clinical syndrome in which impaired cardiac function and
circulatory congestion are the defining features, and results in
insufficient delivery of blood and nutrients to body tissues. The
condition occurs when the heart is damaged or overworked and unable
to pump out all the blood that returns to it from the systemic
circulation. As less blood is pumped out, blood returning to the
heart backs up and fluid builds up in other parts of the body.
Heart failure also impairs the kidneys' ability to dispose of
sodium and water, complicating fluid retention further. Heart
failure is characterized by autonomic dysfunction, neurohormonal
activation and overproduction of cytokines, which contribute to
progressive circulatory failure. Symptoms of heart failure include:
dyspnea (shortness of breath) while exercising or resting and
waking at night due to sudden breathlessness, both indicative of
pulmonary edema; general fatigue or weakness, edema of the feet,
ankles and legs, rapid weight gain, chronic cough, including that
producing mucus or blood. Depending on its clinical presentation,
heart failure is classified as de novo, transient or chronic. Acute
heart failure, i.e. the rapid or gradual onset of symptoms
requiring urgent therapy, may develop de novo or as a result of
chronic heart failure becoming decompensated. Diabetes is a common
comorbidity in patients with heart failure and is associated with
poorer outcomes as well as potentially compromising the efficacy of
treatments. Other important comorbidities include systemic
hypertension, chronic airflow obstruction, sleep apnea, cognitive
dysfunction, anemia, chronic kidney disease and arthritis. Chronic
left heart failure is frequently associated with the development of
pulmonary hypertension. The frequency of certain comorbidities
varies by gender: among women, hypertension and thyroid disease are
more common, while men more commonly suffer from chronic
obstructive pulmonary disease (COPD), peripheral vascular disease,
coronary artery disease and renal insufficiency. Depression is a
frequent comorbidity of heart failure and the two conditions can
and often do complicate one another. Cachexia has long been
recognized as a serious and frequent complication of heart failure,
affecting up to 15% of all heart failure patients and being
associated with poor prognosis. Cardiac cachexia is defined as the
nonedematous, nonvoluntary loss of at least 6% of body weight over
a period of six months.
[0167] The term "sleep apnea" refers to the most common of the
sleep-disordered breathing disorders. It is a condition
characterized by intermittent, cyclical reductions or total
cessations of airflow, which may or may not involve obstruction of
the upper airway. There are three types of sleep apnea: obstructive
sleep apnea, the most common form, central sleep apnea and mixed
sleep apnea.
[0168] "Central sleep apnea (CSA)", is caused by a malfunction in
the brain's normal signal to breathe, rather than physical blockage
of the airway. The lack of respiratory effort leads to an increase
in carbon dioxide in the blood, which may rouse the patient. CSA is
rare in the general population, but is a relatively common
occurrence in patients with systolic heart failure.
[0169] As used herein, the term "metabolic syndrome", "insulin
resistance syndrome" or "syndrome X", refers to a group or
clustering of metabolic conditions (abdominal obesity, elevated
fasting glucose, "dyslipidemia" (i.e., elevated lipid levels) and
elevated blood pressure (HBP)) which occur together more often than
by chance alone and that together promote the development of type 2
diabetes and cardiovascular disease. Metabolic syndrome is
characterized by a specific lipid profile of increased
triglycerides, decreased high-density lipoprotein cholesterol
(HDL-cholesterol) and in some cases moderately elevated low-density
lipoprotein cholesterol (LDL-cholesterol) levels, as well as
accelerated progression of "atherosclerotic disease" due to the
pressure of the component risk factors. There are several types of
dyslipidemias: "hypercholesterolemia" refers to elevated levels of
cholesterol. Familial hypercholesterolemia is a specific form of
hypercholesterolemia due to a defect on chromosome 19
(19p13.1-13.3). "Hyperglyceridemia" refers to elevated levels of
glycerides (e.g., "hypertrigliceridemia" involves elevated levels
of triglycerides). "Hyperlipoproteinemia" refers to elevated levels
of lipoproteins (usually LDL unless otherwise specified).
[0170] As used herein, the term "peripheral vascular disease
(PVD)", also commonly referred to as "peripheral arterial disease
(PAD)" or "peripheral artery occlusive disease (PAOD)", refers to
the obstruction of large arteries not within the coronary, aortic
arch vasculature, or brain. PVD can result from atherosclerosis,
inflammatory processes leading to stenosis, an embolism, or
thrombus formation. It causes either acute or chronic "ischemia
(lack of blood supply)". Often PVD is a term used to refer to
atherosclerotic blockages found in the lower extremity. PVD also
includes a subset of diseases classified as microvascular diseases
resulting from episodal narrowing of the arteries (e.g., "Raynaud's
phenomenon"), or widening thereof (erythromelalgia), i.e. vascular
spasms.
[0171] The term "thrombosis" refers to the formation of a blood
clot ("thrombus") inside a blood vessel, obstructing the flow of
blood through the circulatory system. When a blood vessel is
injured, the body uses platelets (thrombocytes) and fibrin to form
a blood clot to prevent blood loss. Alternatively, even when a
blood vessel is not injured, blood clots may form in the body if
the proper conditions present themselves. If the clotting is too
severe and the clot breaks free, the traveling clot is now known as
an "embolus". The term "thromboembolism" refers to the combination
of thrombosis and its main complication, "embolism". When a
thrombus occupies more than 75% of surface area of the lumen of an
artery, blood flow to the tissue supplied is reduced enough to
cause symptoms because of decreased oxygen (hypoxia) and
accumulation of metabolic products like lactic acid ("gout"). More
than 90% obstruction can result in anoxia, the complete deprivation
of oxygen, and "infarction", a mode of cell death.
[0172] An "embolism" (plural embolisms) is the event of lodging of
an embolus (a detached intravascular mass capable of clogging
arterial capillary beds at a site far from its origin) into a
narrow capillary vessel of an arterial bed which causes a blockage
(vascular occlusion) in a distant part of the body. This is not to
be confused with a thrombus which blocks at the site of origin.
[0173] A "stroke", or cerebrovascular accident (CVA), is the rapid
loss of brain function(s) due to disturbance in the blood supply to
the brain. This can be due to "ischemia" (lack of blood flow)
caused by blockage (thrombosis, arterial embolism), or a hemorrhage
(leakage of blood). As a result, the affected area of the brain
cannot function, which might result in an inability to move one or
more limbs on one side of the body, inability to understand or
formulate speech, or an inability to see one side of the visual
field. Risk factors for stroke include old age, hypertension,
previous stroke or transient ischemic attack (TIA), diabetes, high
cholesterol, cigarette smoking and atrial fibrillation. High blood
pressure is the most important modifiable risk factor of stroke. An
"ischemic stroke" is occasionally treated in a hospital with
thrombolysis (also known as a "clot buster"), and some hemorrhagic
strokes benefit from neurosurgery. Prevention of recurrence may
involve the administration of antiplatelet drugs such as aspirin
and dipyridamole, control and reduction of hypertension, and the
use of statins. Selected patients may benefit from carotid
endarterectomy and the use of anticoagulants.
[0174] "Ischemia" is a restriction in blood supply to tissues,
causing a shortage of oxygen and glucose needed for cellular
metabolism (to keep tissue alive). Ischemia is generally caused by
problems with blood vessels, with resultant damage to or
dysfunction of tissue. It also means local anemia in a given part
of a body sometimes resulting from congestion (such as
vasoconstriction, thrombosis or embolism).
[0175] According to the American Psychiatric Association's
Diagnostic and Statistical Manual of Mental Disorders, Fourth
Edition (DSM-IV), the term "sexual dysfunction" encompasses a
series of conditions "characterized by disturbances in sexual
desire and in the psychophysiological changes associated with the
sexual response cycle"; while problems of this type are common,
sexual dysfunction is only considered to exist when the problems
cause distress for the patient. Sexual dysfunction can be either
physical or psychological in origin. It can exist as a primary
condition, generally hormonal in nature, although most often it is
secondary to other medical conditions or to drug therapy for said
conditions. All types of sexual dysfunction can be further
classified as life-long, acquired, situational or generalized (or
combinations thereof).
[0176] The DSM-IV-TR specifies five major categories of "female
sexual dysfunction": sexual desire/interest disorders; "sexual
arousal disorders (including genital, subjective and combined)";
orgasmic disorder; dyspareunia and vaginismus; and persistent
sexual arousal disorder.
[0177] "Female sexual arousal disorder (FSAD)" is defined as a
persistent or recurring inability to attain or maintain sufficient
levels of sexual excitement, causing personal distress. FSAD
encompasses both the lack of subjective feelings of excitement
(i.e., subjective sexual arousal disorder) and the lack of somatic
responses such as lubrication and swelling (i.e., genital/physical
sexual arousal disorder). FSAD may be strictly psychological in
origin, although it generally is caused or complicated by medical
or physiological factors. Hypoestrogenism is the most common
physiologic condition associated with FSAD, which leads to
urogenital atrophy and a decrease in vaginal lubrication.
[0178] As used herein, "erectile dysfunction (ED)" is a male sexual
dysfunction characterized by the inability to develop or maintain
an erection of the penis during sexual performance. A penile
erection is the hydraulic effect of blood entering and being
retained in sponge-like bodies within the penis. The process is
often initiated as a result of sexual arousal, when signals are
transmitted from the brain to nerves in the penis. Erectile
dysfunction is indicated when an erection is difficult to produce.
The most important organic causes are cardiovascular disease and
diabetes, neurological problems (for example, trauma from
prostatectomy surgery), hormonal insufficiencies (hypogonadism) and
drug side effects.
[0179] As used herein, the term "bronchoconstriction" is used to
define the constriction of the airways in the lungs due to the
tightening of surrounding smooth muscle, with consequent coughing,
wheezing, and shortness of breath. The condition has a number of
causes, the most common being as well as asthma. Exercise and
allergies can bring on the symptoms in an otherwise asymptomatic
individual. Other conditions such as chronic obstructive pulmonary
disease (COPD) can also present with bronchoconstriction.
[0180] Specific diseases of disorders which may be treated and/or
prevented by administering an sGC stimulator of the invention,
include but are not limited to: hypertension (e.g., diabetic
hypertension, arterial hypertension, pulmonary hypertension,
resistant hypertension, peripheral artery disease, etc.), heart
failure (e.g., left ventricular diastolic dysfunction (LVDD) and
left ventricular systolic dysfunction (LVSD), sleep apnea
associated with heart failure), arteriosclerotic disease (e.g.,
atherosclerosis), thromboembolic disorders (e.g., chronic
thromboembolic pulmonary hypertension, thrombosis, stroke (in
particular, ischemic stroke), embolism, pulmonary embolism),
Alzheimer's disease, renal diseases (e.g., renal fibrosis, ischemic
renal disease, renal failure, renal insufficiency, chronic kidney
disease), hepatic disease (e.g., liver fibrosis or cirrhosis),
respiratory disease (e.g., pulmonary fibrosis, asthma, chronic
obstructive pulmonary disease, interstitial lung disease), sexual
disorders (e.g., erectile dysfunction, male and female sexual
dysfunction, vaginal atrophy), sickle cell anemia, neuro
inflammatory diseases or disorders and metabolic disorders (e.g.,
lipid related disorders).
[0181] Further specific diseases of disorders which may be treated
and/or prevented by administering an sGC stimulator of the
invention, include but are not limited to: age-associated memory
impairment, mixed dementia, sleep wake disorders, and Sneddon's
syndrome.
[0182] Further specific diseases of disorders which may be treated
and/or prevented by administering an sGC stimulator of the
invention, include but are not limited to: acute pain, central pain
syndrome, chemotherapy induced neuropathy and neuropathic pain,
diabetic neuropathy, fibromyalgia, inflammatory pain, neuropathic
pain, neuropathic pain associated with a CNS disease, painful
diabetic peripheral neuropathy, post-operative pain, tonic pain,
and visceral pain.
[0183] Further specific diseases of disorders which may be treated
and/or prevented by administering an sGC stimulator of the
invention, include but are not limited to: altitude (mountain)
sickness, cerebral small vessel disease, cerebral vasculitis,
cerebral vasospasm, diabetic heart failure (diabetic HF), diabetic
angiopathy, diabetic macular edema, diabetic microangiopathies,
Heart failure with preserved ejection fraction (HFpEF), hepatic
encephalopathy, moyamoya, non-diabetic nephropathy, and Parkinson's
Dysphagia.
[0184] Further specific diseases of disorders which may be treated
and/or prevented by administering an sGC stimulator of the
invention, include but are not limited to: angina, ataxia
telangliectasia, autism spectrum disorder, chronic fatigue, chronic
traumatic encephalopathy (CTE), cognitive impairment associated
with diabetes, cognitive impairment associated with Multiple
Sclerosis, cognitive impairment associated with obstructive sleep
apnea, cognitive impairment associated with schizophrenia (CIAS),
cognitive impairment associated with sickle cell, concussion,
dysphagia, eye fibrosis, Fabry Disease, Gaucher Disease,
glioblastoma, inflammation caused by cerebral malaria (SoC),
inflammation caused by infectious disease, intellectual disability,
microvascular angina, myopic choroidal neovascularization,
neuromyelitis optica, neuropathic pain with Multiple Sclerosis,
neuropathic pain with shingles (herpes zoster), neuropathic pain
with spine surgery, Parkinson's Dementia, peripheral and autonomic
neuropathies, peripheral retinal degeneration, post-traumatic
stress syndrome, post herpetic neuralgia, post-operative dementia,
proliferative vitroretinopathy, radiation induced fibrosis,
radiculopathy, refractory epilepsy, retinal vein occlusion,
Sjogren's syndrome, spinal cord injury, spinal muscular atrophy,
spinal subluxations, tauopathies, ulcers, and wet age-related
macular degeneration.
[0185] The compounds of Formula I as well as pharmaceutically
acceptable salts thereof, as stimulators of sGC, are useful in the
prevention and/or treatment of the following types of diseases,
conditions and disorders which can benefit from sGC stimulation or
an upregulation of the NO pathway:
(1) Peripheral, pulmonary, hepatic, kidney, cardiac or cerebral
vascular/endothelial disorders/conditions or diseases otherwise
related to circulation:
[0186] disorders related to high blood pressure and decreased
coronary blood flow such as increased acute and chronic coronary
blood pressure, arterial hypertension and vascular disorder
resulting from cardiac and renal complications (e.g. heart disease,
stroke, cerebral ischemia, renal failure); resistant hypertension,
diabetic hypertension, congestive heart failure; diastolic or
systolic dysfunction; coronary insufficiency; arrhythmias;
reduction of ventricular preload; cardiac hypertrophy; heart
failure/cardiorenal syndrome; portal hypertension; endothelial
dysfunction or injury;
[0187] thromboembolic disorders and ischemias such as myocardial
infarction, stroke (in particular, ischemic stroke), transient
ischemic attacks (TIAs); obstructive thromboanginitis; stable or
unstable angina pectoris; coronary spasms, variant angina,
Prinzmetal's angina; prevention of restenosis after thrombolysis
therapies; thrombogenic disorders;
[0188] peripheral arterial disease, peripheral occlusive arterial
disease; peripheral vascular disease; hypertonia; Raynaud's
syndrome or phenomenon, critical limb ischemia, vasculitis;
peripheral embolism; intermittent claudication; vaso-occlusive
crisis; Duchenne and Becker muscular dystrophies; microcirculation
abnormalities; control of vascular leakage or permeability;
[0189] shock; sepsis; cardiogenic shock; control of leukocyte
activation; inhibition or modulation of platelet aggregation;
[0190] pulmonary/respiratory conditions such as pulmonary
hypertension, pulmonary arterial hypertension, and associated
pulmonary vascular remodeling (e.g. localized thrombosis and right
heart hypertrophy); pulmonary hypertonia; primary pulmonary
hypertension, secondary pulmonary hypertension, familial pulmonary
hypertension, sporadic pulmonary hypertension, pre-capillary
pulmonary hypertension, idiopathic pulmonary hypertension,
thrombotic pulmonary arteriopathy, plexogenic pulmonary
arteriopathy; cystic fibrosis; bronchoconstriction or pulmonary
bronchoconstriction; acute respiratory distress syndrome; lung
fibrosis, lung transplant;
[0191] pulmonary hypertension associated with or related to: left
ventricular dysfunction, hypoxemia, WHO groups I, II, III, IV and V
hypertensions, mitral valve disease, constrictive pericarditis,
aortic stenosis, cardiomyopathy, mediastinal fibrosis, pulmonary
fibrosis, anomalous pulmonary venous drainage, pulmonary
venooclusive disease, pulmonary vasculitis, collagen vascular
disease, congenital heart disease, pulmonary venous hypertension,
interstitial lung disease, sleep-disordered breathing, sleep apnea,
alveolar hypoventilation disorders, chronic exposure to high
altitude, neonatal lung disease, alveolar-capillary dysplasia,
sickle cell disease, other coagulation disorders, chronic
thromboembolism, pulmonary embolism (due to tumor, parasites or
foreign material), connective tissue disease, lupus,
schistosomiasis, sarcoidosis, chronic obstructive pulmonary
disease, asthma, emphysema, chronic bronchitis, pulmonary capillary
hemangiomatosis; histiocytosis X, lymphangiomatosis and compressed
pulmonary vessels (such as due to adenopathy, tumor or fibrosing
mediastinitis);
[0192] arterosclerotic diseases or conditions such as
atherosclerosis (e.g., associated with endothelial injury, platelet
and monocyte adhesion and aggregation, smooth muscle proliferation
and migration); restenosis (e.g., developed after thrombolysis
therapies, percutaneous transluminal angioplasties (PTAs),
percutaneous transluminal coronary angioplasties (PTCAs) and
bypass); inflammation;
[0193] cardiovascular disease associated with metabolic syndrome
(e.g., obesity, dyslipidemia, diabetes, high blood pressure); lipid
related disorders such as dyslipidemia, hypercholesterolemia,
hypertriglyceridemia, sitosterolemia, fatty liver disease, and
hepatitis; preeclampsia; polycystic kidney disease progression;
subcutaneous fat; obesity;
[0194] liver cirrhosis, associated with chronic liver disease,
hepatic fibrosis, hepatic stellate cell activation, hepatic fibrous
collagen and total collagen accumulation; liver disease of
necro-inflammatory and/or of immunological origin; and urogenital
system disorders, such as renal fibrosis and renal failure
resulting from chronic kidney diseases or insufficiency (e.g. due
to accumulation/deposition and tissue injury, progressive
sclerosis, glomerulonephritis); prostate hypertrophy systemic
sclerosis; cardiac interstitial fibrosis; cardiac remodeling and
fibrosis; cardiac hypertrophy; non-alcoholic steatohepatitis or
NASH;
(2) ischemia, reperfusion damage; ischemia/reperfusion associated
with organ transplant, lung transplant, pulmonary transplant,
cardiac transplant; conserving blood substituents in trauma
patients; (3) sexual, gynecological and urological disorders of
conditions: erectile dysfunction; impotence; premature ejaculation;
female sexual dysfunction (e.g., female sexual arousal dysfunction,
hypoactive sexual arousal disorder), vaginal atrophy, dyspaneuria,
atrophic vaginitis; benign prostatic hyperplasia (BPH) or
hypertrophy or enlargement, bladder outlet obstruction; bladder
pain syndrome (BPS), interstitial cystitis (IC), overactive
bladder, neurogenic bladder and incontinence; diabetic nephropathy;
(4) ocular diseases or disorders: glaucoma, retinopathy, diabetic
retinopathy (including proliferative and non-proliferative),
blepharitis, dry eye syndrome, Sjogren's Syndrome; (5) hearing
diseases or disorders: hearing impairment, partial or total hearing
loss; partial or total deafness; tinnitus; noise-induced hearing
loss; (6) topical or skin disorders or conditions: dermal fibrosis,
scleroderma, skin fibrosis; (7) wound healing: for instance in
diabetics; microvascular perfusion improvement (e.g., following
injury, to counteract the inflammatory response in perioperative
care), anal fissures, diabetic ulcers; (8) other diseases or
conditions: cancer metastasis, osteoporosis, gastroparesis;
functional dyspepsia; diabetic complications, diseases associated
with endothelial dysfunction, and neurologic disorders associated
with decreased nitric oxide production; achalasia or esophageal
achalasia. (9) a CNS disease, health condition or disorder selected
from Alzheimer's disease, amyotrophic lateral sclerosis (ALS or Lou
Gehrig's disease), Down syndrome, dementia, vascular dementia,
vascular cognitive impairment, Mixed Dementia, Binswanger's
dementia (subcortical arteriosclerotic encephalopathy), Cerebral
Autosomal-Dominant Arteriopathy with Subcortical Infarcts and
Leukoencephalopathy (CADASIL or CADASIL syndrome), frontotemporal
lobar degeneration or dementia, HIV-associated dementia (including
asymptomatic neurocognitive impairment (ANI), minor neurocognitive
disorder (MND), and HIV-associated dementia (HAD) (also called AIDS
dementia complex [ADC] or HIV encephalopathy), Lewy body dementia,
pre-senile dementia (mild cognitive impairment, MCI), glaucoma,
Huntington's diseases (or chorea, HD), or a cognitive defect
associated with HD; multiple sclerosis (MS) (including Clinically
isolated syndrome (CIS), Relapsing-remitting MS (RRMS), Primary
progressive MS (PPMS), and Secondary progressive MS (SPMS),)
multiple system atrophy (MSA), Parkinson's disease, Parkinsonism
Plus, spinocerebellar ataxias, Steel-Richardson-Olszewski disease
(progressive supranuclear palsy), attention deficit disorder (ADD)
and attention deficit hyperactivity disorder (ADHD); (10) a CNS
disorder or condition selected from Alzheimer's disease or
pre-Alzheimer's disease, mild to moderate Alzheimer's disease or
moderate to severe Alzheimer's disease; (11) a CNS disorder is
selected from either traumatic (closed or open, penetrating head
injuries), traumatic brain injury (TBI, including, for example,
concussions and Chronic traumatic encephalopathy (CTE)), or
nontraumatic (stroke (including ischemic stroke), aneurism,
hypoxia) injury to the brain or cognitive impairment or dysfunction
resulting from brain injuries or neurodegenerative disorders; (12)
a CNS disease or disorder is selected from dystonias, including for
example, generalized, focal, segmental, sexual, intermediate, acute
dystonic reaction, and genetic/primary dystonia; and dyskinesias,
including for example, acute, chronic/tardive, and non-motor and
levo-dopa induced dyskinesia (LID); (13) a CNS disease or disorder
is selected from disorders characterized by a relative reduction in
synaptic plasticity and synaptic processes including, for example,
Fragile X, Rhett's disorder, Williams syndrome, Renpenning's
syndrome, autism spectrum disorders, including autism, Asperger's
syndrome, pervasive development disorder and childhood
disintegrative disorder; (14) a CNS disorder is neuropathic pain;
(15) a CNS disorder is a psychiatric, mental, mood or affective
disorder selected from a bipolar disorder, schizophrenia, general
psychosis, drug-induced psychosis, a delusional disorder,
schizoaffective disorder, obsessive compulsive disorder (OCD), a
depressive disorder, an anxiety disorder, a panic disorder,
post-traumatic stress disorder (PTSD); or (16) a CNS disorder is
selected from chemo brain, levo-dopa induced addictive behavior,
alcoholism, narcotic dependence (including but not limited to
amphetamine, opiates or other substances) and substance abuse.
[0195] In other embodiments of the invention, the compounds of
Formula I as well as pharmaceutically acceptable salts thereof are
useful in the prevention and/or treatment of the following types of
diseases, conditions and disorders which can benefit from sGC
stimulation or an upregulation of the NO pathway:
hypertension, resistant hypertension, diabetic hypertension,
pulmonary hypertension (PH), pulmonary arterial hypertension, PH
associated with COPD, chronic airflow obstruction, asthma or
pulmonary fibrosis, thrombosis, embolism, thromboembolic disorders,
Alzheimer's disease, atherosclerosis, right heart hypertrophy,
heart failure, diastolic dysfunction, systolic dysfunction, sleep
apnea associated with heart failure, liver cirrhosis, renal
fibrosis, renal failure resulting from chronic kidney diseases or
insufficiency, metabolic disorder, dyslipidemia,
hypercholesterolemia, hypertriglyceridemia, sitosterolemia, fatty
liver disease, hepatitis, erectile dysfunction, female sexual
dysfunction, female sexual arousal dysfunction and vaginal
atrophy.
[0196] In some embodiments, the invention relates to a method of
treating a disease, health condition or disorder in a subject,
comprising administering a therapeutically effective amount of a
compound of any of the above depicted Formulae, or a
pharmaceutically acceptable salt thereof, to the subject in need of
treatment, wherein the disease, health condition or disorder is
selected from one of the diseases listed above.
[0197] In other embodiments the disease, health condition or
disorder is selected from a peripheral, pulmonary, hepatic, kidney,
cardiac or cerebralvascular/endothelial disorder or condition, or a
disease otherwise related to circulation selected from: increased
acute and chronic coronary blood pressure, arterial hypertension
and vascular disorder resulting from cardiac and renal
complications, heart disease, stroke (in particular, ischemic
stroke), cerebral ischemia, renal failure; resistant hypertension,
diabetic hypertension, congestive heart failure; diastolic or
systolic dysfunction; coronary insufficiency; arrhythmias;
reduction of ventricular preload; cardiac hypertrophy; heart
failure/cardiorenal syndrome; portal hypertension; endothelial
dysfunction or injury; myocardial infarction; stroke or transient
ischemic attacks (TIAs); obstructive thromboanginitis; stable or
unstable angina pectoris; coronary spasms, variant angina,
Prinzmetal's angina; restenosis as a result of thrombolysis
therapies and thrombogenic disorders.
[0198] In still other embodiments, the disease, health condition or
disorder is selected from a peripheral vascular/endothelial
disorder or condition or a disease otherwise related to circulation
selected from: peripheral arterial disease, peripheral occlusive
arterial disease; peripheral vascular disease; hypertonias;
Raynaud's syndrome or phenomenon or disease; critical limb
ischemia; vasculitis; peripheral embolism; intermittent
claudication; vaso-occlusive crisis; Duchenne and Becker muscular
dystrophies; microcirculation abnormalities; and vascular leakage
or permeability issues.
[0199] In further embodiments, the disease, health condition or
disorder is a pulmonary disorder or condition or a disease
otherwise related to circulation selected from: pulmonary
hypertension; pulmonary arterial hypertension and associated
pulmonary vascular remodeling; localized thrombosis; right heart
hypertrophy; pulmonary hypertonia; primary pulmonary hypertension,
secondary pulmonary hypertension, familial pulmonary hypertension,
sporadic pulmonary hypertension, pre-capillary pulmonary
hypertension, idiopathic pulmonary hypertension, thrombotic
pulmonary arteriopathy, plexogenic pulmonary arteriopathy; cystic
fibrosis; bronchoconstriction or pulmonary bronchoconstriction;
acute respiratory distress syndrome; lung fibrosis and lung
transplant. In some of these embodiments, the pulmonary
hypertension is pulmonary hypertension associated with or related
to: left ventricular dysfunction, hypoxemia, WHO groups I, II, III,
IV and V hypertensions, mitral valve disease, constrictive
pericarditis, aortic stenosis, cardiomyopathy, mediastinal
fibrosis, pulmonary fibrosis, anomalous pulmonary venous drainage,
pulmonary venooclusive disease, pulmonary vasculitis, collagen
vascular disease, congenital heart disease, pulmonary venous
hypertension, interstitial lung disease, sleep-disordered
breathing, sleep apnea, alveolar hypoventilation disorders, chronic
exposure to high altitude, neonatal lung disease,
alveolar-capillary dysplasia, sickle cell disease, coagulation
disorders, chronic thromboembolism; pulmonary embolism, due to
tumor, parasites or foreign material; connective tissue disease,
lupus, schistosomiasis, sarcoidosis, chronic obstructive pulmonary
disease, asthma, emphysema, chronic bronchitis, pulmonary capillary
hemangiomatosis; histiocytosis X; lymphangiomatosis and compressed
pulmonary vessels due to adenopathy, tumor or fibrosing
mediastinitis.
[0200] In still other embodiments, the health condition or disorder
is a vascular or endothelial disorder or condition or a disease
otherwise related to circulation selected from: arterosclerotic
diseases; atherosclerosis, atherosclerosis associated with
endothelial injury, atherosclerosis associated with platelet and
monocyte adhesion and aggregation, atherosclerosis associated with
smooth muscle proliferation and migration; restenosis, restenosis
developed after thrombolysis therapies; restenosis developed after
percutaneous transluminal angioplasties; restenosis developed after
percutaneous transluminal coronary angioplasties and bypass;
inflammation; cardiovascular disease associated with metabolic
syndrome, obesity, dyslipidemia, diabetes or high blood pressure;
lipid related disorders, dyslipidemia, hypercholesterolemia,
hypertriglyceridemia, sitosterolemia, fatty liver disease, and
hepatitis; preeclampsia; polycystic kidney disease progression; and
subcutaneous fat.
[0201] In yet other embodiments, the disease, health condition or
disorder selected from liver cirrhosis, liver cirrhosis associated
with chronic liver disease, hepatic fibrosis, hepatic stellate cell
activation, hepatic fibrous collagen and total collagen
accumulation; and liver disease of necro-inflammatory or of
immunological origin.
[0202] In further embodiments, the disease, health condition or
disorder is a urogenital system disorder selected from renal
fibrosis; renal failure resulting from chronic kidney diseases or
insufficiency; renal failure due to accumulation or deposition and
tissue injury, progressive sclerosis or glomerulonephritis; and
prostatic hypertrophy.
[0203] In further embodiments, the disease, health condition or
disorder is systemic sclerosis.
[0204] In further embodiments, the disease, health condition or
disorder is a cardiac disorder selected from cardiac interstitial
fibrosis; cardiac remodeling and fibrosis and cardiac
hypertrophy.
[0205] In some embodiments, the disorder is a CNS disease, health
condition or disorder selected from Alzheimer's disease,
amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), Down
syndrome, dementia, vascular dementia, Mixed Dementia, vascular
cognitive impairment, Binswanger's dementia (subcortical
arteriosclerotic encephalopathy), Cerebral Autosomal-Dominant
Arteriopathy with Subcortical Infarcts and Leukoencephalopathy
(CADASIL or CADASIL syndrome), frontotemporal lobar degeneration or
dementia, HIV-associated dementia (including asymptomatic
neurocognitive impairment (ANI), minor neurocognitive disorder
(MND), and HIV-associated dementia (HAD) (also called AIDS dementia
complex [ADC] or HIV encephalopathy), Lewy body dementia,
pre-senile dementia (mild cognitive impairment, MCI), glaucoma,
Huntington's diseases (or chorea, HD), or a cognitive defect
associated with HD; multiple sclerosis (MS), multiple system
atrophy (MSA), Parkinson's disease, Parkinsonism Plus,
spinocerebellar ataxias, Steel-Richardson-Olszewski disease
(progressive supranuclear palsy), attention deficit disorder (ADD)
and attention deficit hyperactivity disorder (ADHD).
[0206] In further embodiments, the disease, health condition or
disorder is a CNS disorder or condition selected from Alzheimer's
disease or pre-Alzheimer's disease, mild to moderate Alzheimer's
disease or moderate to severe Alzheimer's disease.
[0207] In other embodiments, the CNS disorder is selected from
either traumatic (closed or open, penetrating head injuries),
traumatic brain injury (TBI), or nontraumatic (stroke (in
particular, ischemic stroke), aneurism, hypoxia) injury to the
brain or cognitive impairment or dysfunction resulting from brain
injuries or neurodegenerative disorders.
[0208] In other embodiments, the CNS disease or disorder is
selected from dystonias, including for example, generalized, focal,
segmental, sexual, intermediate, acute dystonic reaction, and
genetic/primary dystonia; and dyskinesias, including for example,
acute, chronic/tardive, and non-motor and levo-dopa induced
dyskinesia (LID).
[0209] In other embodiments, the CNS disease or disorder is
selected from disorders characterized by a relative reduction in
synaptic plasticity and synaptic processes including, for example,
Fragile X, Rhett's disorder, Williams syndrome, Renpenning's
syndrome, autism spectrum disorders, including autism, Asperger's
syndrome, pervasive development disorder and childhood
disintegrative disorder.
[0210] In other embodiments, the CNS disorder is neuropathic
pain.
[0211] In other embodiments, the CNS disorder is a psychiatric,
mental, mood or affective disorder selected from a bipolar
disorder, schizophrenia, general psychosis, drug-induced psychosis,
a delusional disorder, schizoaffective disorder, obsessive
compulsive disorder (OCD), a depressive disorder, an anxiety
disorder, a panic disorder, post-traumatic stress disorder
(PTSD).
[0212] In other embodiments, the CNS disorder is selected from
chemo brain, levo-dopa induced addictive behavior, alcoholism,
narcotic dependence (including but not limited to amphetamine,
opiates or other substances) and substance abuse.
[0213] In some embodiments, the disease or disorder is achalasia or
esophageal achalasia.
[0214] In other embodiments, the disease or disorder is
non-alcoholic steatohepatitis or NASH.
[0215] In further embodiments, the disease, health condition or
disorder is selected from ischemia, reperfusion damage;
ischemia/reperfusion associated with organ transplant, lung
transplant, pulmonary transplant or cardiac transplant; conserving
blood substituents in trauma patients.
[0216] In further embodiments, the disease, health condition or
disorder is a sexual, gynecological or urological disorder of
condition selected from erectile dysfunction; impotence; premature
ejaculation; female sexual dysfunction; female sexual arousal
dysfunction; hypoactive sexual arousal disorder; vaginal atrophy,
dyspaneuria, atrophic vaginitis; benign prostatic hyperplasia (BPH)
or hypertrophy or enlargement; bladder outlet obstruction; bladder
pain syndrome (BPS); interstitial cystitis (IC); overactive
bladder, neurogenic bladder and incontinence; diabetic
nephropathy.
[0217] In further embodiments, the disease, health condition or
disorder is selected from vaginal atrophy, dyspaneuria and atrophic
vaginitis.
[0218] In further embodiments, the disease, health condition or
disorder is selected from benign prostatic hyperplasia (BPH) or
hypertrophy or enlargement; bladder outlet obstruction; bladder
pain syndrome (BPS); interstitial cystitis (IC); overactive
bladder, neurogenic bladder and incontinence.
[0219] In further embodiments, the disease, health condition or
disorder is a sexual, condition selected from erectile dysfunction;
impotence; premature ejaculation; female sexual dysfunction; female
sexual arousal dysfunction and hypoactive sexual arousal
disorder.
[0220] In further embodiments, the disease or disorder is diabetic
nephropathy.
[0221] In further embodiments, the disease, health condition or
disorder is Duchenne and Becker muscular dystrophies.
[0222] In further embodiments, the disease is an ocular diseases or
disorder selected from glaucoma, retinopathy, diabetic retinopathy
(including proliferative and non-proliferative), blepharitis, dry
eye syndrome and Sjogren's Syndrome.
[0223] In further embodiments, the disease is a hearing diseases or
disorder selected from hearing impairment, partial or total hearing
loss; partial or total deafness; tinnitus; and noise-induced
hearing loss.
[0224] In further embodiments, the disease is a topical or skin
disorders or condition selected from dermal fibrosis, scleroderma
and skin fibrosis.
[0225] In further embodiments, the treatment involves wound
healing; wound healing in diabetics; improvement of microvascular
perfusion; improvement of microvascular perfusion issues following
injury; treatment of anal fissures; and treatment of diabetic
ulcers.
[0226] In further embodiments, the disease or condition is selected
from cancer metastasis; osteoporosis; gastroparesis; functional
dyspepsia; diabetic complications; diseases associated with
endothelial dysfunction and neurologic disorders associated with
decreased nitric oxide production.
[0227] In further embodiments, the disease or condition is selected
from age-associated memory impairment, mixed dementia, sleep wake
disorders, and Sneddon's syndrome.
[0228] In further embodiments, the disease or condition is selected
from acute pain, central pain syndrome, chemotherapy induced
neuropathy and neuropathic pain, diabetic neuropathy, fibromyalgia,
Inflammatory pain, neuropathic pain, neuropathic pain associated
with a CNS disease, painful diabetic peripheral neuropathy,
post-operative pain, tonic pain, and visceral pain.
[0229] In further embodiments, the disease or condition is selected
from altitude (mountain) sickness, cerebral small vessel disease,
cerebral vasculitis, cerebral vasospasm, diabetic heart failure
(diabetic HF), diabetic angiopathy, diabetic macular edema,
diabetic microangiopathies, Heart failure with preserved ejection
fraction (HFpEF), hepatic encephalopathy, moyamoya, non-diabetic
nephropathy, and Parkinson's Dysphagia.
[0230] In further embodiments, the disease or condition is selected
from angina, ataxia telangliectasia, autism spectrum disorder,
chronic fatigue, chronic traumatic encephalopathy (CTE), cognitive
impairment associated with diabetes, cognitive impairment
associated with Multiple Sclerosis, cognitive impairment associated
with obstructive sleep apnea, cognitive impairment associated with
schizophrenia (CIAS), cognitive impairment associated with sickle
cell, concussion, dysphagia, eye fibrosis, Fabry Disease, Gaucher
Disease, glioblastoma, inflammation caused by cerebral malaria
(SoC), inflammation caused by infectious disease, intellectual
disability, microvascular angina, myopic choroidal
neovascularization, neuromyelitis optica, neuropathic pain with
Multiple Sclerosis, neuropathic pain with shingles (herpes zoster),
neuropathic pain with spine surgery, Parkinson's Dementia,
peripheral and autonomic neuropathies, peripheral retinal
degeneration, post-traumatic stress syndrome, post herpetic
neuralgia, post-operative dementia, proliferative vitroretinopathy,
radiation induced fibrosis, radiculopathy, refractory epilepsy,
retinal vein occlusion, Sjogren's syndrome, spinal cord injury,
spinal muscular atrophy, spinal subluxations, tauopathies, ulcers,
and wet age-related macular degeneration.
[0231] In further embodiments, the disease or condition is selected
from an orphan pain indication. In particular, the orphan pain
indication is selected from Acetazolamide-responsive myotonia,
Autoerythrocyte sensitization syndrome, Autosomal dominant
Charcot-Marie-Tooth disease type 2V, Autosomal dominant
intermediate Charcot-Marie-Tooth disease with neuropathic pain,
Autosomal recessive limb-girdle muscular dystrophy type 2A,
Channelopathy-associated congenital insensitivity to pain, Chronic
pain requiring intraspinal analgesia, Complex regional pain
syndrome, Complex regional pain syndrome type 1, Complex regional
pain syndrome type 2, Congenital insensitivity to pain with
hyperhidrosis, Congenital insensitivity to pain with severe
intellectual disability, Congenital insensitivity to
pain-hypohidrosis syndrome, Diffuse palmoplantar keratoderma with
painful fissures, Familial episodic pain syndrome, Familial
episodic pain syndrome with predominantly lower limb involvement,
Familial episodic pain syndrome with predominantly upper body
involvement, Hereditary painful callosities, Hereditary sensory and
autonomic neuropathy type 4, Hereditary sensory and autonomic
neuropathy type 5, Hereditary sensory and autonomic neuropathy type
7, Interstitial cystitis, Painful orbital and systemic
neurofibromas-marfanoid habitus syndrome, Paroxysmal extreme pain
disorder, Persistent idiopathic facial pain, Qualitative or
quantitative defects of calpain, and Tolosa-Hunt syndrome.
[0232] In another embodiment, compounds of the invention can be
delivered in the form of implanted devices, such as stents. A stent
is a mesh `tube` inserted into a natural passage/conduit in the
body to prevent or counteract a disease-induced, localized flow
constriction. The term may also refer to a tube used to temporarily
hold such a natural conduit open to allow access for surgery.
[0233] A drug-eluting stent (DES) is a peripheral or coronary stent
(a scaffold) placed into narrowed, diseased peripheral or coronary
arteries that slowly releases a drug to block cell proliferation,
usually smooth muscle cell proliferation. This prevents fibrosis
that, together with clots (thrombus), could otherwise block the
stented artery, a process called restenosis. The stent is usually
placed within the peripheral or coronary artery by an
Interventional cardiologist or Interventional Radiologist during an
angioplasty procedure. Drugs commonly used in DES in order to block
cell proliferation include paclitaxel or rapamycin analogues
[0234] In some embodiments of the invention, a sGC stimulator of
the invention can be delivered by means of a drug-eluting stent
coated with said sGC stimulator. A drug-eluting stent coated with a
sGC stimulator of the invention may be useful in the prevention of
stent restenosis and thrombosis during percutaneous coronary
interventions. A drug-eluting stent coated with a sGC stimulator of
the invention may be able to prevent smooth cell proliferation as
well as to assist re-vascularization and re-generation of the
endothelial tissue of the artery in which the stent is
inserted.
[0235] An alternative to percutaneous coronary intervention for the
treatment of intractable angina due to coronary artery occlusive
disease is the procedure named Coronary Artery Bypass Grafting
(CABG). CABG provides only palliation of an ongoing process that is
further complicated by the rapid development of graft
atherosclerosis. The saphenous vein graft is the most commonly used
conduit in CABG surgery. The long-term clinical success of venous
CABG is hampered for three main reasons: accelerated graft
atherosclerosis, incomplete endothelialization and thrombosis.
[0236] In some embodiments, a sGC stimulator of the invention can
be used for the prevention of saphenous graft failure during CABG.
Compounds of the invention may assist the process of
endothelialization and help prevent thrombosis. In this indication,
the sGC stimulator is delivered locally in the form of a gel.
[0237] The terms, "disease", "disorder" and "condition" may be used
interchangeably here to refer to an sGC, cGMP and/or NO mediated
medical or pathological condition.
[0238] As used herein, the terms "subject" and "patient" are used
interchangeably. The terms "subject" and "patient" refer to an
animal (e.g., a bird such as a chicken, quail or turkey, or a
mammal), specifically a "mammal" including a non-primate (e.g., a
cow, pig, horse, sheep, rabbit, guinea pig, rat, cat, dog, and
mouse) and a primate (e.g., a monkey, chimpanzee and a human), and
more specifically a human. In some embodiments, the subject is a
non-human animal such as a farm animal (e.g., a horse, cow, pig or
sheep), or a pet (e.g., a dog, cat, guinea pig or rabbit). In some
embodiments, the subject is a human.
[0239] The invention also provides a method for treating one of the
above diseases, conditions and disorders in a subject, comprising
administering a therapeutically effective amount of a compound of
Formula I, or a pharmaceutically acceptable salt thereof, to the
subject in need of the treatment. Alternatively, the invention
provides the use of a compound of Formula I, or a pharmaceutically
acceptable salt thereof, in the treatment of one of these diseases,
conditions and disorders in a subject in need of the treatment. The
invention further provides a method of making or manufacturing a
medicament useful for treating one of these diseases, conditions
and disorders comprising using a compound of Formula I, or a
pharmaceutically acceptable salt thereof.
[0240] The term "biological sample", as used herein, refers to an
in vitro or ex vivo sample, and includes, without limitation, cell
cultures or extracts thereof; biopsied material obtained from a
mammal or extracts thereof; blood, saliva, urine, faeces, semen,
tears, lymphatic fluid, ocular fluid, vitreous humour,
cerebrospinal fluid (CSF), or other body fluids or extracts
thereof.
[0241] "Treat", "treating" or "treatment" with regard to a disorder
or disease refers to alleviating or abrogating the cause and/or the
effects of the disorder or disease. As used herein, the terms
"treat", "treatment" and "treating" refer to the reduction or
amelioration of the progression, severity and/or duration of an
sGC, cGMP and/or NO mediated condition, or the amelioration of one
or more symptoms (preferably, one or more discernible symptoms) of
said condition (i.e. "managing" without "curing" the condition),
resulting from the administration of one or more therapies (e.g.,
one or more therapeutic agents such as a compound or composition of
the invention). In specific embodiments, the terms "treat";
"treatment" and "treating" refer to the amelioration of at least
one measurable physical parameter of an sGC, cGMP and/or NO
mediated condition. In other embodiments the terms "treat",
"treatment" and "treating" refer to the inhibition of the
progression of an sGC, cGMP and/or NO mediated condition, either
physically by, e.g., stabilization of a discernible symptom or
physiologically by, e.g., stabilization of a physical parameter, or
both.
[0242] The term "preventing" as used herein refers to administering
a medicament beforehand to avert or forestall the appearance of one
or more symptoms of a disease or disorder. The person of ordinary
skill in the medical art recognizes that the term "prevent" is not
an absolute term. In the medical art it is understood to refer to
the prophylactic administration of a drug to substantially diminish
the likelihood or seriousness of a condition, or symptom of the
condition and this is the sense intended in this disclosure. The
Physician's Desk Reference, a standard text in the field, uses the
term "prevent" hundreds of times. As used therein, the terms
"prevent", "preventing" and "prevention" with regard to a disorder
or disease, refer to averting the cause, effects, symptoms or
progression of a disease or disorder prior to the disease or
disorder fully manifesting itself.
[0243] In one embodiment, the methods of the invention are a
preventative or "pre-emptive" measure to a patient, specifically a
human, having a predisposition (e.g. a genetic predisposition) to
developing an sGC, cGMP and/or NO related disease, disorder or
symptom.
[0244] In other embodiments, the methods of the invention are a
preventative or "pre-emptive" measure to a patient, specifically a
human, suffering from a disease, disorder or condition that makes
him at risk of developing an sGC, cGMP or NO related disease,
disorder or symptom.
[0245] The compounds and pharmaceutical compositions described
herein can be used alone or in combination therapy for the
treatment or prevention of a disease or disorder mediated,
regulated or influenced by sGC, cGMP and/or NO.
[0246] Compounds and compositions here disclosed are also useful
for veterinary treatment of companion animals, exotic animals and
farm animals, including, without limitation, dogs, cats, mice,
rats, hamsters, gerbils, guinea pigs, rabbits, horses, pigs and
cattle.
[0247] In other embodiments, the invention provides a method of
stimulating sGC activity in a biological sample, comprising
contacting said biological sample with a compound or composition of
the invention. Use of a sGC stimulator in a biological sample is
useful for a variety of purposes known to one of skill in the art.
Examples of such purposes include, without limitation, biological
assays and biological specimen storage.
Combination Therapies
[0248] The compounds and pharmaceutical compositions described
herein can be used in combination therapy with one or more
additional therapeutic agents. For combination treatment with more
than one active agent, where the active agents are in separate
dosage formulations, the active agents may be administered
separately or in conjunction. In addition, the administration of
one element may be prior to, concurrent to, or subsequent to the
administration of the other agent.
[0249] When co-administered with other agents, e.g., when
co-administered with another pain medication, an "effective amount"
of the second agent will depend on the type of drug used. Suitable
dosages are known for approved agents and can be adjusted by the
skilled artisan according to the condition of the subject, the type
of condition(s) being treated and the amount of a compound
described herein being used. In cases where no amount is expressly
noted, an effective amount should be assumed. For example,
compounds described herein can be administered to a subject in a
dosage range from between about 0.01 to about 10,000 mg/kg body
weight/day, about 0.01 to about 5000 mg/kg body weight/day, about
0.01 to about 3000 mg/kg body weight/day, about 0.01 to about 1000
mg/kg body weight/day, about 0.01 to about 500 mg/kg body
weight/day, about 0.01 to about 300 mg/kg body weight/day, about
0.01 to about 100 mg/kg body weight/day.
[0250] When "combination therapy" is employed, an effective amount
can be achieved using a first amount of a compound of Formula I or
a pharmaceutically acceptable salt thereof and a second amount of
an additional suitable therapeutic agent.
[0251] In one embodiment of this invention, a compound of Formula
I, or a pharmaceutically acceptable salt thereof, and the
additional therapeutic agent are each administered in an effective
amount (i.e., each in an amount which would be therapeutically
effective if administered alone). In another embodiment, the
compound of Formula I and the additional therapeutic agent are each
administered in an amount which alone does not provide a
therapeutic effect (a sub-therapeutic dose). In yet another
embodiment, the compound of Formula I can be administered in an
effective amount, while the additional therapeutic agent is
administered in a sub-therapeutic dose. In still another
embodiment, the compound of Formula I can be administered in a
sub-therapeutic dose, while the additional therapeutic agent, for
example, a suitable cancer-therapeutic agent is administered in an
effective amount.
[0252] As used herein, the terms "in combination" or
"co-administration" can be used interchangeably to refer to the use
of more than one therapy (e.g., one or more prophylactic and/or
therapeutic agents). The use of the terms does not restrict the
order in which therapies (e.g., prophylactic and/or therapeutic
agents) are administered to a subject.
[0253] Co-administration encompasses administration of the first
and second amounts of the compounds in an essentially simultaneous
manner, such as in a single pharmaceutical composition, for
example, capsule or tablet having a fixed ratio of first and second
amounts, or in multiple, separate capsules or tablets for each. In
addition, such co-administration also encompasses use of each
compound in a sequential manner in either order. When
co-administration involves the separate administration of the first
amount of a compound of Formula I and a second amount of an
additional therapeutic agent, the compounds are administered
sufficiently close in time to have the desired therapeutic effect.
For example, the period of time between each administration which
can result in the desired therapeutic effect, can range from
minutes to hours and can be determined taking into account the
properties of each compound such as potency, solubility,
bioavailability, plasma half-life and kinetic profile. For example,
a compound of Formula I and the second therapeutic agent can be
administered in any order within about 24 hours of each other,
within about 16 hours of each other, within about 8 hours of each
other, within about 4 hours of each other, within about 1 hour of
each other or within about 30 minutes of each other.
[0254] More, specifically, a first therapy (e.g., a prophylactic or
therapeutic agent such as a compound described herein) can be
administered prior to (e.g., 5 minutes, 15 minutes, 30 minutes, 45
minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48
hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5
weeks, 6 weeks, 8 weeks, or 12 weeks before), concomitantly with,
or subsequent to (e.g., 5 minutes, 15 minutes, 30 minutes, 45
minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48
hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5
weeks, 6 weeks, 8 weeks, or 12 weeks after) the administration of a
second therapy (e.g., a prophylactic or therapeutic agent such as
an anti-cancer agent) to a subject.
[0255] Examples of other therapeutic agents that may be combined
with a compound of Formula I, or a pharmaceutically acceptable salt
thereof, either administered separately or in the same
pharmaceutical composition include, but are not limited to:
(1) Endothelium-derived releasing factor (EDRF) or NO gas. (2) NO
donors such as a nitrosothiol, a nitrite, a sydnonimine, a NONOate,
a N-nitrosamine, a N-hydroxyl nitrosamine, a nitrosimine,
nitrotyrosine, a diazetine dioxide, an oxatriazole 5-imine, an
oxime, a hydroxylamine, a N-hydroxyguanidine, a hydroxyurea or a
furoxan. Some examples of these types of compounds include:
glyceryl trinitrate (also known as GTN, nitroglycerin,
nitroglycerine, and trinitrogylcerin), the nitrate ester of
glycerol; sodium nitroprusside (SNP), wherein a molecule of nitric
oxide is coordinated to iron metal forming a square bipyramidal
complex; 3-morpholinosydnonimine (SIN-1), a zwitterionic compound
formed by combination of a morpholine and a sydnonimine;
S-nitroso-N-acetylpenicillamine (SNAP), an N-acetylated amino acid
derivative with a nitrosothiol functional group;
diethylenetriamine/NO (DETA/NO), a compound of nitric oxide
covalently linked to diethylenetriamine; an m-nitroxymethyl phenyl
ester of acetyl salicylic acid. More specific examples of some of
these classes of NO donors include: the classic nitrovasodilators,
such as organic nitrate and nitrite esters, including
nitroglycerin, amyl nitrite, isosorbide dinitrate, isosorbide
5-mononitrate, and nicorandil; isosorbide (Dilatrate.RTM.-SR,
Imdur.RTM., Ismo.RTM., Isordil.RTM., Isordil.RTM., Titradose.RTM.,
Monoket.RTM.), 3-morpholinosydnonimine; linsidomine chlorohydrate
("SIN-1"); S-nitroso-N-acetylpenicillamine ("SNAP");
S-nitrosoglutathione (GSNO), sodium nitroprusside,
S-nitrosoglutathione mono-ethyl-ester (GSNO-ester),
6-(2-hydroxy-1-methyl-nitrosohydrazino)-N-methyl-1-hexanamine or
diethylamine NONOate. (3) Other substances that enhance cGMP
concentrations such as protoporphyrin IX, arachidonic acid and
phenyl hydrazine derivatives. (4) Nitric Oxide Synthase substrates:
for example, N-hydroxyguanidine based analogs, such as
N[G]-hydroxy-L-arginine (NOHA), 1-(3,
4-dimethoxy-2-chlorobenzylideneamino)-3-hydroxyguanidine, and PR5
(1-(3, 4-dimethoxy-2-chlorobenzylideneamino)-3-hydroxyguanidine);
L-arginine derivatives (such as homo-Arg, homo-NOHA,
N-tert-butyloxy- and N-(3-methyl-2-butenyl)oxy-L-arginine,
canavanine, epsilon guanidine-carpoic acid, agmatine,
hydroxyl-agmatine, and L-tyrosyl-L-arginine);
N-alkyl-N'-hydroxyguanidines (such as
N-cyclopropyl-N'-hydroxyguanidine and N-butyl-N'-hydroxyguanidine),
N-aryl-N'-hydroxyguanidines (such as N-phenyl-N'-hydroxyguanidine
and its para-substituted derivatives which bear --F, --Cl, -methyl,
--OH substituents, respectively); guanidine derivatives such as
3-(trifluoromethyl) propylguanidine. (5) Compounds which enhance
eNOS transcription. (6) NO independent heme-independent sGC
activators, including, but not limited to: BAY 58-2667 (described
in patent publication DE19943635)
##STR00081##
HMR-1766 (ataciguat sodium, described in patent publication
WO2000002851)
##STR00082##
S 3448
(2-(4-chloro-phenylsulfonylamino)-4,5-dimethoxy-N-(4-(thiomorpholi-
ne-4-sulfonyl)-phenyl)-benzamide (described in patent publications
DE19830430 and WO2000002851)
##STR00083##
and
HMR-1069 (Sanofi-Aventis).
[0256] (7) Heme-dependent, NO-independent sGC stimulators
including, but not limited to: YC-1 (see patent publications
EP667345 and DE19744026)
##STR00084##
riociguat (BAY 63-2521, Adempas.RTM., described in DE19834044)
##STR00085##
neliciguat (BAY 60-4552, described in WO 2003095451)
##STR00086##
vericiguat (BAY 1021189)
##STR00087##
BAY 41-2272 (described in DE19834047 and DE19942809)
##STR00088##
BAY 41-8543 (described in DE19834044)
##STR00089##
etriciguat (described in WO 2003086407)
##STR00090##
CFM-1571 (described in patent publication WO2000027394)
##STR00091##
A-344905, its acrylamide analogue A-350619 and the aminopyrimidine
analogue A-778935
##STR00092##
and other sGC stimulators described in one of publications
US20090209556, U.S. Pat. No. 8,455,638, US20110118282
(WO2009032249), US20100292192, US20110201621, U.S. Pat. Nos.
7,947,664, 8,053,455 (WO2009094242), US20100216764, U.S. Pat. No.
8,507,512, (WO2010099054) US20110218202 (WO2010065275),
US20130012511 (WO2011119518), US20130072492 (WO2011149921),
US20130210798 (WO2012058132) and other compounds described in
Tetrahedron Letters (2003), 44(48): 8661-8663. (8) Compounds that
inhibit the degradation of cGMP, such as: PDE5 inhibitors, such as,
for example, sildenafil (Viagra.RTM.) and related agents such as
avanafil, lodenafil, mirodenafil, sildenafil citrate
(Revatio.RTM.), tadalafil (Cialis.RTM. or Adcirca.RTM.), vardenafil
(Levitra.RTM.) and udenafil; alprostadil; dipyridamole and
PF-00489791; and PDE9 inhibitors, such as, for example,
PF-04447943, and PDE10 inhibitors such as, for example, PF-02545920
(PF-10). (9) Calcium channel blockers of the following types:
dihydropyridine calcium channel blockers such asamlodipine
(Norvasc.RTM.), aranidipine (Sapresta.RTM.), azelnidipine
(Calblock.RTM.), barnidipine (HypoCa.RTM.), benidipine
(Coniel.RTM.), cilnidipine (Atelec.RTM., Cinalong.RTM.,
Siscard.RTM.), clevidipine (Cleviprex.RTM.), diltiazem, efonidipine
(Landel.RTM.), felodipine (Plendil.RTM.), lacidipine (Motens.RTM.,
Lacipil.RTM.), lercanidipine (Zanidip.RTM.), manidipine
(Calslot.RTM., Madipine.RTM.), nicardipine (Cardene.RTM., Carden
SR.RTM.), nifedipine (Procardia.RTM., Adalat.RTM.), nilvadipine
(Nivadil.RTM.), nimodipine (Nimotop.RTM.), nisoldipine
(Baymycard.RTM., Sular.RTM., Syscor.RTM.), nitrendipine
(Cardif.RTM., Nitrepin.RTM., Baylotensin.RTM.), pranidipine
(Acalas.RTM.), isradipine (Lomir.RTM.); phenylalkylamine calcium
channel blockers such as verapamil (Calan.RTM., Isoptin.RTM.)
##STR00093##
and gallopamil (Procorum.RTM., D600); benzothiazepines such
asdiltiazem (Cardizem.RTM.)
##STR00094##
and nonselective calcium channel inhibitors such as mibefradil,
bepridil, fluspirilene, and fendiline. (10) Endothelin receptor
antagonists (ERAs) such as the dual (ET.sub.A and ET.sub.B)
endothelin receptor antagonist bosentan (Tracleer.RTM.), sitaxentan
(Thelin.RTM.) or ambrisentan (Letairis.RTM.). (11) Prostacyclin
derivatives or analogues, such asprostacyclin (prostaglandin
I.sub.2), epoprostenol (synthetic prostacyclin, Flolan.RTM.),
treprostinil (Remodulin.RTM.), iloprost (Ilomedin.RTM.), iloprost
(Ventavis.RTM.); and oral and inhaled forms of Remodulin.RTM. under
development. (12) Antihyperlipidemics such as the following types:
bile acid sequestrants like cholestyramine, colestipol, colestilan,
colesevelam or sevelamer; statins like atorvastatin, simvastatin,
lovastatin, fluvastatin, pitavastatin, rosuvastatin and
pravastatin; cholesterol absorption inhibitors such as ezetimibe;
other lipid lowering agents such as icosapent ethyl ester,
omega-3-acid ethyl esters, reducol; fibric acid derivatives such as
clofibrate, bezafibrate, clinofibrate, gemfibrozil, ronifibrate,
binifibrate, fenofibrate, ciprofibrate, choline fenofibrate;
nicotinic acid derivatives such as acipimox and niacin;
combinations of statins, niacin and intestinal cholesterol
absorption-inhibiting supplements (ezetimibe and others) and
fibrates; and antiplatelet therapies such as clopidogrel bisulfate.
(13) Anticoagulants, such as the following types: coumarines
(Vitamin K antagonists) such as warfarin (Coumadin.RTM.),
cenocoumarol, phenprocoumon and phenindione; heparin and
derivatives such as low molecular weight heparin, fondaparinux and
idraparinux; direct thrombin inhibitors such as argatroban,
lepirudin, bivalirudin, dabigatran and ximelagatran (Exanta.RTM.);
and tissue-plasminogen activators, used to dissolve clots and
unblock arteries, such as alteplase. (14) Antiplatelet drugs such
as, for instance, topidogrel, ticlopidine, dipyridamole and
aspirin. (15) ACE inhibitors, for example the following types:
sulfhydryl-containing agents such as captopril (Capoten.RTM.) and
zofenopril; dicarboxylate-containing agents such as enalapril
(Vasotec/Renitec.RTM.), ramipril
(Altace.RTM./Tritace.RTM./Ramace.RTM./Ramiwin.RTM.), quinapril
(Accupril.RTM.), perindopril (Coversyl.RTM./Aceon.RTM.), lisinopril
(Lisodur.RTM./Lopril.RTM./Novatec.RTM./Prinivil.RTM./Zestril.RTM.)
and benazepril (Lotensin.RTM.); phosphonate-containing agents such
as fosinopril; naturally occurring ACE inhibitors such as
casokinins and lactokinins, which are breakdown products of casein
and whey that occur naturally after ingestion of milk products,
especially cultured milk; the lactotripeptides Val-Pro-Pro and
Ile-Pro-Pro produced by the probiotic Lactobacillus helveticus or
derived from casein also having ACE-inhibiting and antihypertensive
functions; other ACE inhibitors such as alacepril, delapril,
cilazapril, imidapril, trandolapril, temocapril, moexipril and
pirapril. (16) Supplemental oxygen therapy. (17) Beta blockers,
such as the following types: non-selective agents such as
alprenolol, bucindolol, carteolol, carvedilol, labetalol, nadolol,
penbutolol, pindolol, oxprenonol, acebutolol, sotalol, mepindolol,
celiprolol, arotinolol, tertatolol, amosulalol, nipradilol,
propranolol and timolol; .beta..sub.1-Selective agents such as
cebutolol, atenolol, betaxolol, bisoprolol, celiprolol, dobutamine
hydrochloride, irsogladine maleate, carvedilol, talinolol, esmolol,
metoprolol and nebivolol; and .beta..sub.2-Selective agents such as
butaxamine. (18) Antiarrhythmic agents such as the following types:
Type I (sodium channel blockers) such as quinidine, lidocaine,
phenytoin, propafenone; Type III (potassium channel blockers) such
as amiodarone, dofetilide and sotalol; and Type V such as adenosine
and digoxin. (19) Diuretics such as thiazide diuretics, for example
chlorothiazide, chlorthalidone and hydrochlorothiazide,
bendroflumethiazide, cyclopenthiazide, methyclothiazide,
polythiazide, quinethazone, xipamide, metolazone, indapamide,
cicletanine; loop diuretics, such as furosemide and toresamide;
potassium-sparing diuretics such as amiloride, spironolactone,
canrenoate potassium, eplerenone and triamterene; combinations of
these agents; other diuretics such as acetazolamid and carperitide.
(20) Direct-acting vasodilators such as hydralazine hydrochloride,
diazoxide, sodium nitroprusside, cadralazine; other vasodilators
such as isosorbide dinitrate and isosorbide 5-mononitrate. (21)
Exogenous vasodilators such as Adenocard.RTM. and alpha blockers.
(22) Alpha-1-adrenoceptor antagonists such as prazosin, indoramin,
urapidil, bunazosin, terazosin and doxazosin; atrial natriuretic
peptide (ANP), ethanol, histamine-inducers, tetrahydrocannabinol
(THC) and papaverine. (23) Bronchodilators of the following types:
short acting .beta..sub.2 agonists, such as albutamol or albuterol
(Ventolin.RTM.) and terbutaline; long acting .beta..sub.2 agonists
(LABAs) such as salmeterol and formoterol; anticholinergics such as
pratropium and tiotropium; and theophylline, a bronchodilator and
phosphodiesterase inhibitor. (24) Corticosteroids such as
beclomethasone, methylprednisolone, betamethasone, prednisone,
prednisolone, triamcinolone, dexamethasone, fluticasone,
flunisolide, hydrocortisone, and corticosteroid analogs such as
budesonide. (25) Dietary supplements such as, for example omega-3
oils; folic acid, niacin, zinc, copper, Korean red ginseng root,
ginkgo, pine bark, Tribulus terrestris, arginine, Avena sativa,
horny goat weed, maca root, muira puama, saw palmetto, and Swedish
flower pollen; vitamin C, Vitamin E, Vitamin K2; testosterone
supplements, testosterone transdermal patch; zoraxel, naltrexone,
bremelanotide and melanotan II. (26) PGD2 receptor antagonists.
(27) Immunosuppressants such as cyclosporine (cyclosporine A,
Sandimmune.RTM., Neoral.RTM.), tacrolimus (FK-506, Prograf.RTM.),
rapamycin (Sirolimus.RTM., Rapamune.RTM.) and other FK-506 type
immunosuppressants, mycophenolate, e.g., mycophenolate mofetil
(CellCept.RTM.). (28) Non-steroidal anti-asthmatics such as
.beta.2-agonists like terbutaline, metaproterenol, fenoterol,
isoetharine, albuterol, salmeterol, bitolterol and pirbuterol;
.beta.2-agonist-corticosteroid combinations such as
salmeterol-fluticasone (Advair.RTM.), formoterol-budesonide
(Symbicort.RTM.), theophylline, cromolyn, cromolyn sodium,
nedocromil, atropine, ipratropium, ipratropium bromide and
leukotriene biosynthesis inhibitors (zileuton, BAY1005). (29)
Non-steroidal anti-inflammatory agents (NSAIDs) such as propionic
acid derivatives like alminoprofen, benoxaprofen, bucloxic acid,
carprofen, fenbufen, fenoprofen, fluprofen, flurbiprofen,
ibuprofen, indoprofen, ketoprofen, miroprofen, naproxen, oxaprozin,
pirprofen, pranoprofen, suprofen, tiaprofenic acid and
tioxaprofen); acetic acid derivatives such as indomethacin,
acemetacin, alclofenac, clidanac, diclofenac, fenclofenac,
fenclozic acid, fentiazac, furofenac, ibufenac, isoxepac, oxpinac,
sulindac, tiopinac, tolmetin, zidometacin and zomepirac; fenamic
acid derivatives such as flufenamic acid, meclofenamic acid,
mefenamic acid, niflumic acid and tolfenamic acid;
biphenylcarboxylic acid derivatives such as diflunisal and
flufenisal; oxicams such as isoxicam, piroxicam, sudoxicam and
tenoxican; salicylates such as acetyl salicylic acid and
sulfasalazine; and the pyrazolones such as apazone, bezpiperylon,
feprazone, mofebutazone, oxyphenbutazone and phenylbutazone. (30)
Cyclooxygenase-2 (COX-2) inhibitors such as celecoxib
(Celebrex.RTM.), rofecoxib (Vioxx.RTM.), valdecoxib, etoricoxib,
parecoxib and lumiracoxib; opioid analgesics such as codeine,
fentanyl, hydromorphone, levorphanol, meperidine, methadone,
morphine, oxycodone, oxymorphone, propoxyphene, buprenorphine,
butorphanol, dezocine, nalbuphine and pentazocine. (31)
Anti-diabetic agents such as insulin and insulin mimetics;
sulfonylureas such as glyburide, glybenclamide, glipizide,
gliclazide, gliquidone, glimepiride, meglinatide, tolbutamide,
chlorpropamide, acetohexamide and olazamide; biguanides such as
metformin (Glucophage.RTM.); .alpha.-glucosidase inhibitors such as
acarbose, epalrestat, voglibose, miglitol; thiazolidinone compounds
such as rosiglitazone (Avandia.RTM.), troglitazone (Rezulin.RTM.),
ciglitazone, pioglitazone (Actos.RTM.) and englitazone; insulin
sensitizers such as pioglitazone and rosiglitazone; insulin
secretagogues such as repaglinide, nateglinide and mitiglinide;
incretin mimetics such as exanatide and liraglutide; amylin
analogues such as pramlintide; glucose lowering agents such as
chromium picolinate, optionally combined with biotin; dipeptidyl
peptidase IV inhibitors such as sitagliptin, vildagliptin,
saxagliptin, alogliptin and linagliptin. (32) HDL
cholesterol-increasing agents such as anacetrapib and dalcetrapib.
(33) Antiobesity drugs such as methamphetamine hydrochloride,
amfepramone hydrochloride (Tenuate.RTM.), phentermine
(Ionamin.RTM.), benzfetamine hydrochloride (Didrex.RTM.),
phendimetrazine tartrate (Bontril.RTM., Prelu-2 .RTM.,
Plegine.RTM.), mazindol (Sanorex.RTM.), orlistat (Xenical.RTM.),
sibutramine hydrochloride monohydrate (Meridia.RTM.,
Reductil.RTM.), rimonabant (Acomplia.RTM.), amfepramone, chromium
picolinate; combination such as phentermine/topiramate,
bupropion/naltrexone, sibutramine/metformin, bupropion
SR/zonisamide SR, salmeterol, xinafoate/fluticasone propionate;
lorcaserin hydrochloride, phentermine/topiramate, cetilistat,
exenatide, liraglutide, metformin hydrochloride,
sibutramine/metformin, bupropion SR/zonisamide SR, CORT-108297,
canagliflozin, chromium picolinate, GSK-1521498, LY-377604,
metreleptin, obinepitide, P-57AS3, PSN-821, salmeterol
xinafoate/fluticasone propionate, sodium tungstate, somatropin
(recombinant), tesamorelin, tesofensine, velneperit, zonisamide,
beloranib hemioxalate, insulinotropin, resveratrol, sobetirome,
tetrahydrocannabivarin and beta-lapachone. (34) Angiotensin
receptor blockers such as losartan, valsartan, candesartan,
cilexetil, eprosaran, irbesartan, telmisartan, olmesartran,
medoxomil, azilsartan and medoxomil. (35) Renin inhibitors such as
aliskiren hemifumirate. (36) Centrally acting alpha-2-adrenoceptor
agonists such as methyldopa, clonidine and guanfacine. (37)
Adrenergic neuron blockers such as guanethidine and guanadrel. (38)
Imidazoline I-1 receptor agonists such as rimenidine dihydrogen
phosphate and moxonidine hydrochloride hydrate. (39) Aldosterone
antagonists such as spironolactone and eplerenone. (40) Potassium
channel activators such as pinacidil. (41) Dopamine D1 agonists
such as fenoldopam mesilate; other dopamine agonists such as
ibopamine, dopexamine and docarpamine. (42) 5-HT2 antagonists such
as ketanserin. (43) Vasopressin antagonists such as tolvaptan. (44)
Calcium channel sensitizers such as levosimendan or activators such
as nicorandil. (45) PDE-3 inhibitors such as amrinone, milrinone,
enoximone, vesnarinone, pimobendan, and olprinone. (46) Adenylate
cyclase activators such as colforsin dapropate hydrochloride. (47)
Positive inotropic agents such as digoxin and metildigoxin;
metabolic cardiotonic agents such as ubidecarenone; brain
natriuretic peptides such as nesiritide. (48) Drugs used for the
treatment of erectile dysfunction such as alprostadil, aviptadil,
and phentolamine mesilate. (49) Drugs used in the treatment of
obesity, including but not limited to, methamphetamine
hydrochloride (Desoxyn.RTM.), amfepramone hydrochloride
(Tenuate.RTM.), phentermine (Ionamin.RTM.), benzfetamine
hydrochloride (Didrex.RTM.), phendimetrazine hydrochloride
(Bontril.RTM., Prelu-2.RTM., Plegine.RTM.), mazindol (Sanorex.RTM.)
and orlistat (Xenical.RTM.). (50) Drugs used for the treatment of
Alzheimer's disease and dementias such as the following types:
acetyl cholinesterase inhibitors including galantamine
(Razadyne.RTM.), rivastigmine (Exelon.RTM.), donepezil
(Aricept.RTM.) and tacrine (Cognex.RTM.); NMDA receptor antagonists
such as memantine (Namenda.RTM.); and oxidoreductase inhibitors
such as idebenone. (51) Psychiatric medications such as the
following types: ziprasidone (Geodon.TM.), risperidone
(Risperdal.TM.), olanzapine (Zyprexa.TM.), valproate; dopamine D4
receptor antagonists such as clozapine; dopamine D2 receptor
antagonists such as nemonapride; mixed dopamine D1/D2 receptor
antagonists such as zuclopenthixol; GABA A receptor modulators such
as carbamazepine; sodium channel inhibitors such as lamotrigine;
monoamine oxidase inhibitors such as moclobemide and indeloxazine;
primavanserin, perospirone; and PDE4 inhibitors such as rolumilast.
(52) Drugs used for the treatment of movement disorders or symptoms
such as the following types: catechol-O-methyl transferase
inhibitors such as entacapone; monoamine oxidase B inhibitors such
as selegiline; dopamine receptor modulators such as levodopa;
dopamine D3 receptor agonists such as pramipexole; decarboxylase
inhibitors such as carbidopa; other dopamine receptor agonists such
as pergolide, ropinirole, cabergoline; ritigonide, istradefylline,
talipexole; zonisamide and safinamide; and synaptic vesicular amine
transporter inhibitors such as tetrabenazine. (53) Drugs used for
the treatment of mood or affective disorders or OCD such as the
following types tricyclic antidepressants such as amitriptyline
(Elavil.RTM.), desipramine (Norpramin.RTM.), imipramine
(Tofranil.RTM.), amoxapine (Asendin.RTM.), nortriptyline and
clomipramine; selective serotonin reuptake inhibitors (SSRIs) such
as paroxetine (Paxil.RTM.), fluoxetine (Prozac.RTM.), sertraline
(Zoloft.RTM.), and citralopram (Celexa.RTM.); doxepin
(Sinequan.RTM.), trazodone (Desyrel.RTM.) and agomelatine;
selective norepinephrine reuptake inhibitors (SNRIs) such as
venlafaxine, reboxetine and atomoxetine; dopaminergic
antidepressants such as bupropion and amineptine. (54) Drugs for
the enhancement of synaptic plasticity such as the following types:
nicotinic receptor antagonists such as mecamylamine; and mixed
5-HT, dopamine and norepinephrine receptor agonists such as
lurasidone. (55) Drugs used for the treatment of ADHD such as
amphetamine; 5-HT receptor modulators such as vortioxetine and
alpha-2 adrenoceptor agonists such as clonidine. (56) Neutral
endopeptidase (NEP) inhibitors such as sacubitril, omapatrilat; and
(57) Methylene blue (MB).
Kits
[0257] The compounds and pharmaceutical formulations described
herein may be contained in a kit. The kit may include single or
multiple doses of two or more agents, each packaged or formulated
individually, or single or multiple doses of two or more agents
packaged or formulated in combination. Thus, one or more agents can
be present in first container, and the kit can optionally include
one or more agents in a second container. The container or
containers are placed within a package, and the package can
optionally include administration or dosage instructions. A kit can
include additional components such as syringes or other means for
administering the agents as well as diluents or other means for
formulation. Thus, the kits can comprise: a) a pharmaceutical
composition comprising a compound described herein and a
pharmaceutically acceptable carrier, vehicle or diluent; and b) a
container or packaging. The kits may optionally comprise
instructions describing a method of using the pharmaceutical
compositions in one or more of the methods described herein (e.g.
preventing or treating one or more of the diseases and disorders
described herein). The kit may optionally comprise a second
pharmaceutical composition comprising one or more additional agents
described herein for co therapy use, a pharmaceutically acceptable
carrier, vehicle or diluent. The pharmaceutical composition
comprising the compound described herein and the second
pharmaceutical composition contained in the kit may be optionally
combined in the same pharmaceutical composition.
[0258] A kit includes a container or packaging for containing the
pharmaceutical compositions and may also include divided containers
such as a divided bottle or a divided foil packet. The container
can be, for example a paper or cardboard box, a glass or plastic
bottle or jar, a re-sealable bag (for example, to hold a "refill"
of tablets for placement into a different container), or a blister
pack with individual doses for pressing out of the pack according
to a therapeutic schedule. It is feasible that more than one
container can be used together in a single package to market a
single dosage form. For example, tablets may be contained in a
bottle which is in turn contained within a box.
[0259] An example of a kit is a so-called blister pack. Blister
packs are well known in the packaging industry and are being widely
used for the packaging of pharmaceutical unit dosage forms
(tablets, capsules, and the like). Blister packs generally consist
of a sheet of relatively stiff material covered with a foil of a
preferably transparent plastic material. During the packaging
process, recesses are formed in the plastic foil. The recesses have
the size and shape of individual tablets or capsules to be packed
or may have the size and shape to accommodate multiple tablets
and/or capsules to be packed. Next, the tablets or capsules are
placed in the recesses accordingly and the sheet of relatively
stiff material is sealed against the plastic foil at the face of
the foil which is opposite from the direction in which the recesses
were formed. As a result, the tablets or capsules are individually
sealed or collectively sealed, as desired, in the recesses between
the plastic foil and the sheet. Preferably the strength of the
sheet is such that the tablets or capsules can be removed from the
blister pack by manually applying pressure on the recesses whereby
an opening is formed in the sheet at the place of the recess. The
tablet or capsule can then be removed via said opening.
[0260] It may be desirable to provide written memory aid containing
information and/or instructions for the physician, pharmacist or
subject regarding when the medication is to be taken. A "daily
dose" can be a single tablet or capsule or several tablets or
capsules to be taken on a given day. When the kit contains separate
compositions, a daily dose of one or more compositions of the kit
can consist of one tablet or capsule while a daily dose of another
or more compositions of the kit can consist of several tablets or
capsules. A kit can take the form of a dispenser designed to
dispense the daily doses one at a time in the order of their
intended use. The dispenser can be equipped with a memory-aid, so
as to further facilitate compliance with the regimen. An example of
such a memory-aid is a mechanical counter which indicates the
number of daily doses that have been dispensed. Another example of
such a memory-aid is a battery-powered micro-chip memory coupled
with a liquid crystal readout, or audible reminder signal which,
for example, reads out the date that the last daily dose has been
taken and/or reminds one when the next dose is to be taken.
EXAMPLES
[0261] All references provided in the Examples are herein
incorporated by reference. As used herein, all abbreviations,
symbols and conventions are consistent with those used in the
contemporary scientific literature. See, e.g. Janet S. Dodd, ed.,
The ACS Style Guide: A Manual for Authors and Editors, 2.sup.nd
Ed., Washington, D.C.: American Chemical Society, 1997, herein
incorporated in its entirety by reference.
Example 1: Compound Syntheses
Intermediate Ia
##STR00095##
[0263] 8-(2-Fluorobenzyl)imidazo[1,2-a]pyrazine-6-carbonitrile
(1a): The title compound was synthesized in 2 steps according to a
patent literature procedure (WO2015/187470A1) as a yellow solid
(0.60 g, 39% yield over 2 steps). .sup.1H NMR (500 MHz,
Methanol-d.sub.4) .delta. (ppm) 9.09 (s, 1H), 8.14 (s, 1H), 7.91
(s, 1H), 7.35 (t, 1H), 7.28 (m, 1H), 7.10 (m, 2H), 4.60 (s, 2H).
Using a similar procedure for the synthesis of 1a, the following
nitrile intermediates were prepared. The reaction conditions (such
as reagents ratio, temperature and reaction time) were modified as
needed. [0264] 8-Phenylimidazo[1,2-a]pyrazine-6-carbonitrile;
[0265] 8-Benzylimidazo[1,2-a]pyrazine-6-carbonitrile; [0266]
8-(4-Fluorobenzyl)imidazo[1,2-a]pyrazine-6-carbonitrile; [0267]
8-(2,3-Difluorobenzyl)imidazo[1,2-a]pyrazine-6-carbonitrile; [0268]
8-(2,5-Difluorobenzyl)imidazo[1,2-a]pyrazine-6-carbonitrile; [0269]
8-(3,3,4,4,4-Pentafluorobutyl)imidazo[1,2-a]pyrazine-6-carbonitrile,
[0270]
8-(2-Fluorobenzyl)-2-methylimidazo[1,2-a]pyrazine-6-carbonitrile;
[0271] 8-(3,5-Difluorobenzyl)imidazo[1,2-a]pyrazine-6-carbonitrile;
[0272]
8-(3,5-Difluoro-4-methylbenzyl)imidazo[1,2-a]pyrazine-6-carbonitri-
le.
[0273] Alternatively, Intermediate 1a and related analogs (Such as
Intermediate 1b) can be synthesized by the following procedure:
Step 1: Synthesis of
6-bromo-8-(2-fluorobenzyl)imidazo[1,2-a]pyrazine
[0274] A suspension of dry zinc powder (47 g, 720 mmol, dried by
heating in vacuo) in THF (750 mL) was treated with
1,2-dibromoethane (1 mL) and the resultant mixture was heated to
50.degree. C. Chlorotrimethylsilane (1 mL) was then added. After
stirring at 48-50.degree. C. for 30 min, the mixture was cooled to
ambient temperature. Dry lithium chloride (30 g, 710 mmol, dried by
heating in vacuo) was added, followed by dropwise addition of a
solution of 2-fluorobenzyl bromide (74 g, 390 mmol) in THF (100 mL)
(note: exothermic, reaction temperature was maintained below
48.degree. C.). The mixture was stirred for 1 hour at ambient
temperature. A slurry of 6,8-dibromoimidazo[1,2-a]pyrazine (99 g,
360 mmol) and Pd(PPh.sub.3).sub.2Cl.sub.2 (7.8 g, 11 mmol) in THF
(500 mL) was degassed by bubbling with nitrogen for 10 min and
added quickly to the 2-fluorobenzylzinc bromide reagent with the
aid of THF (100 mL). The reaction vessel was purged with nitrogen
and the mixture was stirred overnight at ambient temperature until
complete consumption of starting material. The reaction was
quenched with saturated NH.sub.4Cl solution (800 mL). The brown
organic phase was concentrated to dryness, re-dissolved in DCM (1.3
L) and filtered through a bed of Celite. The organic layer in the
filtrate was collected, decolorized with activated charcoal (45 g),
filtered through Celite and concentrated to dryness. The crude
material was dried azeotropically with toluene (2.times.500 mL) and
carried forward without purification.
Step 2: Synthesis of
8-(2-fluorobenzyl)imidazo[1,2-a]pyrazine-6-carbonitrile
[0275] A reaction mixture comprised of the crude material (360
mmol, theoretical yield) from the previous step, zinc cyanide (35
g, 300 mmol), Pd.sub.2(dba).sub.3 (16 g, 18 mmol),
1,1'-bis(diphenylphosphino)ferrocene (dppf) (14 g, 25 mmol), and
zinc powder (1.0 g) in DMF (800 mL) was degassed under nitrogen for
10 minutes and then heated at 85.degree. C. until complete
consumption of starting material. The reaction was cooled to
ambient temperature and poured into EtOAc (1.5 L), 10% NH.sub.4Cl
solution (1.1 L) and 5% NaCl solution (1.0 L). The organic layer
was filtered through a bed of Celite and washed with EtOAc
(2.times.750 mL). The organic filtrate was washed with 10% NaCl
solution (2.times.1.0 L), decolorized with activated charcoal (75
g), filtered through Celite and washed with EtOAc (2.times.300 mL).
The filtrate was concentrated to dryness and suspended in a mixture
of DCM (150 mL) and MTBE (300 mL). After stirring for 1 hour, the
product was collected by filtration, washed with MTBE (2.times.100
mL) and dried in a vacuum oven at 45.degree. C. The title compound
was obtained as a brown solid (52 g, 57% yield). .sup.1H NMR (500
MHz, Methanol-d.sub.4) .delta. (ppm) 9.09 (s, 1H), 8.13 (s, 1H),
7.91 (s, 1H), 7.35 (app. t, 1H), 7.27 (m, 2H), 7.13-7.06 (m, 2H),
4.60 (s, 2H).
Intermediate 1b
##STR00096##
[0277] 8-(3-Fluorobenzyl)imidazo[1,2-a]pyrazine-6-carbonitrile
(1b): The title compound was synthesized in 2 steps.
Step 1: Synthesis of
6-bromo-8-(3-fluorobenzyl)imidazo[1,2-a]pyrazine
[0278] A suspension of dry zinc powder (2.6 g, 40 mmol) in THF (50
mL) was treated with 1,2-dibromoethane (0.30 mL, 3.5 mmol) and the
resultant mixture was heated at 50.degree. C. for 5 minutes.
Chlorotrimethylsilane (0.30 mL, 2.4 mmol) was then added and the
mixture was cooled to ambient temperature. Dry lithium chloride
(1.7 g, 40 mmol) was added, followed by dropwise addition of a
solution of 3-fluorobenzyl bromide (4.8 g, 26 mmol) in THF (25 mL)
(note: exothermic, reaction temperature was maintained below
35.degree. C.). The mixture was stirred for 1 hour at ambient
temperature, followed by addition of a slurry of
6,8-dibromoimidazo[1,2-a]pyrazine (5.9 g, 21 mmol) and
Pd(PPh.sub.3).sub.2Cl.sub.2 (0.25 g, 0.36 mmol) in THF (75 mL). The
reaction mixture was degassed with nitrogen and stirred overnight
at ambient temperature until complete consumption of starting
material. The reaction mixture was concentrated and diluted with
DCM (100 mL) and 10% NH.sub.4Cl solution (100 mL). The thick
mixture was filtered through a bed of Celite, and the organic layer
in the filtrate was collected. The organic layer was dried and
decolorized with Na.sub.2SO.sub.4 (10 g) and activated charcoal (7
g), filtered through Celite and concentrated to yield a crude
orange oil (7.1 g) which was carried forward without
purification.
Step 2: Synthesis of
8-(3-fluorobenzyl)imidazo[1,2-a]pyrazine-6-carbonitrile
[0279] A reaction mixture comprised of the crude material (21 mmol,
theoretical yield) from the previous step, zinc cyanide (3.0 g, 26
mmol), Pd.sub.2(dba).sub.3 (1.9 g, 2.1 mmol),
1,1'-bis(diphenylphosphino)ferrocene (dppf) (1.5 g, 2.7 mmol), and
zinc powder (0.30 g, 4.6 mmol) in DMF (70 mL) was degassed under
nitrogen for 5 minutes and then heated at 110.degree. C. until
complete consumption of starting material. The reaction was cooled
to ambient temperature, diluted with EtOAc (150 mL) and filtered
through a bed of celite. The organic filtrate was washed with 10%
NH.sub.4Cl solution (2.times.100 mL), dried over Na.sub.2SO.sub.4,
filtered and concentrated to afford a brown oil which was purified
by column chromatography (15 to 40% EtOAc/hexanes gradient) to
afford the title compound as an off-white solid (2.4 g, 45%
yield).
[0280] .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. (ppm) 9.37 (s,
1H), 8.25 (s, 1H), 7.98 (s, 1H), 7.29-7.39 (m, 1H), 7.23 (d, 2H),
6.99-7.12 (m, 1H), 4.45-4.56 (m, 2H).
[0281] Using a similar procedure for the synthesis of Intermediates
1a and 1b, the following nitrile intermediates were prepared. The
reaction conditions (such as reagents ratio, temperature and
reaction time) were modified as needed. [0282]
8-(2,6-Difluorobenzyl)imidazo[1,2-a]pyrazine-6-carbonitrile; [0283]
8-(3-Fluoro-4-methylbenzyl)imidazo[1,2-a]pyrazine-6-carbonitrile.
Intermediate 2
##STR00097##
[0285] 8-Benzyl-[1,2,4]triazolo[1,5-a]pyrazine-6-carbonitrile (2):
The title compound was synthesized in 2 steps according to a patent
literature procedure (WO2016/081668A1) as a gold residue (0.12 g,
23% yield over 2 steps).
[0286] .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. (ppm) 9.96 (s,
1H), 8.94 (s, 1H), 7.39 (d, 2H) 7.30 (dd, 2H), 7.23 (t, 1H), 4.53
(s, 2H).
[0287] Using a similar procedure for the synthesis of 2, the
following nitrile intermediate was prepared. The reaction
conditions (such as reagents ratio, temperature and reaction time)
were modified as needed. [0288]
8-(2-Fluorobenzyl)-[1,2,4]triazolo[1,5-a]pyrazine-6-carbonitrile.
[0289]
8-(2,3-Difluorobenzyl)-[1,2,4]triazolo[1,5-a]pyrazine-6-carbonitri-
le; [0290]
8-(3-Fluorobenzyl)-[1,2,4]triazolo[1,5-a]pyrazine-6-carbonitril- e;
[0291]
8-(2,5-Difluorobenzyl)-[1,2,4]triazolo[1,5-a]pyrazine-6-carbonit-
rile; [0292]
8-(3,5-Difluorobenzyl)-[1,2,4]triazolo[1,5-a]pyrazine-6-carbonitrile.
Compound I-1
##STR00098##
[0293] General Procedure A:
8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1-
,2-a]pyrazine (I-1)
[0294] To a solution of
8-(2-fluorobenzyl)imidazo[1,2-a]pyrazine-6-carbonitrile (la) (4.0
g, 16 mmol) in methanol (40 mL) was added anhydrous hydrazine (3.1
mL, 100 mmol). After stirring at ambient temperature overnight,
complete disappearance of starting material was observed. The
reaction was concentrated in vacuo, residual hydrazine was removed
with methanol and toluene chasing, and the resultant foam was dried
under vacuum overnight. The brown foam was taken up in DCM (75 mL)
and 2,2,2-trifluoroacetic anhydride (3.8 ml, 27 mmol) was added
dropwise to prevent a strong exothermic reaction. The reaction was
stirred at ambient temperature until complete consumption of the
amidrazone intermediate. The solvent was removed in vacuo and dried
to a yellow residue. The residue was taken up in AcOH (10 mL) and
EtOH (100 mL) and heated at 90.degree. C. for 1 hour. The reaction
mixture was cooled to ambient temperature and concentrated to half
the reaction volume. The resultant thick suspension was filtered,
and the filtrate was concentrated to brown oil. The crude material
was purified using silica gel chromatography (10-100% EtOAc/hexanes
gradient) to isolate the title compound (4.0 g, 69% yield) as a tan
solid.
[0295] .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. (ppm) 15.46 (s,
1H), 9.45 (s, 1H), 8.26 (s, 1H), 7.87 (s, 1H), 7.43 (t, 1H),
7.22-7.32 (m, 1H), 7.14-7.22 (m, 1H), 7.09 (t, 1H), 4.60 (s, 2H).
LCMS [M+H]=363.1
Compound I-2
##STR00099##
[0297]
8-(3-Fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imi-
dazo[1,2-a]pyrazine (I-2) was synthesized according to General
Procedure A as an off-white solid (170 mg, 60% yield). The reaction
conditions (such as reagents ratio, temperature and reaction time)
were modified as needed.
[0298] .sup.1H NMR (500 MHz, Methanol-d.sub.4) .delta. (ppm) 9.22
(s, 1H), 8.17 (s, 1H), 7.87 (s, 1H), 7.35-7.24 (m, 3H), 6.92 (app.
t, 1H), 4.61 (s, 2H). LCMS [M+H]=363.2
Compound I-3
##STR00100##
[0300]
6-(3-(Difluoromethyl)-1H-1,2,4-triazol-5-yl)-8-(3-fluorobenzyl)imid-
azo[1,2-a]pyrazine (I-3) was synthesized according to General
Procedure A, with the exception that 2,2-difluoroacetic anhydride
was used as the acylating agent, as an off-white solid (160 mg, 55%
yield). The reaction conditions (such as reagents ratio,
temperature and reaction time) were modified as needed.
[0301] .sup.1H NMR (500 MHz, Methanol-d.sub.4) .delta. (ppm) 9.17
(s, 1H), 8.17 (s, 1H), 7.86 (s, 1H), 7.35-7.25 (m, 3H), 6.92 (m,
1H), 6.90 (t, 1H), 4.61 (s, 2H). LCMS [M+H]=345.2
Compound I-17
##STR00101##
[0303]
8-(2,3-Difluorobenzyl)-6-(3-(difluoromethyl)-1H-1,2,4-triazol-5-yl)-
-[1,2,4]triazolo[1,5-a]pyrazine (I-17) was synthesized according to
General Procedure A, with the exception that 2,2-difluoroacetic
anhydride was used as the acylating agent, as a white solid (120
mg, 62% yield). The reaction conditions (such as reagents ratio,
temperature and reaction time) were modified as needed.
[0304] .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. (ppm) 15.3 (s,
1H), 9.58 (s, 1H), 8.83 (s, 1H), 7.27-7.35 (m, 2H), 7.08-7.19 (m,
2H), 4.69 (s, 2H).
[0305] LCMS [M+H]=364.2
Compound I-19
##STR00102##
[0307]
8-(2,6-Difluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl-
)imidazo[1,2-a]pyrazine (I-19) was synthesized according to General
Procedure A as an off-white solid (300 mg, 87% yield). The reaction
conditions (such as reagents ratio, temperature and reaction time)
were modified as needed.
[0308] .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. (ppm) 15.3 (s,
1H), 9.43 (s, 1H), 8.25 (s, 1H), 7.85 (s, 1H), 7.37 (m, 1H), 7.08
(app. t, 2H), 4.63 (s, 2H).
[0309] LCMS [M+H]=381.2
Compound I-20
##STR00103##
[0311]
8-(2,6-Difluorobenzyl)-6-(3-(difluoromethyl)-1H-1,2,4-triazol-5-yl)-
imidazo[1,2-a]pyrazine (I-20) was synthesized according to General
Procedure A, with the exception that 2,2-difluoroacetic anhydride
was used as the acylating agent, as an off-white solid (240 mg, 72%
yield). The reaction conditions (such as reagents ratio,
temperature and reaction time) were modified as needed.
[0312] .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. (ppm) 14.9 (s,
1H), 9.38 (s, 1H), 8.24 (s, 1H), 7.84 (s, 1H), 7.37 (m, 1H), 7.13
(t, 1H), 7.08 (app. t, 2H), 4.62 (s, 2H).
[0313] LCMS [M+H]=363.2
Compound I-21
##STR00104##
[0315]
6-(3-(Difluoromethyl)-1H-1,2,4-triazol-5-yl)-8-(3-fluorobenzyl)-[1,-
2,4]triazolo[1,5-a]pyrazine (I-21) was synthesized according to
General Procedure A, with the exception that 2,2-difluoroacetic
anhydride was used as the acylating agent, as a white solid (110
mg, 29% yield). The reaction conditions (such as reagents ratio,
temperature and reaction time) were modified as needed.
[0316] .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. (ppm) 15.3 (s,
1H), 9.55 (s, 1H), 8.83 (s, 1H), 7.30-7.37 (m, 3H), 7.19 (t, 1H),
7.04-7.09 (m, 1H), 4.61 (s, 2H).
[0317] LCMS [M+H]=346.2
Compound I-22
##STR00105##
[0319]
8-(3-Fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-[1-
,2,4]triazolo[1,5-a]pyrazine (I-22) was synthesized according to
General Procedure A as an off-white solid (140 mg, 49% yield). The
reaction conditions (such as reagents ratio, temperature and
reaction time) were modified as needed.
[0320] .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. (ppm) 15.7 (s,
1H), 9.62 (s, 1H), 8.85 (s, 1H), 7.32-7.36 (m, 3H), 7.05-7.08 (m,
1H), 4.62 (s, 2H).
[0321] LCMS [M+H]=364.2
Compound I-23
##STR00106##
[0323]
8-(2,5-Difluorobenzyl)-6-(3-(difluoromethyl)-1H-1,2,4-triazol-5-yl)-
-[1,2,4]triazolo[1,5-a]pyrazine (I-23) was synthesized according to
General Procedure A, with the exception that 2,2-difluoroacetic
anhydride was used as the acylating agent, as an off-white solid
(120 mg, 72% yield). The reaction conditions (such as reagents
ratio, temperature and reaction time) were modified as needed.
[0324] .sup.1H NMR (500 MHz, Methanol-d.sub.4) .delta. (ppm) 9.49
(s, 1H), 8.65 (s, 1H), 7.25 (m, 1H), 7.11 (m, 1H), 7.01 (m, 1H),
6.91 (t, 1H), 4.71 (s, 2H).
[0325] LCMS [M+H]=364.2
Compound I-24
##STR00107##
[0327]
8-(3,5-Difluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl-
)-[1,2,4]triazolo[1,5-a]pyrazine (I-24) was synthesized according
to General Procedure A as a white solid (120 mg, 42% yield). The
reaction conditions (such as reagents ratio, temperature and
reaction time) were modified as needed.
[0328] .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. (ppm) 15.7 (s,
1H), 9.63 (s, 1H), 8.86 (s, 1H), 7.23 (d, 2H), 7.11 (t, 1H), 4.63
(s, 2H).
[0329] LCMS [M+H]=382.2
Compound I-25
##STR00108##
[0331]
8-(3,5-Difluorobenzyl)-6-(3-(difluoromethyl)-1H-1,2,4-triazol-5-yl)-
-[1,2,4]triazolo[1,5-a]pyrazine (I-25) was synthesized according to
General Procedure A, with the exception that 2,2-difluoroacetic
anhydride was used as the acylating agent, as a white solid (157
mg, 57% yield). The reaction conditions (such as reagents ratio,
temperature and reaction time) were modified as needed.
[0332] .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. (ppm) 15.2 (s,
1H), 9.50 (s, 1H), 8.77 (s, 1H), 7.16 (d, 2H), 7.14 (t, 1H), 7.03
(m, 1H), 4.55 (s, 2H).
[0333] LCMS [M+H]=364.1
Compound I-4
##STR00109##
[0334] General Procedure B:
8-(2-fluorobenzyl)-6-(3-methyl-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazi-
ne
[0335] To a solution of
8-(2-fluorobenzyl)imidazo[1,2-a]pyrazine-6-carbonitrile (la) (110
mg, 0.45 mmol) in methanol (2.0 mL) was added anhydrous hydrazine
(0.08 mL, 2.7 mmol). After stirring at ambient temperature for 40
hours, complete disappearance of starting material was observed.
The reaction was concentrated in vacuo and the residue was dried
under vacuum overnight. The residue was taken up in DCM (6.0 mL)
and acetic anhydride (0.09 ml, 0.89 mmol) added dropwise to prevent
a strong exothermic reaction. The reaction was stirred at ambient
temperature until complete consumption of the amidrazone
intermediate. The solvent was removed in vacuo and dried to a
yellow residue. The residue was taken up in AcOH (0.2 mL) and EtOH
(10 mL) and heated at 120.degree. C. for 5 hours in a microwave.
The reaction mixture was cooled to ambient temperature and
concentrated in vacuo. The crude material was purified using silica
gel chromatography (10-30% acetonitrile/MeOH (7:1) in DCM gradient)
to isolate the title compound (85 mg, 62% yield) as an off-white
solid.
[0336] .sup.1H NMR (500 MHz, Methanol-d.sub.4) .delta. (ppm) 9.03
(s, 1H), 8.15 (s, 1H), 7.81 (s, 1H), 7.30 (app. t, 1H), 7.23 (m,
1H), 7.10-7.02 (m, 2H), 4.66 (s, 2H), 2.48 (s, 3H). LCMS
[M+H]=309.2
Compound I-5
##STR00110##
[0338]
8-(2-Fluorobenzyl)-6-(3-(perfluoroethyl)-1H-1,2,4-triazol-5-yl)imid-
azo[1,2-a]pyrazine (Compound I-5) was synthesized according to
General Procedure B, with the exception that
2,2,3,3,3-pentafluoropropanoic anhydride was used as the acylating
agent, as a solid (1.5 mg, 1.5% yield). The reaction conditions
(such as reagents ratio, temperature and reaction time) were
modified as needed.
[0339] .sup.1H NMR (500 MHz, Methanol-d.sub.4) .delta. (ppm) 9.26
(s, 1H), 8.18 (s, 1H), 7.85 (s, 1H), 7.34 (t, 1H), 7.24 (s, 1H),
7.09 (m, 2H), 4.69 (s, 2H). LCMS [M+H]=413.2
Compound I-6
##STR00111##
[0341]
8-Benzyl-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a-
]pyrazine (I-6) was synthesized according to General Procedure B,
with the exception that 2,2,2-trifluoroacetic anhydride was used as
the acylating agent, as a white solid (57 mg, 52% yield). The
reaction conditions (such as reagents ratio, temperature and
reaction time) were modified as needed.
[0342] .sup.1H NMR (500 MHz, Methanol-d.sub.4) .delta. (ppm) 9.09
(s, 1H), 8.05 (s, 1H), 7.75 (s, 1H), 7.41 (d, 2H), 7.15 (t, 2H),
7.04-7.10 (m, 1H), 4.50 (s, 2H). LCMS [M+H]=345.2
Compound I-7
##STR00112##
[0344]
8-Benzyl-6-(3-(difluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]-
pyrazine (I-7) was synthesized according to General Procedure B,
with the exception that 2,2-difluoroacetic anhydride was used as
the acylating agent, as a white solid (15 mg, 16% yield). The
reaction conditions (such as reagents ratio, temperature and
reaction time) were modified as needed.
[0345] .sup.1H NMR (500 MHz, Methanol-d.sub.4) .delta. (ppm) 9.05
(s, 1H), 8.06 (s, 1H), 7.75 (s, 1H), 7.41 (d, 2H), 7.13-7.18 (m,
2H), 7.05-7.10 (m, 1H), 6.68-6.91 (m, 1H), 4.50 (s, 2H). LCMS
[M+H]=327.2
Compound I-8
##STR00113##
[0347]
8-(2,5-Difluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl-
)imidazo[1,2-a]pyrazine (I-8) was synthesized according to General
Procedure B, with the exception that 2,2,2-trifluoroacetic
anhydride was used as the acylating agent, as a white solid (18 mg,
31% yield). The reaction conditions (such as reagents ratio,
temperature and reaction time) were modified as needed.
[0348] .sup.1H NMR (500 MHz, Methanol-d.sub.4) .delta. (ppm) 9.14
(s, 1H), 8.09 (s, 1H), 7.77 (s, 1H), 7.07 (m, 1H), 7.00 (m, 1H),
6.86-6.92 (m, 1H), 4.57 (s, 2H). LCMS [M+H]=381.2
Compound I-9
##STR00114##
[0350]
8-(2,5-Difluorobenzyl)-6-(3-(difluoromethyl)-1H-1,2,4-triazol-5-yl)-
imidazo[1,2-a]pyrazine (I-9) was synthesized according to General
Procedure B, with the exception that 2,2-difluoroacetic anhydride
was used as the acylating agent, as an off-white solid (32 mg, 36%
yield). The reaction conditions (such as reagents ratio,
temperature and reaction time) were modified as needed.
[0351] .sup.1H NMR (500 MHz, Methanol-d.sub.4) .delta. (ppm) 9.10
(s, 1H), 8.09 (s, 1H), 7.76 (s, 1H), 7.06 (m, 1H), 7.00 (m, 1H),
6.87-6.92 (m, 1H), 6.79 (t, 1H), 4.56 (s, 2H). LCMS [M+H]=363.2
Compound I-10
##STR00115##
[0353]
8-(2,3-Difluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl-
)imidazo[1,2-a]pyrazine (I-10) was synthesized according to General
Procedure B, with the exception that 2,2,2-trifluoroacetic
anhydride was used as the acylating agent, as a white solid (110
mg, 39% yield). The reaction conditions (such as reagents ratio,
temperature and reaction time) were modified as needed.
[0354] .sup.1H NMR (500 MHz, Methanol-d.sub.4) .delta. (ppm) 9.25
(s, 1H), 8.19 (s, 1H), 7.86 (s, 1H), 7.17-7.10 (m, 2H), 7.05 (m,
1H), 4.72 (s, 2H). LCMS [M+H]=381.2
Compound I-11
##STR00116##
[0356]
8-(2,3-Difluorobenzyl)-6-(3-(difluoromethyl)-1H-1,2,4-triazol-5-yl)-
imidazo[1,2-a]pyrazine (I-11) was synthesized according to General
Procedure B, with the exception that 2,2-difluoroacetic anhydride
was used as the acylating agent, as an off-white solid (55 mg, 25%
yield). The reaction conditions (such as reagents ratio,
temperature and reaction time) were modified as needed.
[0357] .sup.1H NMR (500 MHz, Methanol-d.sub.4) .delta. (ppm) 9.21
(s, 1H), 8.19 (s, 1H), 7.86 (s, 1H), 7.17-7.09 (m, 2H), 7.04 (m,
1H), 6.89 (t, 1H), 4.71 (s, 2H). LCMS [M+H]=363.2
Compound I-12
##STR00117##
[0359]
8-(4-Fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imi-
dazo[1,2-a]pyrazine (I-12) was synthesized according to General
Procedure B, with the exception that 2,2,2-trifluoroacetic
anhydride was used as the acylating agent, as an off-white solid
(75 mg, 84% yield). The reaction conditions (such as reagents
ratio, temperature and reaction time) were modified as needed.
[0360] .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. (ppm) 15.50 (s,
1H), 9.41 (s, 1H), 8.24 (s, 1H), 7.88 (s, 1H) 7.56 (dd, 2H), 7.10
(dd, 2H), 4.52 (s, 2H). LCMS [M+H]=363.2
Compound I-13
##STR00118##
[0362]
8-(3,3,4,4,4-Pentafluorobutyl)-6-(3-(trifluoromethyl)-1H-1,2,4-tria-
zol-5-yl)imidazo[1,2-a]pyrazine (I-13) was synthesized according to
General Procedure B, with the exception that 2,2,2-trifluoroacetic
anhydride was used as the acylating agent, as a pale yellow solid
(30 mg, 60% yield). The reaction conditions (such as reagents
ratio, temperature and reaction time) were modified as needed.
[0363] .sup.1H NMR (500 MHz, Methanol-d.sub.4) .delta. (ppm) 9.24
(s, 1H), 8.19 (s, 1H), 7.86 (s, 1H), 3.59-3.66 (m, 2H), 2.93-3.07
(m, 2H). LCMS [M+H]=401.2
Compound I-14
##STR00119##
[0365]
8-(2-Fluorobenzyl)-6-(3-(difluoromethyl)-1H-1,2,4-triazol-5-yl)imid-
azo[1,2-a]pyrazine (I-14) was synthesized according to General
Procedure B, with the exception that 2,2-difluoroacetic anhydride
was used as the acylating agent, as an off-white solid (46 mg, 56%
yield). The reaction conditions (such as reagents ratio,
temperature and reaction time) were modified as needed.
[0366] .sup.1H NMR (500 MHz, Methanol-d.sub.4) .delta. (ppm) 9.28
(s, 1H), 8.29 (s, 1H), 8.00 (s, 1H), 7.35 (t, 1H), 7.27 (d, 1H),
7.09 (m, 2H), 6.90 (m, 1H), 4.69 (s, 2H). LCMS [M+H]=345.2
Compound I-15
##STR00120##
[0368]
8-Benzyl-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-[1,2,4]triaz-
olo[1,5-a]pyrazine (I-15) was synthesized according to General
Procedure B, with the exception that 2,2,2-trifluoroacetic
anhydride was used as the acylating agent, as a white solid (60 mg,
33% yield). The reaction conditions (such as reagents ratio,
temperature and reaction time) were modified as needed.
[0369] .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. (ppm) 15.72 (s,
1H), 9.60 (s, 1H), 8.84 (s, 1H), 7.50 (d, 2H) 7.30 (app. t, 2H),
7.21 (t, 1H), 4.59 (s, 2H). LCMS [M+H]=346.2
Compound I-16
##STR00121##
[0371]
8-(2-Fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-[1-
,2,4]triazolo[1,5-a]pyrazine (I-16) was synthesized according to
General Procedure B as an off-white solid (1.2 mg, 1.0% yield). The
reaction conditions (such as reagents ratio, temperature and
reaction time) were modified as needed.
[0372] .sup.1H NMR (500 MHz, Methanol-d.sub.4) .delta. (ppm) 9.51
(s, 1H), 8.65 (s, 1H), 7.43 (app. t, 1H), 7.27 (m, 1H), 7.10 (t,
2H), 4.74 (s, 2H). LCMS [M+H]=364.1
Compound I-18
##STR00122##
[0374]
8-(2,3-Difluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl-
)-[1,2,4]triazolo[1,5-a]pyrazine (I-18) was synthesized according
to General Procedure B as a white solid (89 mg, 44% yield). The
reaction conditions (such as reagents ratio, temperature and
reaction time) were modified as needed.
[0375] .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. (ppm) 15.7 (s,
1H), 9.64 (s, 1H), 8.84 (s, 1H), 7.30-7.35 (m, 1H), 7.27-7.30 (m,
1H), 7.12-7.15 (m, 1H), 4.69 (s, 2H).
[0376] LCMS [M+H]=382.2
Compound I-26
##STR00123##
[0378]
6-(3-(Difluoromethyl)-1H-1,2,4-triazol-5-yl)-8-(2-fluorobenzyl)-[1,-
2,4]triazolo[1,5-a]pyrazine (I-26) was synthesized according to
General Procedure B, with the exception that 2,2-difluoroacetic
anhydride was used as the acylating agent, as a white solid (180
mg, 88% yield). The reaction conditions (such as reagents ratio,
temperature and reaction time) were modified as needed.
[0379] .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. (ppm) 15.3 (s,
1H), 9.57 (s, 1H), 8.81 (s, 1H), 7.46 (app. t, 1H), 7.32-7.09 (m,
4H), 4.64 (s, 2H).
[0380] LCMS [M+H]=346.2
Compound I-27
##STR00124##
[0382]
8-(3-Fluoro-4-methylbenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-
-5-yl)imidazo[1,2-a]pyrazine (I-27) was synthesized according to
General Procedure B, with the exception that 2,2,2-trifluoroacetic
anhydride was used as the acylating agent, as a pale yellow solid
(110 mg, 61% yield). The reaction conditions (such as reagents
ratio, temperature and reaction time) were modified as needed.
[0383] .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. (ppm) 15.5 (s,
1H), 9.41 (s, 1H), 8.24 (s, 1H), 7.88 (s, 1H), 7.30 (d, 1H),
7.15-7.23 (m, 2H), 4.50 (s, 2H), 2.15 (s, 3H).
[0384] LCMS [M+H]=377.1
Compound I-28
##STR00125##
[0386]
6-(3-(Difluoromethyl)-1H-1,2,4-triazol-5-yl)-8-(3-fluoro-4-methylbe-
nzyl)imidazo[1,2-a]pyrazine (I-28) was synthesized according to
General Procedure B, with the exception that 2,2-difluoroacetic
anhydride was used as the acylating agent, as a pale yellow solid
(130 mg, 76% yield). The reaction conditions (such as reagents
ratio, temperature and reaction time) were modified as needed.
[0387] .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. (ppm) 15.1 (s,
1H), 9.36 (s, 1H), 8.24 (s, 1H), 7.87 (s, 1H), 7.14-7.35 (m, 4H),
4.49 (s, 2H), 2.15 (s, 3H).
[0388] LCMS [M+H]=359.2
Compound I-29
##STR00126##
[0390]
8-(3,5-Difluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl-
)imidazo[1,2-a]pyrazine (I-29) was synthesized according to General
Procedure B, with the exception that 2,2,2-trifluoroacetic
anhydride was used as the acylating agent, as a pale yellow solid
(150 mg, 68% yield). The reaction conditions (such as reagents
ratio, temperature and reaction time) were modified as needed.
[0391] .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. (ppm) 15.5 (s,
1H), 9.43 (s, 1H), 8.26 (s, 1H), 7.90 (s, 1H), 7.23 (d, 2H), 7.08
(t, 1H), 4.56 (s, 2H).
[0392] LCMS [M+H]=381.1
Compound I-30
##STR00127##
[0394]
8-(3,5-Difluorobenzyl)-6-(3-(difluoromethyl)-1H-1,2,4-triazol-5-yl)-
imidazo[1,2-a]pyrazine (I-30) was synthesized according to General
Procedure B, with the exception that 2,2-difluoroacetic anhydride
was used as the acylating agent, as a pale yellow solid (140 mg,
70% yield). The reaction conditions (such as reagents ratio,
temperature and reaction time) were modified as needed.
[0395] .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. (ppm) 15.1 (s,
1H), 9.38 (s, 1H), 8.26 (s, 1H), 7.89 (s, 1H), 7.04-7.29 (m, 4H),
4.55 (s, 2H).
[0396] LCMS [M+H]=363.1
Compound I-31
##STR00128##
[0398]
8-(2-Fluorobenzyl)-2-methyl-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-
-5-yl)imidazo[1,2-a]pyrazine (I-31) was synthesized according to
General Procedure B, with the exception that 2,2,2-trifluoroacetic
anhydride was used as the acylating agent, as a white solid (35 mg,
55% yield). The reaction conditions (such as reagents, ratio,
temperature and reaction time) were modified as needed.
[0399] .sup.1H NMR (500 MHz, CDCl.sub.3) .delta. (ppm) 11.6 (br. s,
1H), 8.88 (s, 1H), 7.61 (s, 1H), 7.39 (app. t, 1H), 7.26-7.32 (m,
1H), 7.09-7.15 (m, 2H), 4.69 (s, 2H), 2.60 (s, 3H).
[0400] LCMS [M+H]=377.3
Compound I-32
##STR00129##
[0402]
6-(3-(Difluoromethyl)-1H-1,2,4-triazol-5-yl)-8-(2-fluorobenzyl)-2-m-
ethylimidazo[1,2-a]pyrazine (I-32) was synthesized according to
General Procedure B, with the exception that 2,2-difluoroacetic
anhydride was used as the acylating agent, as a white solid (44 mg,
85% yield). The reaction conditions (such as reagents, ratio,
temperature and reaction time) were modified as needed.
[0403] .sup.1H NMR (500 MHz, CDCl.sub.3) .delta. (ppm) 11.5 (br. s,
1H), 8.89 (s, 1H), 7.61 (s, 1H), 7.38 (app. t, 1H), 7.26-7.34 (m,
1H), 7.08-7.14 (m, 2H), 6.77 (t, 1H), 4.69 (s, 2H), 2.60 (s,
3H).
[0404] LCMS [M+H]=359.2
Compound I-33
##STR00130##
[0406]
8-(2,5-Difluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl-
)-[1,2,4]triazolo[1,5-a]pyrazine (I-33) was synthesized according
to General Procedure B, with the exception that
2,2,2-trifluoroacetic anhydride was used as the acylating agent, as
a white solid (72 mg, 41% yield). The reaction conditions (such as
reagents ratio, temperature and reaction time) were modified as
needed.
[0407] .sup.1H NMR (500 MHz, Methanol-d.sub.4) .delta. (ppm) 9.51
(s, 1H), 8.66 (s, 1H), 7.20-7.29 (m, 1H), 7.06-7.15 (m, 1H), 7.01
(m, 1H), 4.72 (s, 2H).
[0408] LCMS [M+H]=382.2
Compound I-34
##STR00131##
[0410]
8-(3,5-Difluoro-4-methylbenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-tri-
azol-5-yl)imidazo[1,2-a]pyrazine (I-34) was synthesized according
to General Procedure B, with the exception that
2,2,2-trifluoroacetic anhydride was used as the acylating agent, as
a white solid (81 mg, 65% yield). The reaction conditions (such as
reagents ratio, temperature and reaction time) were modified as
needed.
[0411] .sup.1H NMR (500 MHz, CDCl.sub.3) .delta. (ppm) 11.9 (br. s,
1H), 9.02 (s, 1H), 7.94 (s, 1H), 7.85 (s, 1H), 6.95 (d, 2H), 4.58
(s, 2H), 2.14 (s, 3H).
[0412] LCMS [M+H]=395.2
Compound I-35
##STR00132##
[0414]
8-(3,5-Difluoro-4-methylbenzyl)-6-(3-(difluoromethyl)-1H-1,2,4-tria-
zol-5-yl)imidazo[1,2-a]pyrazine (I-35) was synthesized according to
General Procedure B, with the exception that 2,2-difluoroacetic
anhydride was used as the acylating agent, as a white solid (83 mg,
62% yield). The reaction conditions (such as reagents ratio,
temperature and reaction time) were modified as needed.
[0415] .sup.1H NMR (500 MHz, CDCl.sub.3) .delta. (ppm) 11.7 (br. s,
1H), 9.02 (s, 1H), 7.92 (s, 1H), 7.83 (s, 1H), 6.98 (d, 2H), 6.81
(t, 1H), 4.58 (s, 2H), 2.15 (s, 3H).
[0416] LCMS [M+H]=377.2
Compound I-36
##STR00133##
[0418]
4-(2-Fluorobenzyl)-1-methyl-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-
-5-yl)-1H-imidazo[4,5-c]pyridine (I-36): The title compound was
synthesized in 3 steps.
Step 1: Synthesis of
6-chloro-4-(2-fluorobenzyl)-1-methyl-1H-imidazo[4,5-c]pyridine
[0419] To a mixture containing bis(triphenylphosphine)palladium(II)
dichloride (290 mg, 0.42 mmol), lithium chloride (350 mg, 8.3 mmol)
and 4,6-dichloro-1-methyl-1H-imidazo[4,5-c]pyridine (840 mg, 4.2
mmol) in THF (2.0 mL) at ambient temperature was added
(2-fluorobenzyl)zinc(II) chloride (0.5 M solution in THF, 10 mL,
5.0 mmol). The mixture was stirred at ambient temperature for 24
hours. The mixture was taken up in EtOAc (100 mL) and water (100
mL). The organic layer was dried over Na.sub.2SO.sub.4, filtered
and evaporated to give an oil. The crude material was purified
using silica gel chromatography (0-80% EtOAc/hexanes gradient) to
give 6-chloro-4-(2-fluorobenzyl)-1-methyl-1H-imidazo[4,5-c]pyridine
(1.0 g, 70% yield) as a yellow solid.
[0420] .sup.1H NMR (500 MHZ, CDCl.sub.3) .delta. (ppm) 7.87 (s,
1H), 7.63-7.79 (m, 1H), 7.26 (br. s, 1H), 7.12-7.19 (m, 1H),
6.96-7.07 (m, 2H), 4.60 (br. s, 2H), 3.80 (s, 3H).
Step 2: Synthesis of
4-(2-fluorobenzyl)-1-methyl-1H-imidazo[4,5-c]pyridine-6-carbonitrile
[0421] A mixture containing zinc cyanide (850 mg, 7.3 mmol),
tetrakis(triphenylphosphine)palladium(0) (420 mg, 0.36 mmol) and
6-chloro-4-(2-fluorobenzyl)-1-methyl-1H-imidazo[4,5-c]pyridine (1.0
g, 3.6 mmol) in DMF (18 mL) was heated to 100.degree. C. for 24
hours. The reaction mixture was quenched with water (10 mL) and
EtOAc (20 mL) and filtered through a pad of Celite. The filtrate
was extracted with EtOAc (100 mL). The organic layer was dried over
Na.sub.2SO.sub.4, filtered and evaporated to give a solid. The
crude material was purified using silica gel chromatography (0-100%
EtOAc/hexanes gradient) to give impure
4-(2-fluorobenzyl)-1-methyl-1H-imidazo[4,5-c]pyridine-6-carbonitrile
(130 mg) as a white solid.
[0422] .sup.1H NMR (500 MHz, CDCl.sub.3) .delta. (ppm) 8.08 (s,
1H), 7.72 (s, 1H), 7.65-7.71 (m, 1H), 7.32 (m, 1H), 6.98-7.09 (m,
2H), 4.64 (s, 2H), 3.92 (s, 3H).
Step 3: Synthesis of
4-(2-fluorobenzyl)-1-methyl-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-
-1H-imidazo[4,5-c]pyridine (I-36)
[0423] A mixture containing anhydrous hydrazine (0.092 mL, 2.9
mmol) and
4-(2-fluorobenzyl)-1-methyl-1H-imidazo[4,5-c]pyridine-6-carbonitrile
(130 mg) in MeOH (2.5 mL) was stirred at ambient temperature for 24
hours. The mixture was concentrated in vacuo and dried
azeotropically with MeOH and benzene. The resulting mixture was
dissolved in DCM (10 mL) and treated with pyridine (0.24 mL, 2.9
mmol) and 2,2,2-trifluoroacetic anhydride (0.21 mL, 1.5 mmol).
After stirring at ambient temperature for 2 hours, the reaction was
diluted in EtOAc (100 mL) and washed with saturated NaHCO.sub.3
solution (50 mL). The organic layer was dried over
Na.sub.2SO.sub.4, filtered and evaporated to give an oil. The crude
material was purified by preparative HPLC to afford
4-(2-fluorobenzyl)-1-methyl-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-
-1H-imidazo[4,5-c]pyridine (6.3 mg, 0.47% yield over two steps) as
a light brown solid.
[0424] .sup.1H NMR (500 MHz, Methanol-d.sub.4) .delta. (ppm) 8.57
(s, 1H), 8.41 (s, 1H), 7.18-7.28 (m, 2H), 6.97-7.12 (m, 2H), 4.67
(s, 2H), 4.04 (s, 3H).
[0425] LCMS [M+H]=377.1
Compound I-72
##STR00134##
[0427]
8-(2-Fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-[1-
,2,4]triazolo[4,3-a]pyrazine (I-72): The title compound was
synthesized in 3 steps.
Step 1: Synthesis of
6-bromo-8-(2-fluorobenzyl)-[1,2,4]triazolo[4,3-a]pyrazine
[0428] A solution of bis(triphenylphosphine)palladium(II)
dichloride (62 mg, 0.088 mmol) and
6-bromo-8-chloro-[1,2,4]triazolo[4,3-a]pyrazine (410 mg, 1.8 mmol)
in THF (5.9 mL) at ambient temperature was purged with argon for 5
min and treated with (2-fluorobenzyl)zinc(II) chloride (0.5 M
solution in THF, 5.3 mL, 2.6 mmol). The mixture was stirred at
60.degree. C. for 24 hours. The reaction was quenched with
saturated NH.sub.4Cl solution (15 mL) and extracted with EtOAc
(4.times.50 mL). The combined organic layers were washed with
brine, dried over Na.sub.2SO.sub.4, filtered and concentrated in
vacuo. The crude material was purified using reverse phase HPLC
(5-95% acetonitrile/water gradient with 0.1% formic acid) to give
6-bromo-8-(2-fluorobenzyl)-[1,2,4]triazolo[4,3-a]pyrazine (110 mg,
43% pure, contaminated with an undesired regioisomer, 9.1% yield)
as a brown solid.
Step 2: Synthesis of
8-(2-fluorobenzyl)-[1,2,4]triazolo[4,3-a]pyrazine-6-carbonitrile
[0429] A solid mixture containing zinc dust (4.7 mg, 0.072 mmol),
zinc cyanide (63 mg, 0.54 mmol),
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)
dichloromethane adduct (29 mg, 0.036 mmol) and
6-bromo-8-(2-fluorobenzyl)-[1,2,4]triazolo[4,3-a]pyrazine (110 mg,
43% pure, 0.15 mmol of desired regioisomer and 0.21 mmol of
undesired regioisomer) was purged with nitrogen for 15 min and then
dissolved in DMF (3 mL). The reaction was heated to 120.degree. C.
for 8 hours. The resultant mixture was partitioned between water
(10 mL), brine (10 mL) and EtOAc (20 mL). The aqueous layer was
extracted with EtOAc (20 mL). The combined organic layers were
dried over Na.sub.2SO.sub.4, filtered and concentrated in vacuo.
The crude material was purified using silica gel chromatography
(20-100% EtOAc/hexanes gradient) to give
8-(2-fluorobenzyl)-[1,2,4]triazolo[4,3-a]pyrazine-6-carbonitrile
(24 mg, 61% yield) as a light tan solid.
Step 3: Synthesis of
8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-[1,2,4]t-
riazolo[4,3-a]pyrazine (I-72)
[0430] A suspension of
8-(2-fluorobenzyl)-[1,2,4]triazolo[4,3-a]pyrazine-6-carbonitrile
(24 mg, 0.094 mmol) in anhydrous methanol (1.5 mL) was treated with
sodium methoxide (0.50 N solution in methanol, 19 .mu.L, 9.4
.mu.mol). After 3.5 hours, anhydrous hydrazine (18 .mu.L, 0.57
mmol) was added and the reaction was stirred at ambient temperature
for 23 hours. The resultant mixture was concentrated, dried in
vacuo and then re-dissolved in DCM/THF (2 mL, 3:1 ratio).
2,2,2-Trifluoroacetic anhydride (21 .mu.L, 0.15 mmol). After 40
minutes, the mixture was concentrated, dissolved in EtOH (2 mL) and
acetic acid (0.2 mL) and heated at 90.degree. C. for 15 hours. The
resultant solution was poured into water (10 mL), neutralized to pH
6 with saturated NaHCO.sub.3 solution and extracted with EtOAc
(2.times.20 mL). The combined organic layers were dried over
Na.sub.2SO.sub.4, filtered and concentrated in vacuo. The crude
material was purified by silica gel chromatography (20-90%
EtOAc/hexanes gradient) to afford
8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-[1,2,4]t-
riazolo[4,3-a]pyrazine (1.4 mg, 4.1% yield) as a light yellow
film.
[0431] .sup.1H NMR (500 MHz, Methanol-d.sub.4) .delta. (ppm) 9.43
(s, 1H), 9.22 (s, 1H), 7.47 (app. t, 1H), 7.29 (m, 1H), 7.13-7.08
(m, 2H), 4.76 (s, 2H).
[0432] LCMS [M+H]=364.2
Compound I-37
##STR00135##
[0434]
6-(2-Fluorobenzyl)-9-methyl-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-
-5-yl)-9H-purine (I-37): The title compound was synthesized in 3
steps.
Step 1: Synthesis of
2-chloro-6-(2-fluorobenzyl)-9-methyl-9H-purine
[0435] To a mixture containing bis(triphenylphosphine)palladium(II)
dichloride (240 mg, 0.34 mmol), lithium chloride (290 mg, 6.8 mmol)
and 2,6-dichloro-9-methyl-9H-purine (690 mg, 3.4 mmol) in THF (17
mL) at ambient temperature was added 2-fluorobenzylzinc(II)
chloride (0.5 M solution in THF, 7.5 mL, 3.7 mmol). The reaction
was stirred at ambient temperature for 24 hours. The resultant
mixture was diluted with EtOAc (100 mL) and water (100 mL). The
organic layer was dried over Na.sub.2SO.sub.4, filtered and
evaporated to give an oil. The crude material was purified using
silica gel chromatography (0-50% EtOAc/hexanes gradient) to afford
2-chloro-6-(2-fluorobenzyl)-9-methyl-9H-purine (620 mg, 66% yield)
as a white solid.
[0436] .sup.1H NMR (500 MHz, CDCl.sub.3) .delta.(ppm) 8.02 (s, 1H),
7.37 (m, 1H), 7.18-7.25 (m, 1H), 7.02-7.10 (m, 2H), 4.54 (s, 2H),
3.88 (s, 3H).
Step 2: Synthesis of
6-(2-fluorobenzyl)-9-methyl-9H-purine-2-carbonitrile
[0437] A mixture containing zinc cyanide (530 mg, 4.5 mmol),
tetrakis(triphenylphosphine)palladium(0) (260 mg, 0.22 mmol) and
2-chloro-6-(2-fluorobenzyl)-9-methyl-9H-purine (620 mg, 2.2 mmol)
in DMF (12 mL) was heated to 100.degree. C. for 24 hours. The
mixture was quenched with water (50 mL) and EtOAc (10 mL) and
filtered through a pad of Celite. The filtrate was extracted with
EtOAc (100 mL). The organic layer was dried over Na.sub.2SO.sub.4,
filtered and evaporated to give an oil. The crude material was
purified using silica gel chromatography (0-100% EtOAc/hexanes
gradient) to afford
6-(2-fluorobenzyl)-9-methyl-9H-purine-2-carbonitrile (490 mg, 82%
yield) as a white solid.
[0438] .sup.1H NMR (500 MHz, CDCl.sub.3) .delta. (ppm) 8.22 (s,
1H), 7.39 (t, 1H), 7.20-7.26 (m, 1H), 7.01-7.12 (m, 2H), 4.61 (s,
2H), 3.95 (s, 3H).
Step 3: Synthesis of
6-(2-fluorobenzyl)-9-methyl-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-
-9H-purine (I-37)
[0439] A mixture containing anhydrous hydrazine (0.090 mL, 2.9
mmol) and 6-(2-fluorobenzyl)-9-methyl-9H-purine-2-carbonitrile (130
mg, 0.48 mmol) in MeOH (2.4 mL) was heated to 60.degree. C. for 2
hours. The mixture was concentrated in vacuo and dried
azeotropically with MeOH and benzene. The resulting solid was
dissolved in DCM (5.0 mL) and treated with pyridine (0.23 mL, 2.9
mmol) and 2,2,2-trifluoroacetic anhydride (0.20 mL, 1.4 mmol).
After stirring at ambient temperature for 24 hours, the reaction
was diluted with DCM (100 mL) and washed with water (100 mL). The
organic layer was dried over Na.sub.2SO.sub.4, filtered and
evaporated to give an oil. The crude material was purified using
silica gel chromatography (0-50% EtOAc/hexanes gradient) to recover
the
2,2,2-trifluoro-N'-((6-(2-fluorobenzyl)-9-methyl-9H-purin-2-yl)(imino)met-
hyl)acetohydrazide intermediate. The solid was combined with MeOH
(1.0 mL) and a few drops of acetic acid. The resultant mixture was
heated at 120.degree. C. for 1 hour in a microwave. The mixture was
cooled to ambient and concentrated in vacuo to give
6-(2-fluorobenzyl)-9-methyl-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-
-9H-purine (25 mg, 14% yield) as a white solid.
[0440] .sup.1H NMR (500 MHz, Methanol-d.sub.4) .delta. (ppm)
8.50-8.54 (m, 1H), 7.28-7.41 (m, 1H), 7.14-7.27 (m, 1H), 6.97-7.12
(m, 2H), 4.63 (s, 2H), 4.01 (s, 3H).
[0441] LCMS [M+H]=378.1
Compound I-38 and Compound I-39
##STR00136##
[0442] General Procedure C:
8-(2-fluorobenzyl)-6-(5-methyl-1-(2,2,2-trifluoroethyl)-1H-1,2,4-triazol--
3-yl)imidazo[1,2-a]pyrazine (I-38) and
8-(2-fluorobenzyl)-6-(3-methyl-1-(2,2,2-trifluoroethyl)-1H-1,2,4-triazol--
5-yl)imidazo[1,2-a]pyrazine (I-39)
[0443] To a suspension of
8-(2-fluorobenzyl)-6-(3-methyl-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazi-
ne (69 mg, 0.22 mmol) and potassium carbonate (68 mg, 0.49 mmol) in
DMF (3.0 mL) was added 2,2,2-trifluoroethyl
trifluoromethanesulfonate (0.050 mL, 0.31 mmol). After stirring at
ambient temperature for 15 hours, the reaction mixture was poured
into a mixture of water and brine (1:2, 20 mL) and extracted with
DCM (2.times.20 mL). The combined organic layers were dried over
Na.sub.2SO.sub.4, filtered and concentrated. The crude material was
purified using silica gel chromatography (20-100% EtOAc/hexanes
gradient) to isolate
8-(2-fluorobenzyl)-6-(5-methyl-1-(2,2,2-trifluoroethyl)-1H-1,2,4-triazol--
3-yl)imidazo[1,2-a]pyrazine (I-38) (18 mg, 21% yield) as a pale
yellow solid and
8-(2-fluorobenzyl)-6-(3-methyl-1-(2,2,2-trifluoroethyl)-1H-1,2,-
4-triazol-5-yl)imidazo[1,2-a]pyrazine (I-39) (52 mg, 60% yield) as
a pale yellow solid. The chemical structures were assigned with the
aid of .sup.1H NMR nOe experiments. In this case, a potential third
regioisomer (usually minor) was not observed.
Compound I-38:
[0444] .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. (ppm) 9.19 (s,
1H), 8.23 (s, 1H), 7.80 (s, 1H), 7.34 (app. t, 1H), 7.27 (m, 1H),
7.17 (app. t, 1H), 7.08 (app. t, 1H), 5.34 (q, 2H), 4.56 (s, 2H),
2.53 (s, 3H).
[0445] LCMS [M+H]=391.2
Compound I-39:
[0446] .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. (ppm) 9.39 (s,
1H), 8.30 (s, 1H), 7.93 (s, 1H), 7.48 (app. t, 1H), 7.35 (m, 1H),
7.21-7.15 (m, 2H), 5.41 (q, 2H), 4.64 (s, 2H), 2.31 (s, 3H).
[0447] LCMS [M+H]=391.2
Compound I-41 and Compound I-42
##STR00137##
[0449]
8-(2-Fluorobenzyl)-6-(1-(4-fluorobenzyl)-5-methyl-1H-1,2,4-triazol--
3-yl)imidazo[1,2-a]pyrazine (I-41) and
8-(2-fluorobenzyl)-6-(1-(4-fluorobenzyl)-3-methyl-1H-1,2,4-triazol-5-yl)i-
midazo[1,2-a]pyrazine (I-42) were synthesized according to General
Procedure C, with the exception that
1-(bromomethyl)-4-fluorobenzene was used as the alkylating agent,
as solids (I-41: 1.3 mg, 3.9% yield and I-42: 2.9 mg, 8.6% yield).
The reaction conditions (such as reagents ratio, temperature and
reaction time) were modified as needed.
Compound I-41:
[0450] .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. (ppm) 9.15 (s,
1H), 8.21 (s, 1H), 7.79 (s, 1H), 7.32 (m, 3H), 7.21 (m, 4H), 7.08
(app. t, 1H), 5.44 (s, 2H), 4.54 (s, 2H), 2.48 (s, 3H).
[0451] LCMS [M+H]=417.3
Compound I-42:
[0452] .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. (ppm) 9.34 (s,
1H), 8.29 (s, 1H), 7.91 (s, 1H), 7.37 (app. t, 1H), 7.20 (m, 1H),
7.03 (m, 6H), 5.61 (s, 2H), 4.63 (s, 2H), 2.25 (s, 3H).
[0453] LCMS [M+H]=417.4
Compound I-47
##STR00138##
[0455]
8-(2-Fluorobenzyl)-6-(1-(3-fluorobenzyl)-5-methyl-1H-1,2,4-triazol--
3-yl)imidazo[1,2-a]pyrazine (I-47) was synthesized according to
General Procedure C, with the exception that
1-(bromomethyl)-3-fluorobenzene was used as the alkylating agent,
as a solid (4.2 mg, 12% yield). The other regioisomers were not
isolated. The reaction conditions (such as reagents ratio,
temperature and reaction time) were modified as needed.
[0456] .sup.1H NMR (500 MHz, Methanol-d.sub.4) .delta. (ppm) 9.04
(s, 1H), 8.11 (s, 1H), 7.78 (s, 1H), 7.38 (m, 1H), 7.23 (m, 2H),
7.06 (m, 5H), 5.47 (s, 2H), 4.65 (s, 2H), 2.51 (s, 3H).
[0457] LCMS [M+H]=417.4
Compound I-48
##STR00139##
[0459]
1-(3-(8-(2-Fluorobenzyl)imidazo[1,2-a]pyrazin-6-yl)-5-methyl-1H-1,2-
,4-triazol-1-yl)-3,3-dimethylbutan-2-one (I-48) was synthesized
according to General Procedure C, with the exception that
1-bromo-3,3-dimethylbutan-2-one was used as the alkylating agent,
as a solid (7.6 mg, 23% yield). The other regioisomers were not
isolated. The reaction conditions (such as reagents ratio,
temperature and reaction time) were modified as needed.
[0460] .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. (ppm) 9.15 (s,
1H), 8.22 (s, 1H), 7.79 (s, 1H), 7.32 (app. t, 1H), 7.25 (m, 1H),
7.17 (app. t, 1H), 7.08 (app. t, 1H), 5.54 (s, 2H), 4.54 (s, 2H),
2.31 (s, 3H), 1.22 (s, 9H).
[0461] LCMS [M+H]=407.4
Compound I-50
##STR00140##
[0463]
8-(2-Fluorobenzyl)-6-(1-(4-fluorobutyl)-5-methyl-1H-1,2,4-triazol-3-
-yl)imidazo[1,2-a]pyrazine (I-50) was synthesized according to
General Procedure C, with the exception that 1-bromo-4-fluorobutane
was used as the alkylating agent, as a solid (0.9 mg, 2.8% yield).
The other regioisomers were not isolated. The reaction conditions
(such as reagents ratio, temperature and reaction time) were
modified as needed.
[0464] .sup.1H NMR (500 MHz, Methanol-d.sub.4) .delta. (ppm) 9.03
(s, 1H), 8.14 (s, 1H), 7.81 (s, 1H), 7.26 (m, 2H), 7.06 (m, 2H),
4.67 (s, 2H), 4.55 (t, 1H), 4.45 (t, 1H), 4.27 (t, 2H), 2.56 (s,
3H), 2.05 (m, 2H), 1.77 (m, 2H).
[0465] LCMS [M+H]=383.3
Compound I-51
##STR00141##
[0467]
3-((3-(8-(2-Fluorobenzyl)imidazo[1,2-a]pyrazin-6-yl)-5-methyl-1H-1,-
2,4-triazol-1-yl)methyl)-5-methylisoxazole (I-51) was synthesized
according to General Procedure C, with the exception that
3-(bromomethyl)-5-methylisoxazole was used as the alkylating agent,
as a solid (4.1 mg, 13% yield). The other regioisomers were not
isolated. The reaction conditions (such as reagents ratio,
temperature and reaction time) were modified as needed.
[0468] .sup.1H NMR (500 MHz, Methanol-d.sub.4) .delta. (ppm) 9.05
(s, 1H), 8.13 (s, 1H), 7.80 (s, 1H), 7.26 (m, 2H), 7.08 (m, 1H),
7.04 (m, 1H), 6.20 (s, 1H), 5.50 (s, 2H), 4.66 (s, 2H), 2.58 (s,
3H), 2.42 (s, 3H).
[0469] LCMS [M+H]=404.3
Compound I-53
##STR00142##
[0471]
6-(1-Ethyl-5-methyl-1H-1,2,4-triazol-3-yl)-8-(2-fluorobenzyl)imidaz-
o[1,2-a]pyrazine (I-53) was synthesized according to General
Procedure C, with the exception that iodoethane was used as the
alkylating agent, as a solid (3.0 mg, 11% yield). The other
regioisomers were not isolated. The reaction conditions (such as
reagents ratio, temperature and reaction time) were modified as
needed.
[0472] .sup.1H NMR (500 MHz, Methanol-d.sub.4) .delta. (ppm) 9.02
(s, 1H), 8.13 (s, 1H), 7.81 (s, 1H), 7.25 (m, 2H), 7.08 (m, 1H),
7.04 (m, 1H), 4.67 (s, 2H), 4.26 (q, 2H), 2.56 (s, 3H), 1.50 (t,
3H).
[0473] LCMS [M+H]=337.3
Compound I-54
##STR00143##
[0475]
8-(2-Fluorobenzyl)-6-(5-methyl-1-(3,3,3-trifluoropropyl)-1H-1,2,4-t-
riazol-3-yl)imidazo[1,2-a]pyrazine (I-54) was synthesized according
to General Procedure C, with the exception that
3-bromo-1,1,1-trifluoropropane was used as the alkylating agent, as
a solid (2.9 mg, 8.8% yield). The other regioisomers were not
isolated. The reaction conditions (such as reagents ratio,
temperature and reaction time) were modified as needed.
[0476] .sup.1H NMR (500 MHz, Methanol-d.sub.4) .delta. (ppm) 9.06
(s, 1H), 8.14 (s, 1H), 7.81 (s, 1H), 7.25 (m, 2H), 7.09 (m, 1H),
7.04 (m, 1H), 4.67 (s, 2H), 4.49 (t, 2H), 2.94 (m, 2H), 2.57 (s,
3H).
[0477] LCMS [M+H]=405.3
Compound I-56
##STR00144##
[0479]
6-(1-Butyl-5-methyl-1H-1,2,4-triazol-3-yl)-8-(2-fluorobenzyl)imidaz-
o[1,2-a]pyrazine (I-56) was synthesized according to General
Procedure C, with the exception that 1-bromobutane was used as the
alkylating agent, as a solid (2.0 mg, 6.8% yield). The other
regioisomers were not isolated. The reaction conditions (such as
reagents ratio, temperature and reaction time) were modified as
needed.
[0480] .sup.1H NMR (500 MHz, Methanol-d.sub.4) .delta. (ppm) 9.02
(s, 1H), 8.14 (s, 1H), 7.80 (s, 1H), 7.26 (m, 2H), 7.08 (m, 1H),
7.04 (m, 1H), 4.67 (s, 2H), 4.22 (t, 2H), 2.55 (s, 3H), 1.90 (app.
quin, 2H), 1.41 (m, 2H), 1.00 (t, 3H).
[0481] LCMS [M+H]=365.3
Compound I-57
##STR00145##
[0483]
5-(8-(2-Fluorobenzyl)imidazo[1,2-a]pyrazin-6-yl)-1H-1,2,4-triazol-3-
-amine (I-57): A suspension of S-methylisothiourea hemisulfate salt
(510 mg, 1.8 mmol),
8-(2-fluorobenzyl)imidazo[1,2-a]pyrazine-6-carboximidhydrazide (520
mg, 1.8 mmol) and sodium hydroxide (73 mg, 1.8 mmol) in water (8
mL) was heated to 120.degree. C. for 60 minutes in the microwave.
The reaction mixture was filtered using methanol as the eluent, and
the resulting filtrate was concentrated to afford the crude
product. This material was purified by reverse phase HPLC (12-37%
acetonitrile/water gradient with 0.1% trifluoroacetic acid) to
afford an orange oil which was a mixture of 2 compounds (360 mg).
This product mixture was used in subsequent reactions without
further purification.
[0484] A small sample of this material was further purified on
reverse phase HPLC (10-55% acetonitrile/water gradient with 0.1%
formic acid) to afford
5-(8-(2-fluorobenzyl)imidazo[1,2-a]pyrazin-6-yl)-1H-1,2,4-triazol--
3-amine (I-57) (3.0 mg) as a white solid.
[0485] .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. (ppm) 12.1 (br.
s, 1H), 8.92 (br. s, 1H), 8.21 (s, 1H), 7.77 (s, 1H), 7.35-7.40 (m,
1H), 7.25-7.29 (m, 1H), 7.15-7.19 (m, 1H), 7.06-7.11 (m, 1H), 6.09
(s, 2H), 4.53 (s, 2H).
[0486] LCMS [M+H]=310.1
Compound I-58
##STR00146##
[0487]
1-(3-Fluorobenzyl)-3-(8-(2-fluorobenzyl)imidazo[1,2-a]pyrazin-6-yl)-
-1H-1,2,4-triazol-5-amine (I-58)
[0488] To a solution of crude
5-(8-(2-fluorobenzyl)imidazo[1,2-a]pyrazin-6-yl)-1H-1,2,4-triazol-3-amine
(360 mg) in DMF (4 mL) was added 1-(bromomethyl)-3-fluorobenzene
(0.11 mL, 0.88 mmol) followed by potassium carbonate (210 mg, 1.6
mmol). The reaction mixture was stirred at ambient temperature for
16 hours and then heated to 50.degree. C. for 24 hours. The
reaction mixture was cooled to ambient temperature, diluted with
water (50 mL) and extracted with EtOAc (4.times.30 mL). The
combined organic phases were dried over Na.sub.2SO.sub.4, filtered
and concentrated to afford a brown residue. First pass purification
of the crude product by silica gel chromatography afforded a
mixture. Further purification of this material by reverse phase
HPLC (10-60% acetonitrile/water gradient with 0.1% trifluoroacetic
acid) afforded
1-(3-fluorobenzyl)-3-(8-(2-fluorobenzyl)imidazo[1,2-a]pyrazin-6-yl)-1H-1,-
2,4-triazol-5-amine (I-58) (6.9 mg), as a pale yellow solid.
[0489] 1H NMR (500 MHz, DMSO-d.sub.6) .delta. (ppm) 9.01 (s, 1H),
8.22 (s, 1H), 7.81 (s, 1H), 7.40-7.44 (m, 1H), 7.30-7.34 (m, 1H),
7.24-7.27 (m, 1H), 7.12-7.18 (m, 2H), 7.06-7.10 (m, 3H), 6.78 (br.
s, 2H), 5.25 (s, 2H), 4.52 (s, 2H).
[0490] LCMS [M+H]=418.3
Compound I-59 and Compound I-60
##STR00147##
[0491]
3-(8-(2-Fluorobenzyl)imidazo[1,2-a]pyrazin-6-yl)-1-(2,2,2-trifluoro-
ethyl)-1H-1,2,4-triazol-5-amine (I-59) and
5-(8-(2-fluorobenzyl)imidazo[1,2-a]pyrazin-6-yl)-1-(2,2,2-trifluoroethyl)-
-1H-1,2,4-triazol-3-amine (I-60)
[0492] A suspension of crude
5-(8-(2-fluorobenzyl)imidazo[1,2-a]pyrazin-6-yl)-1H-1,2,4-triazol-3-amine
(550 mg), 2,2,2-trifluoroethyl trifluoromethanesulfonate (0.30 mL,
2.2 mmol) and potassium carbonate (540 mg, 3.90 mmol) in DMF (4 mL)
was stirred for 16 hours at ambient temperature. The reaction
mixture was then diluted with water (50 mL) and extracted with
EtOAc (3.times.50 mL). The combined organic phases were dried over
Na.sub.2SO.sub.4, filtered and concentrated to afford a residue.
First pass purification was achieved by silica gel chromatography
(0-100% EtOAc/hexanes gradient). A second purification using silica
gel chromatography (0-50% acetonitrile/MeOH (7:1) in DCM gradient)
afforded
5-(8-(2-fluorobenzyl)imidazo[1,2-a]pyrazin-6-yl)-1-(2,2,2-trifluoroethyl)-
-1H-1,2,4-triazol-3-amine (I-60) (40 mg) as a gold solid. Compound
I-59 was detected in this campaign, but not isolated. In a second
campaign, crude
5-(8-(2-fluorobenzyl)imidazo[1,2-a]pyrazin-6-yl)-1H-1,2,4-triazol-3-
-amine (330 mg), 2,2,2-trifluoroethyl trifluoromethanesulfonate
(0.18 mL, 1.3 mmol), and potassium carbonate (320 mg, 2.4 mmol) in
DMF (4 mL) were combined to afford a similar mixture of products.
Purification of this reaction mixture using reverse phase HPLC
(10-55% acetonitrile/water gradient with 0.1% formic acid) afforded
3-(8-(2-fluorobenzyl)imidazo[1,2-a]pyrazin-6-yl)-1-(2,2,2-trifluoroethyl)-
-1H-1,2,4-triazol-5-amine (I-59) (3.5 mg) as a white solid.
Compound I-60:
[0493] .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. (ppm) 9.19 (s,
1H), 8.31 (d, 1H), 7.92 (d, 1H), 7.45-7.50 (m, 1H), 7.30-7.36 (m,
1H), 7.14-7.20 (m, 2H), 5.64 (s, 2H), 5.21 (q, 2H), 4.62 (s,
2H).
[0494] LCMS [M+H]=392.2
Compound I-59:
[0495] .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. (ppm) 8.98 (s,
1H), 8.22 (s, 1H), 7.78 (s, 1H), 7.30-7.34 (m, 1H), 7.24-7.29 (m,
1H), 7.15-7.19 (m, 1H), 7.06-7.09 (m, 1H), 6.76 (s, 2H), 4.98 (q,
2H), 4.43 (s, 2H). The regiochemical assignments were confirmed by
.sup.1H NMR nOe experiments (.about.3% nOe exists between
CH.sub.2CF.sub.3 protons and NH.sub.2 group).
[0496] LCMS [M+H]=392.2
Compound I-62 and Compound I-63
##STR00148##
[0497]
6-(3-Chloro-1H-1,2,4-triazol-5-yl)-8-(2-fluorobenzyl)imidazo[1,2-a]-
pyrazine (I-62) and
6-(3-(1H-imidazol-1-yl)-1H-1,2,4-triazol-5-yl)-8-(2-fluorobenzyl)imidazo[-
1,2-a]pyrazine (I-63)
[0498] A solution containing
8-(2-fluorobenzyl)imidazo[1,2-a]pyrazine-6-carboximidhydrazide (140
mg, 0.51 mmol) and 1,1'-carbonyldiimidazole (CDI) (410 mg, 2.5
mmol) in THF (4 mL) was stirred at ambient temperature for 40
hours. A tan suspension was observed. DCM/MeOH (60 mL, 1:1 ratio)
was added and the resultant mixture was gently warmed to dissolve
the solids. The crude mixture was concentrated and dried in vacuo.
Phosphoryl trichloride (3.0 mL, 32 mmol) was added and the
resultant mixture was heated at 120.degree. C. for 16 hours. The
reaction mixture was concentrated, carefully treated with ice and
neutralized with saturated NaHCO.sub.3 solution. The crude mixture
was extracted with DCM/isopropanol (5:1 ratio, 3.times.20 mL). The
combined organic layers were dried over Na.sub.2SO.sub.4, filtered
and concentrated in vacuo. Purification by silica gel
chromatography (0-25% acetonitrile/MeOH (7:1) in DCM) afforded the
title compounds 1-62 (23 mg, 14% yield, first eluting product) as
an off-white solid and 1-63 (18 mg, 9.9% yield, second eluting side
product) as a light tan solid.
Compound I-62:
[0499] .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. (ppm) 14.9 (s,
1H), 9.31 (s, 1H), 8.25 (s, 1H), 7.85 (s, 1H), 7.43 (app. t, 1H),
7.27 (m, 1H), 7.17 (app. t, 1H), 7.09 (app. t, 1H), 4.58 (s,
2H).
[0500] LCMS [M+H]=329.2
Compound I-63:
[0501] .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. (ppm) 14.8 (s,
1H), 9.36 (s, 1H), 8.32 (m, 2H), 7.86 (s, 1H), 7.76 (s, 1H), 7.43
(app. t, 1H), 7.28 (m, 1H), 7.20-7.15 (m, 2H), 7.10 (app. t, 1H),
4.60 (s, 2H).
[0502] LCMS [M+H]=361.3
Compound I-64 and Compound I-65
##STR00149##
[0503]
rac-6-(3-(2,2-Difluorocyclopropyl)-1H-1,2,4-triazol-5-yl)-8-(2-fluo-
robenzyl)imidazo[1,2-a]pyrazine (I-64) and
5-(8-(2-fluorobenzyl)imidazo[1,2-a]pyrazin-6-yl)-N,N-dimethyl-1H-1,2,4-tr-
iazol-3-amine (I-65)
[0504] A solution of rac-2,2-difluorocyclopropane-1-carboxylic acid
(89 mg, 0.70 mmol) in DMF (2.0 mL) was treated successively with
HATU (400 mg, 1.0 mmol) and 4-methylmorpholine (0.23 mL, 2.1 mmol).
The amber color solution was stirred at ambient temperature for 30
minutes and then added to
8-(2-fluorobenzyl)imidazo[1,2-a]pyrazine-6-carboximidhydrazide (200
mg, 0.70 mmol) with the aid of 0.50 mL of DMF. After 18 hours, the
reaction was diluted with EtOAc (100 mL) and water (50 mL). The
aqueous layer was back-extracted with EtOAc (25 mL). The combined
organic layers were washed with brine, dried over Na.sub.2SO.sub.4,
filtered and concentrated in vacuo to yield
2,2-difluoro-N'-((8-(2-fluorobenzyl)imidazo[1,2-a]pyrazin-6-yl)(imino)met-
hyl)cyclopropane-1-carbohydrazide (400 mg, >99% yield) as a
brown solid which was used without further manipulations. This
intermediate was suspended in ethanol (10 mL) and acetic acid (1.0
mL). The reaction was heated at 90.degree. C. for 15.5 hours.
Contents were concentrated in vacuo and the resulting residue was
purified twice by silica gel chromatography (20-10% EtOAc/hexanes
gradient and 0-4% acetonitrile/MeOH (7:1) in DCM gradient) and
re-purified by reverse phase HPLC (5-95% acetonitrile/water with
0.1% formic acid) to deliver the title compounds 1-64 (51 mg, 19%
yield, first eluting product) as a white solid and 1-65 (20 mg,
8.5% yield, second eluting side-product) as an off-white solid.
Compound I-64:
[0505] .sup.1H NMR (500 MHz, Methanol-d.sub.4) .delta. (ppm) 9.12
(s, 1H), 8.16 (s, 1H), 7.83 (s, 1H), 7.32 (m, 1H), 7.25 (m, 1H),
7.11-7.02 (m, 2H), 4.67 (s, 2H), 2.97 (m, 1H), 2.17 (m, 1H), 2.00
(m, 1H).
[0506] LCMS [M+H]=371.2
Compound I-65:
[0507] .sup.1H NMR (500 MHz, Methanol-d.sub.4) .delta. (ppm) 9.08
and 8.98 (s, 1H, tautomers), 8.13 and 8.10 (s, 1H, tautomers), 7.87
and 7.77 (s, 1H, tautomers), 7.36-7.16 (m, 2H), 7.13-6.98 (m, 2H),
4.64 (s, 2H), 3.09 and 3.03 (s, 6H, tautomers).
[0508] LCMS [M+H]=338.2
Compound I-66
##STR00150##
[0509]
8-(2-Fluorobenzyl)-3-iodo-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-
-yl)imidazo[1,2-a]pyrazine (I-66)
[0510] A solution of
8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1-
,2-a]pyrazine (99 mg, 0.27 mmol) in DMF (2.0 mL) was treated with
N-iodosuccinimide (92 mg, 0.41 mmol) and heated to 60.degree. C.
for 40 hours. The reaction mixture was concentrated and purified by
silica gel chromatography (0-5% acetonitrile/MeOH (7:1) in DCM
gradient) to afford the title compound (I-66) (130 mg, 96% yield)
as a white solid.
[0511] 1H NMR (500 MHz, DMSO-d.sub.6) .delta. (ppm) 15.6 (s, 1H),
8.79 (s, 1H), 8.04 (s, 1H), 7.41 (app. t, 1H), 7.27 (m, 1H), 7.18
(app. t, 1H), 7.08 (app. t, 1H), 4.62 (s, 2H).
[0512] LCMS [M+H]=489.2
Compound I-67
##STR00151##
[0513]
3-Chloro-8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-
-5-yl)imidazo[1,2-a]pyrazine (I-67)
[0514] A solution of
8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1-
,2-a]pyrazine (99 mg, 0.27 mmol) in DMF (2.0 mL) was treated with
N-chlorosuccinimide (55 mg, 0.41 mmol) and heated to 60.degree. C.
for 24 hours. The reaction mixture was concentrated and purified by
silica gel chromatography (0-20% acetonitrile/MeOH (7:1) in DCM
gradient) to afford the title compound (I-67) (56 mg, 51% yield) as
a white solid.
[0515] 1H NMR (500 MHz, Methanol-d.sub.4) .delta. (ppm) 9.04 (s,
1H), 7.88 (s, 1H), 7.39 (app. t, 1H), 7.26 (m, 1H), 7.08 (m, 2H),
4.70 (s, 2H).
[0516] LCMS [M+H]=397.2
Compound I-68
##STR00152##
[0517]
3-Fluoro-8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-
-5-yl)imidazo[1,2-a]pyrazine (I-68)
[0518] A solution of
8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1-
,2-a]pyrazine (100 mg, 0.28 mmol) in acetonitrile (3.0 mL) was
treated with
1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane
bis(tetrafluoroborate) (Selectfluor.RTM.) (120 mg, 0.34 mmol) and
heated to 70.degree. C. for 6 hours. Additional amount of
Selectfluor.RTM. (60 mg, 0.17 mmol) was added and heating was
continued at 70.degree. C. for 3 hours. The reaction mixture was
concentrated and purified by silica gel chromatography (0-20%
acetonitrile/MeOH (7:1) in DCM gradient) to afford the title
compounds 1-68 (10 mg, 9.4% yield) as a white solid.
[0519] 1H NMR (500 MHz, Methanol-d.sub.4) .delta. (ppm) 8.96 (s,
1H), 7.56 (d, 1H), 7.39 (app. t, 1H), 7.25 (m, 1H), 7.08 (m, 2H),
4.65 (s, 2H).
[0520] LCMS [M+H]=381.2
Compound I-70
##STR00153##
[0521]
8-(2-Fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imi-
dazo[1,2-a]pyrazine-3-carbonitrile (I-70)
[0522] A solid mixture comprised of
8-(2-fluorobenzyl)-3-iodo-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)im-
idazo[1,2-a]pyrazine (49 mg, 0.10 mmol), zinc cyanide (18 mg, 0.15
mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)
(3.7 mg, 5.0 .mu.mol), and zinc powder (1.3 mg, 0.020 mmol) was
flushed with nitrogen for 15 minutes. DMF (2 mL) was added and the
reaction was heated at 120.degree. C. in a microwave for 7.5 hours
during which additional amounts of the palladium catalyst (3.7 mg)
and zinc cyanide (24 mg) were added to drive the reaction. The
crude mixture was cooled to ambient temperature, diluted with EtOAc
(10 mL) and filtered through a bed of Celite with EtOAc (20 mL).
The organic filtrate was washed with water/brine (2.times.10 mL,
10:1 ratio) and brine (10 mL), dried over Na.sub.2SO.sub.4,
filtered and concentrated in vacuo. Purification by silica gel
chromatography (0-10% acetonitrile/MeOH (7:1) in DCM gradient)
afforded the title compound 1-70 as an off-white solid (15 mg, 38%
yield).
[0523] .sup.1H NMR (500 MHz, Methanol-d.sub.4) .delta. (ppm) 9.23
(s, 1H), 8.44 (s, 1H), 7.41 (app. t, 1H), 7.26 (m, 1H), 7.10-7.05
(m, 2H), 4.74 (s, 2H).
[0524] LCMS [M+H]=388.3
Compound I-71
##STR00154##
[0525]
8-(2-Fluorobenzyl)-3-methyl-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-
-5-yl)imidazo[1,2-a]pyrazine (I-71)
[0526] A solid mixture comprised of
8-(2-fluorobenzyl)-3-iodo-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)im-
idazo[1,2-a]pyrazine (71 mg, 0.15 mmol), potassium carbonate (60
mg, 0.44 mmol) and tetrakis(triphenylphosphine)palladium(0) (17 mg,
0.015 mmol) was flushed with nitrogen for 5 minutes. DME (3.5 mL)
and water (0.5 mL) were added followed by trimethylboroxine (37
.mu.L, 0.29 mmol). The reaction was heated at 100.degree. C. for 5
hours and then at 120.degree. C. for 1 hour. Additional amounts of
the palladium catalyst (17 mg) and trimethylboroxine (37 .mu.L)
were added and the reaction was heated at 120.degree. C. for 40
hours. The crude mixture was cooled to ambient temperature, poured
into water (20 mL) and neutralized to pH 7 with 1 N HCl solution.
The aqueous mixture was extracted with EtOAc (2.times.20 mL). The
combined organic phases were dried over Na.sub.2SO.sub.4, filtered
and concentrated in vacuo. Purification by silica gel
chromatography (0-40% EtOAc/hexanes gradient) and reverse phase
HPLC (30-80% acetonitrile/water gradient with 0.1% formic acid)
afforded the title compound 1-71 as a white solid (16 mg, 29%
yield).
[0527] .sup.1H NMR (500 MHz, Methanol-d.sub.4) .delta. (ppm) 8.99
(s, 1H), 7.66 (s, 1H), 7.33 (app. t, 1H), 7.24 (m, 1H), 7.11-7.03
(m, 2H), 4.67 (s, 2H), 2.63 (s, 3H).
[0528] LCMS [M+H]=377.2
Example 2a: Biological Activity Measurement by the cGMP GloSensor
Cell-Based Assay, 384-Well Format
[0529] Human embryonic kidney cells (HEK293) cells expressing
GloSensor.TM. 40F cGMP (Part No: CS182801, Promega) were used to
evaluate the activity of test compounds. The luminescent biosensors
(engineered luciferase) that were incorporated into these cells
detect cGMP formed by the compounds stimulating the sGC enzyme and
emit luminescence.
[0530] cGMP GloSensor cells were maintained in Dulbecco's
Modification of Eagle's Medium (DMEM) supplemented with fetal
bovine serum (FBS, 10% final) and hygromycine (200 ug/ml). The day
before assay, cells were plated in DMEM with 10% FBS in a 50 .mu.L
volume at a density of 1.5.times.10.sup.4 cells/well in a
poly-D-lysine coated 384-well flat white-bottom plate (Corning Cat
No 35661). Cells were incubated overnight at 37.degree. C. in a
humidified chamber with 5% CO.sub.2. The next day, medium was
removed and cells were replaced with 40 ul/well of GloSensor.TM., 2
mM (Promega Cat No E1291). Cells were treated for 90 minutes at
25.degree. C. to allow the substrate to equilibrate in the cells.
Test compounds and Diethylenetriamine NONOate (DETA-NONOate, or
DETA-NO) was diluted to 3 mM (20.times.) in serum-free CO.sub.2
independent medium and serially diluted at 4.times. dilutions to
create 5.times. dose curve from which 10 ul was added to the wells
(x .mu.M concentration for test compound solution and 10 .mu.M
concentration for DETA-NONOate solution; wherein x is one of the
following final concentrations: 30000 nM, 7500 nM, 1875 nM, 468.8
nM, 117.2 nM, 29.29 nM, 7.320 nM, 1.830 nM, 0.460 nM, 0.114 nM, and
0.029 nM).
[0531] For the kinetics studies, luminescence was measured right
away for 0.2 sec per well with Envision (Perkin Elmer). For
endpoint SAR screening, data were collected after 55 min incubation
at room temperature.
[0532] Data were normalized to a high control using the following
equation: 100*(Sample-Low Control)/(High Control-Low Control),
where the low control is the average of 16 samples treated with 1%
DMSO, and the high control is the average of 16 samples treated
with 3004 of Compound Y depicted below. Data were fit using a
4-parameter fit (log(agonist) vs. response-variable slope) using
GraphPad Prism Software v.5. n=2 for all compounds. The Absolute
(Abs) EC.sub.50 was interpolated from the curve fit and is defined
as the concentration at which a given compound elicits 50% of the
high control response after data normalization as indicated above.
Compounds failing to elicit a minimum response of 50% are reported
as >30 .mu.M or ND. For compounds run in duplicate or n higher
than 2, the result herein given is the geometric mean of the
several results obtained. Table 2a summarizes results obtained for
selected compounds of the invention in this assay.
##STR00155##
TABLE-US-00002 TABLE 2a Whole cell activity in the GloSensor cell-
based assay, 384-well format (Example 2a) Compound Abs EC50 (nM)
I-1 A I-2 A I-3 B I-4 B I-5 A I-6 B I-7 B I-8 A I-9 A I-10 A I-11 B
I-12 B I-13 C I-14 A I-15 B I-16 A I-17 A I-18 A I-19 C I-20 C I-21
A I-22 A I-23 A I-24 A I-25 A I-26 A I-27 A I-28 A I-29 A I-30 A
I-31 B I-32 C I-33 A I-34 A I-35 A I-36 C I-37 C I-38 A I-39 I-41 A
I-42 C I-47 A I-48 A I-50 B I-51 A I-53 B I-54 B I-56 A I-57 B I-58
A I-59 A I-60 C I-62 A I-63 B I-64 B I-65 B I-66 B I-67 A I-68 A
I-70 B I-71 A I-72 C sGC enzyme activity values in HEK cells,
determined by the GloSensor assay. (~) Code definitions for the sGC
enzyme activity values, expressed as Absolute EC.sub.50 which is
defined as the concentration at which a given compound elicits 50%
of the high control response (Compound Y) after data normalization:
Abs EC50 .ltoreq. 100 nM = A; 100 nM < Abs EC50 .ltoreq. 1000 nM
= B; 1000 nM < Abs EC50 = C. Compounds failing to elicit a
minimum response of 50% are reported as >30 .mu.M or ND.
Example 2b: Biological Activity Measurement by the cGMP GloSensor
Cell-Based Assay, 384-Well Format
[0533] HEK293 cells expressing GloSensor.TM. 40F cGMP (Part No:
CS182801, Promega) were used to evaluate the synergy of the test
compounds with NO. Multiple assays where run in which the
concentrations of test compound also well as the concentration of
Diethylenetriamine NONOate (DETA-NONOate) were varied to determine
the synergy of the test compound with NO. Test compounds and
Diethylenetriamine NONOate (DETA-NONOate or DETA-NO) were diluted
to 3 mM (20.times.) in serum-free CO.sub.2 independent medium and
serially diluted at 4.times. dilutions to create 5.times. dose
curve from which 10 ul was added to the wells (x .mu.M
concentration for test compound solution and y .mu.M concentration
for DETA-NO solution; wherein x is one of the following final
concentrations: 30000 nM, 7500 nM, 1875 nM, 468.8 nM, 117.2 nM,
29.29 nM, 7.320 nM, 1.830 nM, 0.460 nM, 0.114 nM, and 0.029 nM and
y is one of the following final concentrations: 30 .mu.M, 10 .mu.M,
3.33 .mu.M 1.11 .mu.M, and 0 .mu.M).
[0534] Following the analysis as described above, Table 2b
summarizes results obtained for Compound I-1 with the various
DETA-NO amount in this assay.
TABLE-US-00003 TABLE 2b Whole cell activity in the GloSensor
cell-based assay, 384-well format (Example 2b) [DETA-NO] 30 uM 10
uM 3.33 uM 1.11 uM 0 uM I-1 - EC.sub.50 A B B B B sGC enzyme
activity values in HEK cells, determined by the GloSensor assay.
(~) Code definitions for the sGC enzyme activity values, expressed
as Absolute EC.sub.50 which is defined as the concentration at
which a given compound elicits 50% of the high control response
(Compound Y) after data normalization: Abs EC50 .ltoreq. 100 nM =
A; 100 nM < Abs EC50 .ltoreq. 1000 nM = B; 1000 nM < Abs EC50
= C. Compounds failing to elicit a minimum response of 50% are
reported as >30 .mu.M or ND.
[0535] As shown in Table 2b, Compound I-1 synergizes with NO to
stimulate sGC.
Example 3. Biological Activity Measurement by the cGMP Neuronal
Cell-Based Assay
[0536] Rat primary neurons were isolated from fetuses of 18-day
pregnant Sprague-Dawley females. The fetuses were collected in
Hanks' balanced salt solution (HBSS) and brains were rapidly
removed. The cerebral hippocampi were isolated and mechanically
fragmented. Further tissue digestion was performed with 0.25%
(wt/vol) trypsin solution in HBSS without Ca2+ and Mg2+ for 15 min
at 37.degree. C. After trypsination, cells were washed and
resuspended in neurobasal medium supplemented with 0.5 mM
L-glutamine, 12.5 uM glutamic acid, 2% B-27 and 100 U/mL
penicillin, and 100 .mu.g/mL streptomycin. Cells were plated at a
density of 4.times.10.sup.4 cells/well in a poly-D-lysine coated
384-well flat clear-bottom plate (Corning Cat No 354662). Cells
were incubated 6-7 days at 37.degree. C. in a humidified chamber
with 5% CO.sub.2. Media was removed and cells were washed 1.times.
with HBSS containing Ca2+ and Mg2+, and replaced with 40 uL HBSS
containing 0.5 mM IBMX, and incubated for 15 minutes at 37.degree.
C. 10 uL of a 5.times. stock of test compounds with
diethylenetriamine NONOate (DETA-NO) was added. Final concentration
of DETA-NO was 30 .mu.M. Cells were incubated for 20 min at
37.degree. C. Medium was removed, 50 uL of ice-cold 10% acetic acid
was added, and incubated for 60 minutes at 4.degree. C. Following
centrifugation at 4.degree. C. for 5 minutes at 1000.times.g to
pellet cell debris, the supernatant was aspirated to a clean plate
and the samples were analyzed for cGMP content. cGMP concentrations
were determined from each sample using LC-MS/MS.
[0537] Data were normalized to a high control using the following
equation: 100*(Sample-Low Control)/(High Control-Low Control),
where the low control is the average of 15 samples treated with 1%
DMSO, and the high control is the average of 15 samples treated
with 10 .mu.M a known sGC stimulator Compound Y. Data were fit
using a 4-parameter fit (log(agonist) vs. response-variable slope)
using GraphPad Prism Software v.5. n=2 for all compounds. The
Absolute EC.sub.50 was interpolated from the curve fit and is
defined as the concentration at which a given compound elicits 50%
of the high control response. Compounds failing to elicit a minimum
response of 50% are reported as >30 .mu.M. For compounds run in
duplicate or n higher than 2, the result herein given is the
geometric mean of the several results obtained. Table 3 summarizes
results obtained for selected compounds of the invention in this
assay.
TABLE-US-00004 TABLE 3 Biological activity in the cGMP neuronal
cell- based assay (Example 3) Abs Compound EC50 (nM) I-1 A I-6 A
I-7 B I-10 A I-11 A I-14 A I-2 A I-3 A I-5 A I-8 A I-9 A I-12 B
I-13 C I-15 B I-16 A Neuronal-based cell assay. AbsEC50 .ltoreq.
100 nM = A; 100 nM < AbsEC50 .ltoreq. 1000 nM = B; 1000 nM <
AbsEC50 = C. Compounds failing to elicit a minimum response of 50%
are reported as >30 .mu.M or ND.
Example 4: Rat Cerebrospinal Fluid (CSF) Pharmacokinetic
Properties
[0538] Protocol. PK in rats was determined following oral dosing.
For the oral (PO) experiments, a group of 6 male Sprague-Dawley
rats with an indwelling catheter placed in the cisterna magna were
used. The PO group was dosed with 10 mg/kg or 1 mg/kg of a compound
formulated as a solution in PEG400. PO doses were administered by
oral gavage and delivered to the stomach using a syringe and gavage
tube. Following oral dosage administration, the gavage tube was
flushed with approximately 0.5 mL of water to ensure complete
delivery of the full dose.
[0539] Plasma samples were collected as follows: samples of CSF and
blood were collected at 1 hour, 2, and optionally at 4 hours
post-dosing. CSF samples (0.05 mL) were collected through the
intracisternal catheter. Blood samples (0.25 mL) were collected
through retro-orbital sampling. These samples were kept on ice
until processed for plasma. Blood samples were centrifuged at 3200
rpm for 5 minutes at approximately 5.degree. C. within 1 hour of
collection. Plasma was directly transferred to a 96-well plate tube
(0.125 mL). Plug caps were placed on the tubes and the tubes frozen
at approximately -70.degree. C. and stored until analysis. Plasma
was collected and analyzed for the presence of a compound.
[0540] Quantitation of Compounds. The compound in question and the
internal standard were extracted from plasma and CSF by
precipitation. Samples were analyzed using liquid chromatography
(LC) with tandem mass spectrometric detection (MS/MS) using
electrospray ionization. The standard curve range was from 1 to
1000 ng/mL. Results of the compounds described herein in this assay
are illustrated in Table 4a below (10 mg/kg dose) and Tables 4b and
4c below (1 mg/kg).
[0541] Kp,uu is defined as the concentration ratio of unbound drug
in CSF to unbound drug in plasma. Unbound drug in plasma (or free
plasma concentration) is calculated by multiplying the total plasma
concentration by the unbound fraction as determined by plasma
protein binding. The CSF concentration is then divided by the free
plasma concentration to determine the Kp,uu. (See e.g., Di et al.,
J. Med. Chem., 56, 2-12 (2013))
TABLE-US-00005 TABLE 4a CSF PK properties of select compounds
described herein (Example 4) at a 10 mg/kg dose. CSF Conc. Kp,uu
Compound (nM @ 1 h) (@ 1 h) I-1 210 0.9 I-10 108 3.1 I-11 72 2.1
I-14 284 1.7 I-2 59 0.9 I-3 6 0.8 I-16 272 1.6 I-27 41 0.2 I-28 20
0.2
TABLE-US-00006 TABLE 4b CSF Concentration of a select compound
described herein (Example 4) at a 1 mg/kg dose. CSF Conc. (nM) Cmpd
@ 1 h @ 2 h @ 4 h I-1 21 35 39
TABLE-US-00007 TABLE 4c Kp,uu of a select compound described herein
(Example 4) at a 1 mg/kg dose. Kp,uu Cmpd @ 1 h @ 2 h @ 4 h I-1 1.0
1.4 1.9
Example 5: Dog Cerebrospinal Fluid (CSF) Pharmacokinetic
Properties
[0542] Protocol. PK in dogs was determined following oral dosing. A
group of 4 male beagle dogs were used and the dogs were dosed with
1 mg/kg of a compound formulated as a suspension in 1% HPMC E5,
0.2% Tween 80, and 0.5% MC in water. PO doses were administered by
oral gavage in a gelatin capsule and delivered to the stomach using
a gavage tube. Following oral dosage administration, the gavage
tube was flushed with approximately 10 mL of water to ensure
complete delivery of the full dose.
[0543] Plasma and CSF samples were collected as follows: samples of
CSF and blood were collected at 1, 2, 4 and 8 hours post PO dosing.
CSF samples (0.05 mL) were collected from the lumbosacral region
(L4/5) via direct needle puncture at the appropriate time points.
Blood samples (0.25 mL) were collected via cephalic vein. These
samples were kept on ice until processed for plasma. Blood samples
were centrifuged at 3200 rpm for 5 minutes at approximately
5.degree. C. within 1 hour of collection. Plasma was directly
transferred to a 96-well plate tube (0.125 mL). Plug caps were
placed on the tubes and the tubes frozen at approximately
-70.degree. C. and stored until analysis. Plasma was collected and
analyzed for the presence of a compound.
[0544] Quantitation of Compounds. The compound of the invention and
the internal standard were extracted from plasma and CSF by
precipitation. Samples were analyzed using liquid chromatography
(LC) with tandem mass spectrometric detection (MS/MS) using
electrospray ionization. The standard curve range was from 1 to
1000 ng/mL. Results of the compounds described herein in this assay
are illustrated in Tables 5a and 5b below (1 mg/kg dose).
[0545] Kp,uu is defined as the concentration ratio of unbound drug
in CSF to unbound drug in plasma. Unbound drug in plasma (or free
plasma concentration) is calculated by multiplying the total plasma
concentration by the unbound fraction as determined by plasma
protein binding. The CSF concentration is then divided by the free
plasma concentration to determine the Kp,uu. (See e.g., Di et al.,
J. Med. Chem., 56, 2-12 (2013))
TABLE-US-00008 TABLE 5a CSF Concentration of a select compound
described herein (Example 5) at a 1 mg/kg dose. CSF Conc. (nM) Cmpd
@ 1 h @ 2 h @ 4 h @ 8 h I-1 34 34 19 2.4
TABLE-US-00009 TABLE 5b Kp,uu of a select compound described herein
(Example 5) at a 1 mg/kg dose. Kp,uu Cmpd @ 1 h @ 2 h @ 4 h @ 8 h
I-1 0.7 0.7 0.7 0.4
Example 6: Non-Human Primate (NHP) Cerebrospinal Fluid (CSF)
Pharmacokinetic Properties
[0546] Protocol. PK in NHP was determined following intravenous and
oral dosing. For the intravenous (IV) experiments, a group of 4
male Cynomolgus monkeys were used. The IV group was dosed with 0.3
mg/kg of a compound formulated as a solution in 10% PEG-400, 25% of
a 20% Solutol HS 15 in Water, and 65% DPBS. IV doses were
administered by injection and delivered via catheter into the
cephalic vein. For the oral (PO) experiments, a group of 4 male
Cynomolgus monkeys were used. The PO group was dosed with 1 mg/kg
of a compound formulated as a suspension in 1% HPMC E5, 0.2% Tween
80, 0.5% MC in water. PO doses were administered by oral gavage and
delivered via gelatin capsule.
[0547] Plasma and CSF samples were collected as follows: samples of
CSF and blood were collected at 1, 4 and 24 hours post IV dosing
and 2, 8 and 24 hours post PO dosing. CSF samples (0.05 mL) were
collected either the cisterna magna (primary site) or the
lumbosacral region (L4/5) via direct needle puncture at the
appropriate time points. Blood samples (0.25 mL) were collected
from a peripheral vein. These samples were kept on ice until
processed for plasma. Blood samples were centrifuged at 3200 rpm
for 5 minutes at approximately 5.degree. C. within 1 hour of
collection. Plasma was directly transferred to a 96-well plate tube
(0.125 mL). Plug caps were placed on the tubes and the tubes frozen
at approximately -70.degree. C. and stored until analysis. Plasma
was collected and analyzed for the presence of a compound.
[0548] Quantitation of Compounds. The compound of the invention and
the internal standard were extracted from plasma and CSF by
precipitation. Samples were analyzed using liquid chromatography
(LC) with tandem mass spectrometric detection (MS/MS) using
electrospray ionization. The standard curve range was from 1 to
1000 ng/mL. Results of the compounds described herein in this assay
are illustrated in Tables 6a and 6b below (0.3 mg/kg IV dose, 1
mg/kg PO dose).
[0549] Kp,uu is defined as the concentration ratio of unbound drug
in CSF to unbound drug in plasma. Unbound drug in plasma (or free
plasma concentration) is calculated by multiplying the total plasma
concentration by the unbound fraction as determined by plasma
protein binding. The CSF concentration is then divided by the free
plasma concentration to determine the Kp,uu. (See e.g., Di et al.,
J. Med. Chem., 56, 2-12 (2013))
TABLE-US-00010 TABLE 6a CSF Concentration of a select compound
described herein (Example 6) at a 0.3 mg/kg IV and 1 mg/kg PO dose.
CSF Conc. (nM) @ 1 h, @ 2 h, @ 4 h, @ 8 h, @ 24 h, Cmpd IV PO IV PO
IV @ 24 h, PO I-1 27 42 20 31 6 11
TABLE-US-00011 TABLE 6b Kp,uu of a select compound described herein
(Example 6) at a 0.3 mg/kg IV and 1 mg/kg PO dose. Kp,uu @ 1 h, @ 2
h, @ 4 h, @ 8 h, @ 24 h, @ 24 h, Cmpd IV PO IV PO IV PO I-1 1.8 1.8
3.0 2.5 2.8 2.1
Example 7: Rat Cerebrospinal Fluid (CSF) Biomarker Measurement
[0550] This experiment was to determine the effect of different
doses of a compound of the invention on the cGMP response as well
as the compound concentration in rat CSF and compound concentration
in rat plasma.
[0551] Protocol. Each rat was sampled one time or multiple times
with 3 or more days in between each dosing.
[0552] Day before the experiment. Fast rats overnight with ad
libitum access to water.
[0553] Day of the experiment. Compound and cyclic guanosine
monophosphate (cGMP) in rat CSF was determined following oral
dosing. Male Sprague-Dawley rats with an indwelling catheter placed
in the cisterna magna were used. The rats were dosed with 0 mg/kg
(n=15), 3 mg/kg (n=19) and 10 mg/kg (n=20) of a compound of the
invention formulated as a suspension in 0.5% methylcellulose, 0.5%
Tween80. PO doses were administered by oral gavage and delivered to
the stomach using a syringe and gavage tube. Following oral dosage
administration, the gavage tube was flushed with approximately 0.5
mL of water to ensure complete delivery of the full dose.
[0554] Plasma and CSF samples were collected under isoflurane
anesthesia as follows: samples of CSF were collected at 1 hour and
6 hours post-dosing and samples of blood were collected 1 h
post-dosing. CSF samples were collected through the intracisternal
catheter. Approximately 20 .mu.L of CSF and discard (dead volume is
14-16 .mu.L); then withdraw approximately 50 .mu.L of CSF in
eppendorf tubes containing 5 .mu.L of glacial acetic acid. Snap
freeze CSF by immersion in liquid nitrogen. Blood samples (0.25 mL)
were collected through retro-orbital sampling. These samples were
kept on ice until processed for plasma. Blood samples were
centrifuged at 3200 rpm for 10 minutes at approximately 5.degree.
C. within 1 hour of collection. Plasma was directly transferred to
a 96-well plate tube (0.125 mL). Plug caps were placed on the tubes
and the tubes frozen at approximately -70.degree. C. and stored
until analysis. Plasma was collected and analyzed for the presence
of a compound.
[0555] Quantitation of Compounds and cGMP. The compound of the
invention, cGMP and the internal standard were extracted from
plasma and CSF by precipitation. Samples were analyzed using liquid
chromatography (LC) with tandem mass spectrometric detection
(MS/MS) using electrospray ionization. The standard curve range was
from 1 to 1000 ng/mL. Results of the compounds described herein in
this assay are illustrated in Table 7 below (3 and 10 mg/kg dose).
Statistics were determined by planned comparison t-tests.
[0556] Kp,uu is defined as the concentration ratio of unbound drug
in CSF to unbound drug in plasma. Unbound drug in plasma (or free
plasma concentration) is calculated by multiplying the total plasma
concentration by the unbound fraction as determined by plasma
protein binding. The CSF concentration is then divided by the free
plasma concentration to determine the Kp,uu. (See e.g., Di et al.,
J. Med. Chem., 56, 2-12 (2013)).
TABLE-US-00012 TABLE 7 CSF PK properties of select compounds
described herein (Example 7) at a 3 and 10 mg/kg dose. Compound,
CSF Conc. CSF Conc. Dose (nM @ 1 h) (nM @ 6 h) I-1, 0 mg/kg 3.9 4.7
I-1, 3 mg/kg 7.2* 6.7 I-1, 10 mg/kg 14.8** 13.8* *p < than 0.05
vs. vehicle; **p < than 0.01 vs. vehicle
[0557] Conclusions. Acute dosing of 3 mg/Kg Compound I-1 P.O. in
rat induced a significant increase of cGMP in rat CSF 1 h after
dosing. Acute dosing of 10 mg/Kg Compound I-1 P.O. in rat induced a
significant increase of cGMP in rat CSF 1 h and 6 h after
dosing.
Example 8: Evaluation of Compounds of the Invention on Synaptic
Transmission and Plasticity Impairments in R6/2 Mice Hippocampal
Slices
[0558] Improvements in synaptic transmission and plasticity, as
measured by long term potentiation (LTP), is believed to indicate
the potential of a compound to enhance memory. LTP is an
electrophysiological phenomena that is commonly referred to as the
a cellular phenomenon driving learning and memory.
[0559] Protocol.
[0560] Preparation of acute mice hippocampal slices. Experiments
were carried out with 11 to 12 week-old R6/2 and WT mice provided
by the Jackson Laboratory (USA). Hippocampal slices (350 .mu.m
thickness) were cut with a Macllwain tissue chopper in an ice-cold
oxygenated sucrose solution (Saccharose 250, Glucose 11,
NaHCO.sub.326, KCl 2, NaH.sub.2PO.sub.4 1.2, MgCl.sub.2 7, and
CaCl.sub.2 0.5 in mM). The slices were incubated 1 hour at room
temperature in ACSF of the following composition: Glucose 11,
NaHCO.sub.3 25, NaCl 126, KCl 3.5, NaH.sub.2PO.sub.4 1.2,
MgCl.sub.2 1.3, and CaCl.sub.2 2 in mM. Then, the slices were let
to recover for at least 1 h.
[0561] Slice perfusion and temperature control. During the
experiments, the slices were continuously perfused with the ACSF
(bubbled with 95% O.sub.2-5% CO.sub.2) at the rate of 3 mL/min with
a peristaltic pump (MEA chamber volume: .about.1 mL). Complete
solution exchange in the MEA chamber was achieved 20 s after the
switch of solutions. The perfusion liquid was continuously
pre-heated at 37.degree. C. just before reaching the MEA chamber
with a heated-perfusion cannula (PH01, MultiChannel Systems,
Reutlingen, Germany). The temperature of the MEA chamber was
maintained at 37.+-.0.1.degree. C. with a heating element located
in the MEA amplifier headstage.
[0562] Stimulation Protocols/Compound Application.
[0563] Input/Output (I/O) curve: from 100 to 800 .mu.A, by 100
.mu.A steps. The stimulus intensity was then set to a fixed value
of 250 .mu.A for the short- and long-term synaptic plasticity
measurements.
[0564] Short-term plasticity properties: two pulses with a
decreasing inter-stimuli interval (e.g. 300 ms, 200 ms, 100 ms, 50
ms, 25 ms) were applied. Compound application: fEPSP were recorded
for 10 minutes in control conditions (to verify the baseline
steadiness) followed by a 15-minute exposure to the compound (or 25
minutes in the presence of vehicle only for control slices). A
second I/O protocol and paired-pulse protocol were applied, as
described previously, in the continuous presence of the
compound.
[0565] Long-Term Potentiation (LTP): Following a 10-minute control
period (in the presence of the compound or vehicle for control
slices), LTP was induced by a 10.times.TBS. Potentiation of
synaptic transmission was then monitored for an additional
60-minute period (in the continuous presence of the compound or
vehicle for control slices).
[0566] Results
[0567] Comparison between R6/2 and WT mice. I/O characteristics
were significantly higher in R6/2 mice hippocampal slices when
compared to their WT littermates, for the higher stimulation
intensities (700 and 800 .mu.A). Paired-pulse properties were in
the same range for R6/2 and WT mice hippocampal slices, except for
the 25 ms Inter-Stimulus Interval, for which facilitation was
significantly larger for R6/2 mice. Long-Term Potentiation was
significantly impaired (p value <0.0001, Two-way ANOVA) in
hippocampal slices of R6/2 mice, when compared to age-matching WT
mice.
[0568] Evaluation of 7 nM Compound I-1. I/O characteristics were
not significantly modified after the exposure to 7 nM Compound I-1
in R6/2 hippocampal slices, for all stimulus intensities.
Paired-pulse properties were also in the same range before and
after exposure to 7 nM of Compound I-1 in R6/2 mice hippocampal
slices, and did not significantly differ for any of the ISI.
Exposure to 7 nM Compound I-1 for 15 minutes, did not modify the
fEPSP amplitude.
[0569] In WT mice hippocampal slices (control conditions), HFS
triggered a potentiation of the evoked-response amplitudes that
stabilized around 45% (fEPSP were increased by 46.+-.5%, at end
point). In R6/2 mice hippocampal slices (control conditions), HFS
triggered a potentiation of the evoked-response amplitudes that
stabilized around 15% (fEPSP were increased by 16.+-.3%, at
endpoint). After exposure to 7 nM Compound I-1, HFS triggered a
potentiation of the evoked-response amplitudes that stabilized
around 25% (fEPSP were increased by 26.+-.6%, at endpoint). The
potentiation observed after the exposure to 7 nM Compound I-1 did
not significantly differ to the one recorded in control R6/2 slices
(p value=0.0842, Two-way ANOVA). (FIG. 1).
[0570] Evaluation of 46 nm Compound I-1. I/O characteristics were
similar before and after the exposure to 46 nM Compound I-1 in R6/2
hippocampal slices, for all stimulus intensities. Paired-pulse
properties were not significantly increased after exposure to 46 nM
Compound I-1 in R6/2 mice hippocampal slices, for all of the ISI.
Exposure to 46 nM Compound I-1, for 15 minutes did not modify the
fEPSP amplitude in comparison with control slides.
[0571] In WT mice hippocampal slices (control conditions), HFS
triggered a potentiation of the evoked-response amplitudes that
stabilized around 45% (fEPSP were increased by 46.+-.5%, at end
point). In R6/2 mice hippocampal slices (control conditions), HFS
triggered a potentiation of the evoked-response amplitudes that
stabilized around 15% (fEPSP were increased by 16.+-.3%, at
endpoint). After exposure to 46 nM Compound I-1, HFS triggered a
potentiation of the evoked-response amplitudes that stabilized
around 45% (fEPSP were increased by 44.+-.12%, at endpoint). The
potentiation observed after the exposure to 46 nM Compound I-1 was
significantly larger than the one recorded in control R6/2 slices
(p value=0.0065, Two-way ANOVA). (FIG. 2)
[0572] Evaluation of 308 nm Compound I-1. I/O characteristics
recorded from R6/2 hippocampal slices were not significantly
increased after exposure to 308 nM Compound I-1 for all stimulus
intensities. Paired-pulse properties were significantly lower after
exposure to 308 nM Compound I-1 for the 50 ms ISI only, in R6/2
mice hippocampal slices. The amplitude of fEPSP was slightly
increased over the 15-minute exposure to 308 nM Compound I-1, when
compared to the control R6/2 slides.
[0573] In WT mice hippocampal slices (control conditions), HFS
triggered a potentiation of the evoked-response amplitudes that
stabilized around 45% (fEPSP were increased by 46.+-.5%, at end
point). In R6/2 mice hippocampal slices (control conditions), HFS
triggered a potentiation of the evoked-response amplitudes that
stabilized around 15% (fEPSP were increased by 16.+-.3%, at
endpoint). After exposure to 308 nM Compound I-1, HFS triggered a
potentiation of the evoked-response amplitudes that stabilized
around 35% (fEPSP were increased by 37.+-.9%, at endpoint). The
potentiation observed after the exposure to 308 nM Compound I-1 was
significantly larger than the one recorded in control R6/2 slices
(p value=0.0059, Two-way ANOVA). (FIG. 3)
[0574] Conclusions. Although the highest concentration of Compound
I-1 that was investigated (308 nM) slightly increased the amplitude
of evoked-responses, none of the 3 concentrations displayed a
significant effect on the overall I/O characteristics, in R6/2 mice
hippocampal slices. None of the evaluated Compound I-1
concentrations (7 nM, 46 nM or 308 nM) displayed a significant
effect on the short-term plasticity properties, as measured by
paired-pulses with 25 ms to 300 ms ISI (with the exception of 308
nM Compound I-1, which significantly decreased the facilitation of
paired pulses applied with a 50 ms ISI). Whereas 7 nM Compound I-1
failed to significantly rescue the LTP impairment recorded in R6/2
mice hippocampal slices, this compound completely restored the LTP
deficit at 46 nM and 308 nM concentrations.
Example 9: Compound-Induced cGMP in Mouse Brain
[0575] Objective. To determine the effect of different doses of a
compound of the invention in cGMP response and compound
concentration in different areas of the mouse brain (cortex,
hippocampus, cerebellum and striatum) and compound concentration in
blood
[0576] Protocol. Mice (n=7-8 per experimental condition) were dosed
PO with vehicle (1% hydroxypropyl methyl cellulose, 0.2% Tween80,
0.5% methyl cellulose) or 0.3, 1, 3 or 10 mg/Kg of Compound I-1
prepared in vehicle. Thirty minutes after dosing, under isoflurane
anesthesia, the mouse was decapitated and the brain was removed and
placed into an ice-cold petri dish containing slushy dissection
solution (saturated with 95% O.sub.2.5% CO.sub.2). Using an
ice-cold spatula, the brain was transferred to mouse brain matrix
with coronal spacing for slicing at 1 mm intervals, as shown in
FIG. 5 (not to scale, just a scheme).
[0577] The sliced brain was transferred back into petri dish
containing slushy dissection solution with IBMX 0.5 mM (saturated
with 95% O.sub.2/5% CO.sub.2). The dorsal striatum is dissected
first, followed by the hippocampus second, followed by the medial
prefrontal cortex third, and lastly, the cerebellum fourth. After
each region is dissected the dissected tissue was immediately
placed into an eppendorf that was placed on dry ice for the
previous 30 minutes. Small pieces of tissue froze very fast, within
10 seconds approximately. After all regions were placed in an
eppendorf, the eppendorfs were then snap frozen by immersion into
liquid nitrogen. The whole blood sample was collected from the
trunk area using mitra tips. Tissue samples were stored in the
-80.degree. C. and mitra tips at room temperature. cGMP and
compound levels in brain and blood were determined by LC/MS;
protein quantification of brain samples was determined using BCA
protein assay kit.
[0578] Conclusion: Acute dosing of 10 mg/Kg Compound I-1 P.O. in
mice induced a significant increase of cGMP in all the mouse brain
areas analyzed (hippocampus, cerebellum, cortex and striatum).
(Tables 9a-d)
TABLE-US-00013 TABLE 9a The concentration of cGMP in the mouse
hippocampus normalized to protein concentration in the samples.
Hippocampus nM cGMP/.mu.g protein Vehicle 0.3 MPK I-1 1 MPK I-1 3
MPK I-1 10 MPK I-1 0.035359286 0.042545857 0.04302025 0.051901286
0.117125** **p < than 0.01 vs. vehicle
TABLE-US-00014 TABLE 9b The concentration of cGMP in the mouse
striatum normalized to protein concentration in the samples.
STRIATUM nM cGMP/.mu.g protein Vehicle 0.3 MPK I-1 1 MPK I-1 3 MPK
I-1 10 MPK I-1 0.02185575 0.022608143 0.031235625 0.037185875
0.046120125* *p < than 0.05 vs. vehicle;
TABLE-US-00015 TABLE 9c The concentration of cGMP in the mouse
cerebellum normalized to protein concentration in the samples.
CEREBELLUM nM cGMP/.mu.g protein vehicle 0.3 MPK I-1 1 MPK I-1 3
MPK I-1 10 MPK I-1 0.473119429 0.319919286 0.457655 0.75244675
1.7957685**** ****p < or = to 0.0001 vs. vehicle;
TABLE-US-00016 TABLE 9d The concentration of cGMP in the mouse
cortex normalized to protein concentration in the samples. CORTEX
nM cGMP/.mu.g protein vehicle 0.3 MPK I-1 1 MPK I-1 3 MPK I-1 10
MPK I-1 0.06765825 0.077611714 0.08063575 0.10810275 0.173364125*
*p < than 0.05 vs. vehicle;
Example 10. Novel Object Recognition (NOR) Test
[0579] Objective. To assess the efficacy of compounds of the
invention in reversing memory disruption induced by MK-801 using
the Novel Object Recognition (NOR) test in male Long Evans rats.
The NOR is a test of recognition learning and memory retrieval,
which takes advantage of the spontaneous preference of rodents to
investigate a novel object compared with a familiar one (Ennaceur
and Delacour, 1988). Studies indicated that the NOR procedure
involves several brain regions, including perirhinal cortex
(Ennaceur et al. 1996, 1997 and Aggleton et al. 1997) and the
hippocampus (Wood et al. 1993 and Clark et al. 2000). The NOR test
has been employed extensively to assess the potential
cognitive-enhancing properties of novel test compounds. Because the
NOR paradigm does not involve reward or noxious stimuli, it
provides less confounding variables when being translated into
analogous tests conducted in human clinical trials. In the present
study, a memory saving model was used to test the novel
compound--MK-801 (Dizocilpine), an uncompetitive antagonist of the
NMDA receptor was used to cause deficit of recognition memory.
Compounds of the invention were evaluated through its efficacy in
reversing memory impairment.
[0580] Material and Methods.
[0581] Animals. Adult male Long-Evans rats (275-299 gram at arrival
from Envigo, Indianapolis, Ind.) were used in this study. Rats were
placed in the experimental rooms and assigned unique identification
numbers (tail marks). Rats were housed 2 per cage in polycarbonate
cages with filter tops and acclimated for at least 7 days prior to
testing. Animal room was maintained in a 12/12 h light/dark cycle
(lights on at 07.00 EST), 22.+-.1.degree. C. and relative humidity
at approximately 50%. Food and water were provided ad libitum. All
animals were examined, handled and weighed prior to the study to
assure adequate health and to minimize the non-specific stress
associated with testing. Each animal was randomly assigned across
the treatment groups. The experiments were conducted during the
animal's light cycle phase.
[0582] Test compounds. The following compounds were used in this
study:
[0583] MK-801 (0.1 mg/kg; Sigma-Aldrich) was dissolved in saline
and injected IP 15 min prior to NOR training.
[0584] Galantamine (1 mg/kg; Tocris) was dissolved in saline and
injected IP 15 minutes prior to training.
[0585] Compound I-1 (0.01, 0.1, and 1 mg/kg) was oral administrated
60 minutes prior to training. The dose volume was 4 ml/kg
[0586] Experimental procedures. NOR test was conducted in an
open-field arena (40.times.40 cm) placed in a sound-attenuated room
under dimmed lighting. Each rat was tested separately and care was
taken to remove olfactory/taste cues by cleaning the arena and test
objects with 70% alcohol between trials and rats. All training and
testing trials were video-taped and scored by an observer blind to
treatments.
[0587] On Days 1 and 2, rats were allowed to freely explore the
arena (no objects inside) for a 5-minute habituation period. On Day
3 (training and testing day), rats were administered vehicle
(saline), galantamine or compound solutions followed by MK-801 or
vehicle (saline). After the pretreatment time, each animal was
placed into the test arena in the presence of two identical
objects. Each rat was placed in the arena facing the same direction
at the same position, and the time spent actively exploring the
objects during a 3-minute training period (T1) was recorded. The
rat was returned to its home cage following training. NOR test (T2)
was conducted 1 hours after T1. Each rat was placed back into the
test arena in the presence of one familiar object and one novel
object for 5 minutes, and the time spent exploring both objects was
recorded during 0-1, 0-3 and 0-5 min time ranges. The presentation
order and position of the objects (left/right) in T2 was randomized
between rats to prevent bias from order or place preference.
[0588] Statistical Analysis. Data of NOR test (T2) were expressed
as Recognition Index, which is defined as the ratio of the time
spent exploring the novel object over the total time spent
exploring both objects (Novel/(Familiar+Novel).times.100%) during
the test session. Data were analyzed by using one-way ANOVA
followed by Fisher's LSD post hoc test on 0-1, 0-3 and 0-5 minute
time range separately, with significance set at P<0.05. Animals
with overall object exploration time less than 10 seconds in the 5
min test session were eliminated; rats with recognition index above
90% or below 30% were also eliminated because they suggest strong
(non-memory) bias between two objects. And then statistical
outliers that fell above or below two standard deviations from the
mean were removed from the final analysis. With these criteria, 1-3
rats were eliminated from each experimental group (N=15-16) and
were excluded from statistical analyses for all time range (0-1,
0-3, and 0-5 minute).
[0589] Results. None of the rats in this study showed obvious side
effects at any dose. Rats maintained normal vigilance, activity and
exploration level to objects. ANOVA showed significant main
treatment effects on Recognition Index during 0-1 min time range
[F(8,121)=2.451, P<0.05]. Post hoc test showed that MK-801 0.1
mg/kg caused a strong memory deficit, with a Recognition Index
approaching chance level (50%). Galantamine (1 mg/kg) and Compound
I-1 at 1 mg/kg significantly reversed MK-801-induced memory
deficits (Ps<0.01 and Ps<0.05, respectively, compared to
Vehicle/MK-801 group). During 0-3 minute time range (Table 10),
ANOVA found a significant main treatment effect [F(8,121)=3.404,
P<0.01]. Post hoc test showed that MK-801 0.1 mg/kg caused a
strong memory deficit, with a Recognition Index approaching chance
level (50%). Galantamine (1 mg/kg) and Compound I-1 at 0.1 and 1
mg/kg significantly reversed MK-801-induced memory deficits
(Ps<0.001, Ps<0.01 and P<0.05, respectively, compared to
Vehicle/MK-801 group). Similarly, ANOVA showed a significant main
treatment effect during 0-5 minute time range [F(8,121)=3.179,
P<0.01]. Post hoc test showed that MK-801 at 0.1 mg/kg caused a
strong memory deficit, with a Recognition Index approaching chance
level (50%). Galantamine (1 mg/kg), and Compound I-1 at 1 mg/kg
significantly reversed MK-801-induced memory deficits (P<0.001,
P<0.01 and Ps<0.05, respectively, compared to Vehicle/MK-801
group).
TABLE-US-00017 TABLE 10 Summary of Recognition Index Measurements
(0 to 3 minute time bin) Standard Statistical Standard Error of
Analysis Treatment n-number Mean Deviation the Mean (p-value)
Vehicle + 13 72.4 6.8 1.9 <0.001 Saline Control Vehicle + 12
54.1 7.8 2.3 NA MK-801 Galantamine + 14 66.2 9.3 2.5 0.002 MK-801
I-1 13 60.1 10.0 2.8 0.133 (0.1 mg/kg) + MK-801 I-1 16 64.8 12.0
3.0 0.005 (1 mg/kg) + MK-801 I-1 15 66.8 9.5 2.5 0.001 (10 mg/kg) +
MK-801 Statistical comparisons are made to the "Vehicle + MK-801"
treatment group. Statistical significance is deemed when p value is
less than 0.005.
[0590] Summary Reference compound galantamine 1 mg/kg significantly
reversed the cognitive deficit induced by MK-801 0.1 mg/kg,
suggesting the validity of the test. Compound I-1 at 0.1 mg/kg and
1 mg/kg showed clear efficacy in saving the NOR memory after
treatment of MK-801, suggesting the compound possesses properties
of memory enhancement.
Example 11--Brain Activation in Rats as Measured by fMRI-BOLD
[0591] Objective. Functional magnetic resonance imaging or
functional MRI (fMRI) is a functional neuroimaging procedure using
MRI technology that measures brain activity by detecting changes
associated with blood flow. This technique relies on the fact that
cerebral blood flow and neuronal activation are coupled. When an
area of the brain is in use, blood flow to that region also
increases. Awake rats were studied by fMRI to assess changes
("fingerprint") in brain activity following a single intravenous
administration of a compound of the invention
[0592] Experimental Design. 24 male Sprague-Dawley rats weighing
from 275-350 g were used. Following acclimation, the animals were
placed in the restrainer and positioned in the magnet. Catheters
were placed in each animal to allow for remote dosing when the
animals were in the magnet. Scans were acquired continuously for 5
minutes prior to administration of either a vehicle or a compound
of the invention to establish a baseline for the brain activity.
Following the 5-minute baseline period, either the vehicle or the
compound of the invention was administered to the rat and scans
were acquired continuously for 30-45 minutes.
[0593] Study Design.
TABLE-US-00018 Group Dose No. N Treatment (mg/kg) ROA Imaging 1 10
Vehicle -- IV @ Images were 2 10 I-1 Defined EC.sub.50 acquired by
EC.sub.50 continuously starting 5 min prior to dosing and for 30 3
10 Non-CNS Defined minutes penetrant by post-dosing sGC target
compound BP response
[0594] Summary. As shown in FIG. 4, a greater region of the brain
is activated when the animal is administered a compound of the
invention (Compound I-1) (FIG. 4, right,) then when the animal is
dosed with a sGC stimulator that is peripherally restricted (i.e.,
a compound that does not enter the CNS) (FIG. 4, left).
Specifically, when dosed with a compound of the invention, brain
regions associated with memory (cortical transition areas,
thalamus, and ventral hippocampus), and arousal (the reticular
activating system) were activated.
Example 12--pCREB Phosphorylation in Rat Primary Neurons
[0595] Objective. To assess the ability of Compound I-1 to activate
cAMP response element-binding protein (CREB) in rat primary
neurons. CREB is a cellular transcription factor. It binds to DNA
sequences called cAMP response elements (CRE), and regulates
transcription of the downstream genes (See Bourtchuladze R, et al.,
Cell 1994; 79 (1): 59-68). CREB has a well-documented role in
neuronal plasticity and long-term memory formation in the brain and
has been shown to be integral in the formation of spatial memory
(See Silva A J, et al., Annual Review of Neuroscience 1998; 21:
127-148). CREB proteins are activated by phosphorylation of Serine
133 by various kinases, including cAMP-dependent protein kinase or
Protein Kinase A (PKA), cGMP-dependent protein kinase or Protein
Kinase G (PKG), and Ca2+/calmodulin-dependent protein kinases. (See
Shaywitz A J and Greenberg M E, Annual Review of Biochemistry 1999;
68 (1): 821-861 and Wong J C, et al., J Cell Biochem 2012:
113(11):3587-98). Stimulation of CREB could have therapeutic
benefits for diseases in which cognition, neuronal plasticity, and
or neuronal function is impaired.
[0596] Materials and Methods.
[0597] Compounds. Compound I-1 was dissolved in DMSO as a 10 mM
solution and stored at -20.degree. C. To achieve desired test
concentrations, stock concentrations were serially diluted into
DMSO and then diluted to the appropriate concentration in assay
buffer.
[0598] Rat primary neurons culture. Neurons were isolated from
Sprague Dawley rat embryos on embryonic day 18 (E18). Approximately
10 embryos were obtained from each rat, and whole brains were
isolated from the embryos. Hippocampus and cortex were dissected
from the brains under a stereoscopic microscope using two pairs of
fine tweezers. The meninges were carefully removed. After
dissection, the tissues were chopped and washed gently once with 10
mL of Ca.sup.2+ and Mg.sup.2+ free Hank's solution (HBSS, Corning
cat #21-022-CM) in a 15-mL conical tube. After washing, 5 mL of a
solution of 0.25% trypsin (Invitrogen cat #15090-046) and 0.1%
deoxyribonuclease I (DNase I, Sigma cat #DN-25) were added to the
tissues in the tube, which were then incubated at 37.degree. C. for
15 min. After incubation and digestion with the enzymes, tissues
were washed three times with ice-cold HBSS. After washing, 3 mL of
a solution of 0.1% of DNase I was added to the tube and the tissues
were slowly pipetted using a glass Pasteur pipette 12 times, and
then centrifuged at 500.times.g for 10 min. The cell pellet was
resuspended in the culture medium (Neurobasal medium, Gibco cat
#21103-049), 2% of B27 supplement (Gibco Cat #17504-044), 0.5 mM
L-glutamine (Corning cat #25-005-Cl), 25 .mu.M L-glutamic acid
(Sigma cat #G1251) and 1% penicillin/streptomycin (Gibco cat
#15070-063)). Subsequently, the cell suspension was plated into
poly-L-lysine coated 96-well plates at 100,000 cells/well.
Twenty-four h after plating, half of the culture medium was removed
and replaced with culture medium as described above but without
glutamic acid. Cells were maintained in a 37.degree. C. humidified
incubator with 5% CO.sub.2 and used between days 6-10.
[0599] Assay Conditions. For each test concentration, Compound I-1
was diluted in 100% DMSO to 100-fold of its final assay
concentration. Immediately prior to the assay, Compound I-1 was
diluted 10-fold into HBSS (containing calcium and magnesium)
(10.times. the final assay concentration) containing 100 .mu.M
DETA-NONOate (10.times. the final assay concentration). Medium was
removed and cells were washed once with 90 .mu.L HBSS (Corning cat
#21-023-CV). Cells were then incubated with 90 .mu.L HBSS for 30
min at 37.degree. C. 10 .mu.L from the test
article/HBSS/DETA-NONOate plate was added to the cells, which were
incubated for additional 30 min at 37.degree. C. Final DMSO
concentrations were 1%, final DETA-NONOate concentration was 10
.mu.M; and final Compound I-1 concentrations were 10,000 nM, 1000
nM, 100 nM, 10 nM, 1 nM, 0.1 nM, 0.01 nM, and 0.0 nM. Medium was
removed and cell were lysed and assay was performed according to
Cisbio protocol (phospho-CREB (Ser133) catalog #64CREPEG) and the
plate was read using Envision instrument (PerkinElmer).
[0600] Data Analysis. Data were analyzed with a 4-parameter fit
(log(agonist) vs. response-variable slope) using GraphPad Prism
Software v.7. The EC.sub.50 was interpolated from the curve fit and
is defined as the concentration at which Compound I-1 elicits 50%
of its maximal response.
[0601] Results. Phosphorylation of CREB at Ser133 stimulated by
Compound I-1 was concentration-dependent, with an EC.sub.50 of 3.0
nM. The 95% confidence interval ranged from 0.5 nM to 17.8 nM.
Example 13--Evaluation of Compounds of the Invention in Pain Models
and Tests
[0602] Objective. To evaluate the efficacy of compounds of the
invention in acute and tonic pain, inflammatory pain,
post-operative pain, and visceral pain.
[0603] Materials and Methods: Acute and Tonic Pain
[0604] Paw Pressure Test. Static mechanical hyperalgesia is
measured. This test requires the application of an increasing
pressure on the hind paws between a flat surface and a blunt
pointer. To evaluate the analgesic action of a compound, one hind
paw of the animal was inflamed by an injection or injured by
ligation, while the other hind paw was not injured or inflamed. The
apparatus exerted a steadily increasing force on the hind paws. The
reaction threshold was determined as the pressure (g) required to
elicit paw withdrawal and/or vocalization. The animals were gently
handled by the experimenter and static mechanical hyperalgesia were
assessed two times for both hind paws.
[0605] Tail Flick Test. A radiant heat was applied on the tail.
When the rat felt discomfort, it reacted by a sudden tail movement
(tail flick) which automatically stopped the stimulation and the
timer for the measurement by the animal reaction time or
nociceptive reaction latency (period from the beginning of the
stimulation until detection of the response of the animal). A
cut-off was previously fixed at 10 sec in order to prevent tissue
damage.
[0606] Acetic Acid Test. Abdominal contraction was induced by
intraperitoneal injection of 0.6% acetic acid solution in rats (10
mL/kg). The number of writhing (a twisting or contorting of the
body due to pain) was recorded from the 5.sup.th to the 15.sup.th
minute after injection.
[0607] Formalin Test. 2.5% formalin solution was injected by
subplantar route into the right hind paw. Scoring of pain behavior
was performed in rats for 36 minutes every 3 minutes according to
the following scores:
0=normal behavior of the injected hind limb to support the body
1=slight touching of the injected paw on the floor to lightly
support or not support the body 2=total withdrawal of the injected
paw 3=licking, biting or shaking of the injected paw
[0608] Materials and Methods: Inflammatory Pain
[0609] Carrageenan. Induction: Three hours before assessment of the
nociceptive threshold using the paw pressure test 100 .mu.L of a 2%
carrageenan suspension was injected into the plantar aspect of the
right hind paw. The Paw Pressure test was then conducted as
described above.
[0610] Kaolin. Induction: In rats, unilateral arthritis was induced
by an intra-articular injection of a 10% kaolin suspension into the
knee joint of the right hind paw under gas anesthesia (3.5%
isoflurane/3 L/min). Gait score: The gait score will be evaluated 3
h 30 min after kaolin administration by:
0: normal gait 1: mid disability 2: intermittent raising of the paw
3: elevated paw
[0611] Materials and Methods. Post-Operative Pain: Brennan
Model.
[0612] Surgery: Surgery was done under gas anesthesia (2.5%
isoflurane/3 L/min). For all rats, the plantar aspect of the left
hind paw was exposed and a 1 cm longitudinal incision was made
using a surgical blade, through the skin and fascia of the plantar
aspect of the foot, starting 0.5 cm from the proximal edge of the
heel and extending toward the toes. The plantaris muscle was
elevated and incised longitudinally whereas the insertions remained
intact. After hemostasis with gentle pressure, the skin was
stitched up with two sutures. After surgery, animals recovered in
their cages.
[0613] Electronic Von Frey Test: Tactile allodynia was assessed
using the electronic Von Frey test 24 h after surgery. The test
requires the application of an increasing pressure onto the plantar
aspect of the hind paws. The apparatus exerted a steady force on
the hind paws. Reaction thresholds were determined as the pressure
(g) required to elicit paw withdrawal. Each reaction threshold
measurement was repeated three times for both hind paws with
intervals of approximately 2 to 3 mins.
[0614] The results for acute and tonic pain, inflammatory pain, and
post-operative pain models and test for animals treated with 10
mg/kg of Compound I-1 PO were significant and are presented
below.
[0615] Results.
TABLE-US-00019 Compound I-1, p.o., Pain Model Model-test 10 mg/kg
Internal Reference % of Reference ID % of activity vs. activity vs.
vehicle vehicle Acute and Healthy rats-paw -6% Morphine 69% Tonic
Pain pressure test 4 mg/kg s.c. Healthy rats-tail 25% Morphine 66%
flick test 4 mg/kg s.c. Acetic acid test- 7% (-) U50, 488 H 100%
Abdominal 3 mg/kg s.c. cramps Formalin test- 57% Morphine 57% Score
(early 4 mg/kg s.c. phase) Formalin test- 32% Morphine 38% Score 4
mg/kg s.c. (late phase) Inflammatory Carrageenan- 38% Indomethacin
100% Pain paw pressure 30 mg/kg p.o. test Kaolin- 40% Indomethacin
58% gait score 30 mg/kg p.o. Post- Brennan model- 31% Morphine 88%
operative Electronic Von 4 mg/kg s.c. Pain Frey test
Testing: 120 minutes after treatment. N=4/model/test. Results are
expressed for each group as a percentage of activity calculated
from the mean value of the vehicle-treated animals and compared to
naive animals, control paw, or cut-off value, depending on the
test.
[0616] Conclusions. Compound I-1 demonstrated effects in the
formalin test for acute pain. Compound I-1 demonstrated effects in
the carrageenan and kaolin models of inflammatory pain. Compound
I-1 demonstrated effects in the test for post-operative pain.
Example 14. Antihyperalgesic Effects of Single and Repeated
Administrations of Compound I-- in a Rat Model of Diabetic
Neuropathy (STZ Model)
[0617] Objective. To assess the antihyperalgesic effects of single
and repeated administrations of a compound of the invention in a
model of diabetic neuropathy (streptozotocin model) using the paw
pressure test in rats. Gabapentin will be used as internal
comparator. Morphine HCl will be used as a reference substance to
validate the assay.
[0618] In humans, one of the leading causes of neuropathic pain is
diabetic neuropathy. Several diabetic animal models are available
but the most commonly used for the study of pain is the
streptozotocin model. In this experimental model, neuropathy is
reproduced in rats using a single intraperitoneal injection of
streptozotocin which induces diabetes and consequently hyperalgesia
and allodynia (See Rakieten N et al., Cancer Chemother, 1963
(Rep.29):91). Seven days later (D7), diabetic animals present a
significant increase in glycemia associated with weight loss,
polydipsia and polyuria. Animals develop a mechanical hyperalgesia
which can be measured after Day 18 using a mechanical nociceptive
stimulation (paw pressure test) (See Randall L O and Selitto J J,
Arch Int Pharmacodyn, 1957(111):409-419).
[0619] Materials
[0620] Animals. Seventy (70) male Sprague-Dawley rats (SPF status,
Janvier, France), weighing 210-300 g the day of diabetes induction
were used. Rats were housed in a temperature (20-24.degree. C.) and
relative humidity (45%-65%) controlled room and acclimated to an
artificial day/night cycle of 12 hours light (6.30 a.m. to 6.30
p.m.)/12 hours darkness. Rats had free access to tap water and were
fed ad libitum with pelleted complete diet (reference A04,
S.A.F.E.). Animals were housed 3 per cage (cages Type E) and were
acclimated for a period of at least 5 days before any testing. Each
rat was identified by tail markings. Based on the SPF status of the
animal facilities, there was no reason to expect that contaminants
were present in the food, water or bedding, at levels capable of
interfering with the results of the tests.
[0621] Reagents. Streptozotocin (STZ, Sigma-Aldrich) was
extemporaneously prepared as a solution in Citrate (Citric acid
trisodium salt, Sigma-Aldrich) buffer 1 mM pH 4-4.5 (in water for
injection). 0.9% NaCl was used as vehicle for Gabapentin (Zhejiang
Excel pharma Co. Ltd.), Morphine HCl (Francopia) and Compound I-1.
Insulin (Sanofi-Aventis) was prepared at 10 UI/ml in 0.9% NaCl
[0622] Equipment. Accu-Chek.COPYRGT. (Roche Diagnostics S.A.,
France) and Accu-Chek.RTM. tests strips (Roche Diagnostics S.A.,
France) was used to measure the glycemia. Ugo Basile Analgesimeter
(Ugo Basile, Italy) will be used for the paw pressure test.
[0623] Data Processing. SigmaStat software version 3.5 (SPSS
Science Software, Erkrath, Germany) Lab X direct software version
2.4 (Mettler Toledo, France)
[0624] Methods.
[0625] Pain Test. Static mechanical hyperalgesia was assessed using
the Paw Pressure test or Randall & Selitto test (See Randall L
O and Selitto J J, Arch Int Pharmacodyn, 1957(111):409-419, the
teaching of which are incorporated herein by reference). This test
requires the application of an increasing pressure on the hind paws
between a flat surface and a blunt pointer. This test is usually
used with animals with one hind paw inflamed by an injection or
injured by ligation, and one normal hindpaw, to evaluate compounds
for analgesic action. The apparatus exerts a steadily increasing
force and reaction threshold is determined as the pressure (g)
required to elicit paw withdrawal and/or vocalization. In the
experiment, animals were gently handled by the experimenter and
static mechanical hyperalgesia will be assessed. Each reaction
threshold was measured for both hind paws.
[0626] Experimental Design. Seven experimental groups of 10 rats
each will be used:
Group 1: Sham animals (Citrate buffer)/Vehicle, p.o., solution,
daily from Day 18 to Day 21 (D18 to D21) Group 2: STZ (75 mg/kg,
i.p.)/Vehicle, p.o., solution, daily from D18 to D21 Group 3: STZ
(75 mg/kg, i.p.)/Compound I-1 (1 mg/kg, p.o.), solution, daily from
D18 to D21 Group 4: STZ (75 mg/kg, i.p.)/Compound I-1 (3 mg/kg,
p.o.), solution, daily from D18 to D21 Group 5: STZ (75 mg/kg,
i.p.)/Compound I-1 (10 mg/kg, p.o.), solution, daily from D18 to
D21 Group 6: STZ (75 mg/kg, i.p.)/Gabapentin (100 mg/kg, p.o.) in
0.9% NaCl, solution, acute on testing days (D18 and D21) Group 7:
STZ (75 mg/kg, i.p.)/Morphine (4 mg/kg, s.c.) in 0.9% NaCl,
solution, acute on testing days (D18 and D21) Vehicle, Compound I-1
were orally administered at 5 ml/kg. Gabapentin was orally
administered at 10 ml/kg. Morphine HCl was subcutaneously
administered (5 ml/kg). Doses are expressed in terms of free active
substance. Dosing and testing were performed in a random order by a
blinded experimenter except for the Sham and the Morphine-treated
groups.
[0627] Procedure.
[0628] Induction. Chronic peripheral neuropathy was induced by a
single intraperitoneal injection of Streptozotocin (75 mg/kg, i.p.)
on D0. Six experimental groups were treated with streptozotocin and
one will be treated with Citrate buffer 1 mM (vehicle of
streptozotocin) after Glycemia measurement. On D7, glycemia was
measured and rats having level >250 mg/dl were treated
subcutaneously with Insulin (Lantus.RTM., 2 IU/rat), three times a
week with injections every two days from D7-8 to D14, on D18 at the
end of the day and on D20 to prevent excessive cachexia. On D7,
animals with a glycemia <250 mg/dl were treated again with
Streptozotocin (75 mg/kg, i.p.). Glycemia was measured on D14 and
rats having level >250 mg/dl were treated subcutaneously with
Insulin (Lantus.RTM., 2 IU/rat), three times a week with injections
every two days from D14 to D19.
[0629] Behavioral Testing. STZ animals are selected (baseline) on
D18 and tested (animal dosing and behavioral test) on D18 and D21.
The time course was as follows:
[0630] On Day 0 (D0), glycemia was measured before diabetes
induction by injection of streptozotocin (75 mg/kg, i.p.) to select
animals meeting the inclusion criteria (glycemia <150
mg/dl).
[0631] On D7 and on D18, glycemia was measured in to select animals
with a glycemia higher than 250 mg/dl (except for the Group #1 sham
animals).
[0632] On D18, nociceptive reaction thresholds (vocalization or paw
withdrawal) was measured in all groups in order to select diabetic
animals meeting the inclusion criteria: 20 g<paw withdrawal
threshold <240 g. Sham animals with a paw withdrawal threshold
included between 280 g and 520 g for both hind paws were selected.
Animals having a body weight <200 g or >400 g were excluded
from the study.
[0633] On D18 vehicle, Compound I-1, gabapentin and morphine will
be given (T0). The antihyperalgesic effect of the vehicle, Compound
I-1, gabapentin and morphine were evaluated on both hind paws using
the Paw pressure test 60, 120, 180, and 240 min post drug
administration. Morphine-treated animals were also tested 30 min
after administration, but these data were not used as morphine
showed significant antihyperalgesic effects 60 min after
treatment.
[0634] Rats from groups 1 to 5 received a daily treatment on D19,
D20 and D21.
[0635] On D21, glycemia and nociceptive thresholds were measured
before the daily treatment in all groups. Vehicle, Compound I-1
gabapentin and morphine were given (T0). The antihyperalgesic
effect of the morphine was evaluated 30 min post administration
using the Paw pressure test and 120 min post vehicle, Compound I-1,
gabapentin and morphine administration.
[0636] Data Presentation and Statistical analysis. Results are
expressed as:
[0637] The paw withdrawal threshold (mean.+-.s.e.m.) in grams of
contact pressure for each group, calculated from individual paw
withdrawal thresholds. The percentage of variation of the paw
withdrawal threshold calculated from the mean value of the
vehicle-treated group.
[0638] To determine a statistical effect of the test substance(s)
and the reference substance, data was analyzed by a parametrical or
non-parametrical test depending on the normal distribution of the
results. The significance level is indicted below.
[0639] Results.
[0640] On D18, at 0 minutes all the groups treated with STZ had
hyperalgesia with nociceptive threshold around 200 g as compared to
normal rats with nociceptive threshold approximately 350 g. At 60
min following administration of the substance (i.e., vehicle,
Compound I-1 at 1, 3, or 10 mg/kg, gabapentin, or morphine), the
nociceptive threshold for gabapentin (272.+-.6.6, p<0.01),
morphine (420.+-.35 p<0.001) and Compound I-1 at 10 mg/kg
(328.+-.32.6 p<0.001) were statistically different demonstrating
efficacy as compared to the vehicle-only treated group. Similarly,
at 120 min, the nociceptive threshold for gabapentin (302.+-.17.7,
p<0.001), morphine (317.+-.27.6 p<0.001) and Compound I-1 at
10 mg/kg (387.+-.30.2 p<0.001) were statistically different and
efficacious as compared to the vehicle-only treated group. By 180
min, only the nociceptive threshold for Compound I-1 at 10 mg/kg
(319.+-.23.1 p<0.001) was efficacious and statistically
different as compared to the vehicle-only treated group. By 240
minutes post-administration, no group was statistically significant
from the vehicle. On D21, at baseline prior to the administration
of the substance, only the nociceptive threshold for Compound I-1
at 10 mg/kg (259.+-.25.6 p<0.01) was statistically different as
compared to the vehicle-only treated group indicating
anti-hyperalgesic efficacy was still present at Cmin. By 120 min,
after dosing at D21, the nociceptive threshold for gabapentin
(274.+-.19.2, p<0.01), morphine (283.+-.16.7 p<0.001) and
Compound I-1 at 10 mg/kg (346.+-.20.5 p<0.001) were
statistically different and efficacious as compared to the
vehicle-only treated group.
[0641] Conclusion. Compound I-1 demonstrated an anti-hyperalgesic
response when tested at 10 mg/kg in the STZ model of diabetic
neuropathy. The effect in pain was observed acutely for up to 3
hours at levels at least comparable to morphine or gabapentin.
After 3-days of dosing compound I-1 demonstrated efficacy in pain
when tested at Cmin indicating a long-term effect. Also, when
tested after 4-days of dosing, compound I-1 maintained its efficacy
in the STZ model of neuropathic pain.
[0642] Various embodiments of the invention can be described in the
text below. As explained supra, it is to be understood that
pharmaceutically acceptable salts are included in these
embodiments, even though the phrase "pharmaceutically acceptable
salt" is not written.
[1]. A compound of Formula I. [2]. A compound of [1] above, or
according to other embodiments of the invention, wherein W is a
ring B and the compound is one of Formula IIB. [3]. A compound of
[1] or [2] above, or according to other embodiments of the
invention, wherein n is an integer selected from 1 or 2 and each
J.sup.B is independently selected from halogen, a C.sub.1-4 alkyl,
--OR.sup.B or --OR.sup.B1. [4]. A compound of [1], [2] or [3]
above, or according to other embodiments of the invention, wherein
n is 1. [5]. A compound of [1], [2] or [3] above, or according to
other embodiments of the invention, wherein n is 2. [6]. A compound
of [1], [2], [3], [4] or [5] above, or according to other
embodiments of the invention, wherein each J.sup.B is independently
selected from halogen atoms. [7]. A compound of [1], [2], [3], [4],
[5] or [6] above, or according to other embodiments of the
invention, wherein each J.sup.B is independently selected from
fluoro or chloro. [8]. A compound of [1], [2], [3], [4], [5], [6]
or [7] above, or according to other embodiments of the invention,
wherein each J.sup.B is fluoro. [9]. A compound of [1], [2], [3],
[4] or [5] above, or according to other embodiments of the
invention, wherein each J.sup.B is a C.sub.1-4 alkyl. [10]. A
compound of [1], [2], [3], [4], [5] or [9] above, or according to
other embodiments of the invention, wherein each J.sup.B is
selected from ethyl or methyl. [11]. A compound of [1], [2], [3],
[4], [5], [9] or [10] above, or according to other embodiments of
the invention, wherein each J.sup.B is methyl. [12]. A compound of
[1], [2], [3], [5], [6] or [7] above, or according to other
embodiments of the invention, wherein one J.sup.B is fluoro and the
other J.sup.B is chloro. [13]. A compound of [1] or [2] above, or
according to other embodiments of the invention, wherein n is 0.
[14]. A compound of any one of [1] to [13] above, or according to
other embodiments of the invention, wherein ring B is phenyl. [15].
A compound of [1] to [3], [6] to [12], or [14] above, or according
to other embodiments of the invention, wherein n is 1 or 2. [16]. A
compound of [1] to [12], [14] or [15] above, or according to other
embodiments of the invention, wherein a J.sup.B is ortho to the
attachment of the methylene linker between ring B and the core of
the molecule, and the J.sup.B is halogen. [17]. A compound of [1]
to [13], [15] or [16] above, or according to other embodiments of
the invention, wherein ring B is a 6-membered heteroaryl ring.
[18]. A compound of [1] to [13], or [15] to [17] above, or
according to other embodiments of the invention, wherein ring B is
a pyridyl ring. [19]. A compound of [1] to [13], or [15] to [17]
above, or according to other embodiments of the invention, wherein
ring B is a pyrimidinyl ring. [20]. A compound of [1] above, or
according to other embodiments of the invention, wherein W is
absent and the compound is one of Formula IIA. [21]. A compound of
[1] or [20] above, or according to other embodiments of the
invention, wherein J.sup.B is a C.sub.1-4 alkyl chain, optionally
substituted by up to 5 instances of fluorine. [22]. A compound of
[1], [20] or [21] above, or according to other embodiments of the
invention, wherein J.sup.B is a C.sub.1-2 alkyl chain, optionally
substituted by up to 5 instances of fluorine. [23]. A compound of
[1], [20], [21] or [22] above, or according to other embodiments of
the invention, wherein J.sup.B is an ethyl chain, optionally
substituted by 3 instances of fluorine. [24]. A compound of [1],
[20], [21] or [22] above, or according to other embodiments of the
invention, wherein J.sup.B is an ethyl chain, optionally
substituted by 5 instances of fluorine. [25]. A compound of any one
of [1] to [24] above, or according to other embodiments of the
invention, wherein G, Z and Q are each N. [26]. A compound of [1]
to [19], or [25] above, or according to other embodiments of the
invention, wherein the compound is one of Formula III, or any of
its tautomers thereof. [27]. A compound of any one of [1] to [26]
above, or according to other embodiments of the invention, wherein
R.sup.11 is H, NR.sup.a2R.sup.b2, --C(O)NR.sup.a2R.sup.b2,
--C(O)R.sup.15a, --SO.sub.2R.sup.b2, --SR.sup.b2, halo,
--OCF.sub.3, --CN, hydroxyl, C.sub.2-6 alkenyl optionally and
independently substituted with 0-2 occurrences of R.sup.b2,
C.sub.2-6 alkynyl optionally and independently substituted with 0-2
occurrences of R.sup.b2, C.sub.1-6 alkyl optionally and
independently substituted with 0-5 occurrences of R.sup.15,
C.sub.1-6 alkoxy optionally and independently substituted with 0-3
occurrences of R.sup.15, phenyl optionally and independently
substituted with 0-3 occurrences of R.sup.15, 5- or 6-membered
heteroaryl optionally and independently substituted with 0-3
occurrences of R.sup.15, C.sub.3-8 cycloalkyl optionally and
independently substituted with 0-3 occurrences of R.sup.15 or 3-8
membered heterocyclyl optionally and independently substituted with
0-3 occurrences of R.sup.15. [28]. A compound of any one of [1] to
[27] above, or according to other embodiments of the invention,
wherein R.sup.11 is H or C.sub.1-6 alkyl optionally and
independently substituted with 0-5 occurrences of R.sup.15. [29]. A
compound of any one of [1] to [28] above, or according to other
embodiments of the invention, wherein R.sup.11 is C.sub.1-6 alkyl
optionally and independently substituted with 0-5 occurrences of
R.sup.15. [30]. A compound of any one of [1] to [29] above, or
according to other embodiments of the invention, wherein R.sup.11
is methyl optionally and independently substituted with 0-3
occurrences of R.sup.15. [31]. A compound of any one of [1] to [30]
above, or according to other embodiments of the invention, wherein
R.sup.15 is halo in each instance. [32]. A compound of any one of
[1] to [31] above, or according to other embodiments of the
invention, wherein R.sup.15 is fluoro in each instance. [33]. A
compound of any one of [1] to [30] above, or according to other
embodiments of the invention, wherein R.sup.11 is unsubstituted
methyl. [34]. A compound of any one of [1] to [32] above, or
according to other embodiments of the invention, wherein R.sup.11
is methyl substituted with 2 occurrences of R.sup.15. [35]. A
compound of any one of [1] to [32], or [34] above, or according to
other embodiments of the invention, wherein R.sup.11 is
--CF.sub.2H. [36]. A compound of any one of [1] to [32] above, or
according to other embodiments of the invention, wherein R.sup.11
is methyl independently substituted with 3 occurrences of R.sup.15.
[37]. A compound of any one of [1] to [32], or [36] above, or
according to other embodiments of the invention, wherein R.sup.11
is --CF.sub.3. [38]. A compound of any one of [1] to [29] above, or
according to other embodiments of the invention, wherein R.sup.11
is ethyl optionally and independently substituted with 0-5
occurrences of R.sup.15. [39]. A compound of any one of [1] to [38]
above, or according to other embodiments of the invention, wherein
q is 0. [40]. A compound of any one of [1] to [39] above, or
according to other embodiments of the invention, wherein the core
formed by rings E and A is selected from:
##STR00156## ##STR00157##
wherein the C atom with a symbol * represents the attachment point
to the ring containing G, Z, and Q; and the C atom with a symbol **
represents the point of attachment of the 2 instances of J. [41]. A
compound of any one of [1] to [40] above, or according to other
embodiments of the invention, wherein the core formed by rings E
and A is selected from:
##STR00158##
[42]. A compound of any one of [1] to [41] above, or according to
other embodiments of the invention, wherein each instance of
J.sup.C is hydrogen. [43]. A compound of any one of [1] to [42]
above, or according to other embodiments of the invention, wherein
the compound is selected from those listed in Table I. [44]. A
pharmaceutical composition comprising at least one pharmaceutically
acceptable excipient or carrier and a compound of any one of [1] to
[42] above, or according to other embodiments of the invention.
[45]. A method for treating a disease, health condition or disorder
selected from a CNS disease, health condition or disorder, the
method comprising administering to a subject in need of treatment a
therapeutically effective amount of a compound of any of [1] to
[43] above, or a pharmaceutical composition of [44] above, or
according to other embodiments of the invention, wherein the
disease, health condition or disorder is selected from:
[0643] Alzheimer's disease, amyotrophic lateral sclerosis (ALS or
Lou Gehrig's disease), Down syndrome, dementia, vascular dementia,
mixed dementia, vascular cognitive impairment, Binswanger's
dementia (subcortical arteriosclerotic encephalopathy), Cerebral
Autosomal-Dominant Arteriopathy with Subcortical Infarcts and
Leukoencephalopathy (CADASIL or CADASIL syndrome), frontotemporal
lobar degeneration or dementia, HIV-associated dementia (including
asymptomatic neurocognitive impairment (ANI), minor neurocognitive
disorder (MND), and HIV-associated dementia (HAD) (also called AIDS
dementia complex [ADC] or HIV encephalopathy), Lewy body dementia,
pre-senile dementia (mild cognitive impairment, MCI), glaucoma,
Huntington's diseases (or chorea, HD), or a cognitive defect
associated with HD; multiple sclerosis (MS), multiple system
atrophy (MSA), Parkinson's disease, Parkinsonism Plus,
spinocerebellar ataxias, Steel-Richardson-Olszewski disease
(progressive supranuclear palsy), attention deficit disorder (ADD)
and attention deficit hyperactivity disorder (ADHD);
[0644] neuropathic pain;
[0645] a psychiatric, mental, mood or affective disorder selected
from a bipolar disorder, schizophrenia, general psychosis,
drug-induced psychosis, a delusional disorder, schizoaffective
disorder, obsessive compulsive disorder (OCD), a depressive
disorder, an anxiety disorder, a panic disorder, or post-traumatic
stress disorder (PTSD);
[0646] traumatic (closed or open, penetrating head injuries,
including concussion and CTE) or non-traumatic (stroke (in
particular, ischemic stroke), aneurism, hypoxia) injury to the
brain or cognitive impairment or dysfunction resulting from brain
injuries or neurodegenerative disorders;
[0647] dystonias, including generalized, focal, segmental, sexual,
intermediate, acute dystonic reaction, and genetic/primary
dystonia; and dyskinesias, including acute, chronic/tardive, and
non-motor and levo-dopa induced dyskinesia (LID);
[0648] disorders characterized by a relative reduction in synaptic
plasticity and synaptic processes including, Fragile X, Rhett's
disorder, Williams syndrome, Renpenning's syndrome, autism spectrum
disorders, including autism, Asperger's syndrome, pervasive
development disorder and childhood disintegrative disorder;
[0649] chemo brain, levo-dopa induced addictive behavior,
alcoholism, narcotic dependence (including to amphetamine, opiates
or other substances) and substance abuse.
[46]. A method according to [45] above, or according to other
embodiments of the invention, wherein the disease, health condition
or disorder is selected from Alzheimer's disease, amyotrophic
lateral sclerosis (ALS or Lou Gehrig's disease), Down syndrome,
dementia, vascular dementia, mixed dementia, vascular cognitive
impairment, Binswanger's dementia (subcortical arteriosclerotic
encephalopathy), Cerebral Autosomal-Dominant Arteriopathy with
Subcortical Infarcts and Leukoencephalopathy (CADASIL or CADASIL
syndrome), frontotemporal lobar degeneration or dementia,
HIV-associated dementia (including asymptomatic neurocognitive
impairment (ANI), minor neurocognitive disorder (MND), and
HIV-associated dementia (HAD) (also called AIDS dementia complex
[ADC] or HIV encephalopathy), Lewy body dementia, pre-senile
dementia (mild cognitive impairment, MCI), glaucoma, Huntington's
diseases (or chorea, HD), or a cognitive defect associated with HD;
multiple sclerosis (MS), multiple system atrophy (MSA), Parkinson's
disease, Parkinsonism Plus, spinocerebellar ataxias,
Steel-Richardson-Olszewski disease (progressive supranuclear
palsy), attention deficit disorder (ADD) or attention deficit
hyperactivity disorder (ADHD). [47]. A method according to [45]
above, or according to other embodiments of the invention, wherein
the disease, health condition or disorder is neuropathic pain.
[48]. A method according to [45] above, or according to other
embodiments of the invention, wherein the disease, health condition
or disorder is selected from a psychiatric, mental, mood or
affective disorder selected from a bipolar disorder, schizophrenia,
general psychosis, drug-induced psychosis, a delusional disorder,
schizoaffective disorder, obsessive compulsive disorder (OCD), a
depressive disorder, an anxiety disorder, a panic disorder, or
post-traumatic stress disorder (PTSD). [49]. A method according to
[45] above, or according to other embodiments of the invention,
wherein the disease, health condition or disorder is selected from
traumatic or non-traumatic injury to the brain or cognitive
impairment or dysfunction resulting from brain injuries or
neurodegenerative disorders. [50]. A method according to [45]
above, or according to other embodiments of the invention, wherein
the disease, health condition or disorder is selected from
Alzheimer's disease or pre-Alzheimer's disease, mild to moderate
Alzheimer's disease or moderate to severe Alzheimer's disease.
[51]. A method according to [45] above, or according to other
embodiments of the invention, wherein the disease, health condition
or disorder is selected from a dystonia or a dyskinesia. [52]. A
method according to [45] above, or according to other embodiments
of the invention, wherein the disease, health condition or disorder
is selected from a disorder characterized by a relative reduction
in synaptic plasticity and synaptic processes, including Fragile X,
Rhett's disorder, Williams syndrome, Renpenning's syndrome, autism
spectrum disorders, including autism, Asperger's syndrome,
pervasive development disorder and childhood disintegrative
disorder. [53]. A method according to [45] above, or according to
other embodiments of the invention, wherein the disease, health
condition or disorder is selected from chemo brain, levo-dopa
induced addictive behavior, alcoholism, narcotic dependence
(including to amphetamine, opiates or other substances) and
substance abuse. [54]. A method for treating a disease, health
condition or disorder the method comprising administering to a
subject in need of treatment a therapeutically effective amount of
a compound of any of [1] to [43] above, or a pharmaceutical
composition of [44] above, or according to other embodiments of the
invention, wherein the disease, health condition or disorder is
selected from:
[0650] disorders related to high blood pressure and decreased
coronary blood flow, increased acute and chronic coronary blood
pressure, arterial hypertension, vascular disorder resulting from
cardiac and renal complications, heart disease, stroke, cerebral
ischemia, renal failure, resistant hypertension, diabetic
hypertension, congestive heart failure, diastolic or systolic
dysfunction, coronary insufficiency, arrhythmia, reduction of
ventricular preload, cardiac hypertrophy, heart failure/cardiorenal
syndrome, portal hypertension, endothelial dysfunction or
injury;
[0651] thromboembolic disorder, ischemia, myocardial infarction,
stroke, transient ischemic attack (TIA), obstructive
thromboanginitis, stable or unstable angina pectoris, coronary
spasms, variant angina, Prinzmetal's angina, prevention of
restenosis after thrombolysis therapies, thrombogenic
disorders;
[0652] a CNS disease, health condition or disorder selected from
Alzheimer's disease, amyotrophic lateral sclerosis, Down syndrome,
dementia, vascular dementia, mixed dementia, vascular cognitive
impairment, Binswanger's dementia, Cerebral Autosomal-Dominant
Arteriopathy with Subcortical Infarcts and Leukoencephalopathy,
frontotemporal lobar degeneration or dementia, HIV-associated
dementia (including asymptomatic neurocognitive impairment (ANI),
minor neurocognitive disorder (MND), and HIV-associated dementia
(HAD) (also called AIDS dementia complex [ADC] or HIV
encephalopathy), Lewy body dementia, pre-senile dementia, glaucoma,
Huntington's diseases, or a cognitive defect associated with HD;
multiple sclerosis, multiple system atrophy, Parkinson's disease,
Parkinsonism Plus, spinocerebellar ataxies,
Steel-Richardson-Olszewski disease, attention deficit disorder and
attention deficit hyperactivity disorder, Alzheimer's disease or
pre-Alzheimer's disease, mild to moderate Alzheimer's disease or
moderate to severe Alzheimer's disease, traumatic (closed or open,
penetrating head injuries) brain injury (TBI), nontraumatic
(stroke, aneurism, hypoxia) injury to the brain, cognitive
impairment or dysfunction resulting from brain injuries or
neurodegenerative disorder, dystonia, dyskinesia, a disorder
characterized by a relative reduction in synaptic plasticity and
synaptic processes, Fragile X, Rhett's disorder, Williams syndrome,
Renpenning's syndrome, autism spectrum disorders, including autism,
Asperger's syndrome, pervasive development disorder, childhood
disintegrative disorder, neuropathic pain, bipolar disorder,
schizophrenia, general psychosis, drug-induced psychosis, a
delusional disorder, schizoaffective disorder, obsessive compulsive
disorder, a depressive disorder, an anxiety disorder, a panic
disorder, post-traumatic stress disorder, chemo brain, levo-dopa
induced addictive behavior, alcoholism, narcotic dependence or
substance abuse;
[0653] peripheral arterial disease, peripheral occlusive arterial
disease, peripheral vascular disease, hypertonia, Raynaud's
syndrome or phenomenon, critical limb ischemia, vasculitis,
peripheral embolism, intermittent claudication, vaso-occlusive
crisis, Duchenne muscular dystrophy, Becker muscular dystrophy,
microcirculation abnormalities, control of vascular leakage or
permeability;
[0654] shock, sepsis, cardiogenic shock, control of leukocyte
activation, inhibition or modulation of platelet aggregation;
[0655] pulmonary hypertension, pulmonary arterial hypertension,
associated pulmonary vascular remodeling, localized thrombosis,
right heart hypertrophy, pulmonary hypertonia, primary pulmonary
hypertension, secondary pulmonary hypertension, familial pulmonary
hypertension, sporadic pulmonary hypertension, pre-capillary
pulmonary hypertension, idiopathic pulmonary hypertension,
thrombotic pulmonary arteriopathy, plexogenic pulmonary
arteriopathy, cystic fibrosis, bronchoconstriction or pulmonary
bronchoconstriction, acute respiratory distress syndrome, lung
fibrosis, lung transplant;
[0656] pulmonary hypertension associated with or related to: left
ventricular dysfunction, hypoxemia, WHO groups I, II, III, IV and V
hypertensions, mitral valve disease, constrictive pericarditis,
aortic stenosis, cardiomyopathy, mediastinal fibrosis, pulmonary
fibrosis, anomalous pulmonary venous drainage, pulmonary
venooclusive disease, pulmonary vasculitis, collagen vascular
disease, congenital heart disease, pulmonary venous hypertension,
interstitial lung disease, sleep-disordered breathing, sleep apnea,
alveolar hypoventilation disorders, chronic exposure to high
altitude, neonatal lung disease, alveolar-capillary dysplasia,
sickle cell disease, other coagulation disorders, chronic
thromboembolism, pulmonary embolism (due to tumor, parasites or
foreign material), connective tissue disease, lupus,
schistosomiasis, sarcoidosis, chronic obstructive pulmonary
disease, asthma, emphysema, chronic bronchitis, pulmonary capillary
hemangiomatosis, histiocytosis X, lymphangiomatosis and compressed
pulmonary vessels (such as due to adenopathy, tumor or fibrosing
mediastinitis);
[0657] atherosclerosis (e.g., associated with endothelial injury,
platelet and monocyte adhesion and aggregation, smooth muscle
proliferation and migration), restenosis (e.g., developed after
thrombolysis therapies, percutaneous transluminal angioplasties
(PTAs), percutaneous transluminal coronary angioplasties (PTCAs)
and bypass), inflammation;
[0658] cardiovascular disease associated with metabolic syndrome
(e.g., obesity, dyslipidemia, diabetes, high blood pressure),
dyslipidemia, hypercholesterolemia, hypertriglyceridemia,
sitosterolemia, fatty liver disease, hepatitis, preeclampsia,
polycystic kidney disease progression, subcutaneous fat,
obesity;
[0659] liver cirrhosis associated with chronic liver disease,
hepatic fibrosis, hepatic stellate cell activation, hepatic fibrous
collagen and total collagen accumulation; liver disease of
necro-inflammatory and/or of immunological origin; renal fibrosis
and renal failure resulting from chronic kidney diseases or
insufficiency (e.g. due to accumulation/deposition and tissue
injury, progressive sclerosis, glomerulonephritis); prostate
hypertrophy systemic sclerosis; cardiac interstitial fibrosis;
cardiac remodeling and fibrosis; cardiac hypertrophy; non-alcoholic
steatohepatitis or NASH;
[0660] ischemia, reperfusion damage; ischemia/reperfusion
associated with organ transplant, lung transplant, pulmonary
transplant, cardiac transplant; conserving blood substituents in
trauma patients;
[0661] erectile dysfunction; impotence; premature ejaculation;
female sexual dysfunction, vaginal atrophy, dyspaneuria, atrophic
vaginitis; benign prostatic hyperplasia (BPH) or hypertrophy or
enlargement; bladder outlet obstruction; bladder pain syndrome
(BPS), interstitial cystitis (IC), overactive bladder, neurogenic
bladder and incontinence; diabetic nephropathy;
[0662] glaucoma, retinopathy, diabetic retinopathy (including
proliferative and non-proliferative), blepharitis, dry eye
syndrome, Sjogren's Syndrome;
[0663] hearing impairment, partial or total hearing loss; partial
or total deafness; tinnitus; noise-induced hearing loss;
[0664] dermal fibrosis, scleroderma, skin fibrosis;
[0665] microvascular perfusion improvement (e.g., following injury,
to counteract the inflammatory response in perioperative care),
anal fissures, diabetic ulcers; and cancer metastasis,
osteoporosis, gastroparesis; functional dyspepsia; diabetic
complications, diseases associated with endothelial dysfunction,
neurologic disorders associated with decreased nitric oxide
production, achalasia or esophageal achalasia.
[55]. A method of treating or preventing a disease, health
condition or disorder in a subject in need thereof, comprising
administering, alone or in combination therapy, a therapeutically
effective amount of a compound of any of [1] to [43] above, or a
pharmaceutical composition of [44] above, or according to other
embodiments of the invention, wherein the disease or disorder is
one that benefits from sGC stimulation or from an increase in the
concentration of NO or cGMP or both, or the upregulation of the NO
pathway. [56]. A method of any of [45] to [55] above, or according
to other embodiments of the invention, further comprising a second
amount of an additional suitable therapeutic agent.
[0666] While typical embodiments have been set forth for the
purpose of illustration, the foregoing descriptions and examples
should not be deemed to be a limitation on the scope of the
invention. Accordingly, various modifications, adaptations, and
alternatives may occur to one skilled in the art without departing
from the spirit and scope of the present invention.
* * * * *